

# **GIUSEPPE CURIGLIANO M.D. Ph.D.**

Full Professor of Medical Oncology

## **CURRICULUM VITAE**

Head Division of Early Drug Development, European Institute of Oncology, Milan

Full Professor of Medical Oncology at University of Milano

Chair of the Clinical Practice Guidelines Committee of European Society for Medical  
Oncology

Fellow of the European Academy of Cancer Sciences

Member of the National Health Council (Consiglio Superiore di Sanità)

## PERSONAL DETAILS

---

### Email Address

**Medical Registry No** MI-39318

**Nationalities** Italian, Canadian

**Marital Status** Married

**Languages** English, Italian, basic French

## EDUCATION

---

### Catholic University of Rome and University of Pisa

<b>Lyceum Humanities Degree</b>	Summa cum laude honours, Liceo Michele Morelli, Vibo Valentia	1986
---	--	------

### Medical degrees

MD	Summa cum laude honours: “Prognostic significance of p53 in early stage colorectal cancer” Università Cattolica del Sacro Cuore, Policlinico Gemelli, Roma	1993
----	--	------

Specialist Qualification	Summa cum laude honours in Medical Oncology “Molecular diagnosis of transitional cell carcinoma by Denaturing Gradient Gel Electrophoresis (DGGE) urinalysis” Università Cattolica del Sacro Cuore, Policlinico Gemelli, Roma	1998
-----------------------------	--	------

### Science degrees

PhD	Summa cum laude honours in Clinical Pharmacology “Pharmacogenetic determinants of response to chemotherapy in bladder and non small cell carcinoma” Università di Pisa	2006
-----	---	------

MSc	Summa cum laude honours in Health Management “Clinical Pathways and Activity Based Costing in the management of early breast cancer” Università Cattolica del Sacro Cuore, Milano	2012
-----	--	------

## JOURNAL EDITORIAL BOARD o CURRENT REVIEWER

---

### **Editorial Board Member**

- Cancer Treatment Review (Co-Editor in Chief)
- The Breast (Co-Editor in Chief)
- European Journal of Cancer (Associate Editor for Breast Cancer Section)
- Current Opinion in Oncology (Associate Editor for Breast Cancer Section)
- The Oncologist (Associate Editor for Breast Cancer Section)
- Cardio-Oncology (Associate Editor)
- Journal of Clinical Oncology (Breast Cancer Editor)
- Annals of Oncology (Breast Cancer Editor)
- OncoReview (Associate Editor)
- Current Opinion in Oncology (Associate Editor for Breast Cancer Section)
- Breast Cancer Research and Treatment (Medical Oncology Editor)

### **Current reviewer**

- Nature Clinical Cancer Reviews
- Journal of National Cancer Institute
- The New England Journal of Medicine
- Breast Cancer Research and Treatment
- Nature Clinical Practice Oncology
- Cancer Treatment Review
- Breast Cancer Research
- British Journal of Cancer
- European Journal of Cancer
- Breast Cancer Research
- Critical Review in Hematology-Oncology
- The Lancet Oncology

## HONOURS and PRIZES

### POSTGRADUATE FELLOWSHIPS

Prize "Tullio Terranova" for Clinical Cancer Research	1993
Prize "Istituto Toniolo" for Clinical Cancer Research	1995
Susan G. Komen for the Cure Scholar	2011
Awarded "Cavaliere" by Prime Minister Mario Monti and President Giorgio Napolitano	2012
Premio Personaggio di Prestigio, Associazione De Rubro Monte	2014
European School Oncology "Umberto Veronesi Award"	2017
Fellow of the European Academy of Cancer Sciences	2017
Radici per il Futuro Award, Liceo Classico Michele Morelli	2017

---

Tullio Terranova Travelling Fellow	1993
Clinical Immunology Fellowship at South Carolina Medical School, Charleston, SC, USA	1994
Istituto Toniolo Translational Research fellowship	1995
Clinical Fellowship at Columbia University Comprehensive Cancer Center, New York, NY, USA	1995-96
Federazione Italiana Ricerca sul Cancro (FIRC) Translational Research Fellowship	1997-2000

### MEDICAL ONCOLOGY CAREER

---

#### Catholic University of Rome

Dept of Medicine, Prof. G. Folli, Internal Medicine Research Fellow	September 1989 - September 1991
Giovanni XXIII Institute for Cancer Research, Prof. A. Cittadini Molecular Biology Training Fellowship, Senior Lecturer in Medical Oncology	October 1991 - December 1993

**Medical University of South Carolina,  
South Carolina Medical School,  
Charleston, SC, USA**

Dept of Clinical Immunology, prof. M. La Via  
Senior Research Fellow

December 1993 - December  
1994

**Columbia University, College of Physician  
and Surgeons, Columbia Comprehensive  
Cancer Center, New York, NY, USA**

Molecular Epidemiology Lab, prof. I.B. Weinstein,  
Senior Fellow

January 1995 - February 1996

**Italian Air Force, 53° Stormo Caccia  
Chiarini, Cameri, Novara, IT**

Lieutenant, Chief Medical Officer

March 1996 – September  
1997

**European Institute of Oncology**

Senior Clinical Assistant, Phase I and Clinical  
Pharmacology Unit, Chair dr F. de Braud

January 1999 – April 2004

Deputy Director of the Division of Medical  
Oncology, Chair prof. A. Goldhirsch

May 2005 – May 2010

Co-Chair of the Division of Medical  
Oncology, Chair prof. Aron Goldhirsch

May 2010- March 2013

Head, Early Clinical Trial Division

April 2013

**Dana Farber Cancer Institute**

2010

Visiting scientist  
Breast Cancer Program, Chair Eric P. Winer

**MEMBERSHIP OF SOCIETIES**

---

- European Society for Medical Oncology (ESMO)
- American Society for Clinical Oncology (ASCO)
- Italian Oncology Association (AIOM)
- American Association for Cancer Research (AACR)
- Society for Immunotherapy of Cancer (SITC)
- Italian Society of Clinical Pharmacology (SIF)
- International Cardio-Oncology Society (ICOS)
- Breast International Group (BIG)
- International Breast Cancer Study Group (IBCSG)
- European Society of Breast Cancer Specialists (EUSOMA)

## MEMBERSHIP OF EXECUTIVE COMMITTEES

---

### Local

- European Institute of Oncology
  - Committee of Heads of Clinical Divisions
  - Committee of IEO Education
  - Committee of Clinical Pharmacology Evaluation
  - Committee of Clinical Pathways and Activity Based Costing assessment

### National

- Expert Board for Drug Evaluation of Agenzia Italiana del Farmaco (AIFA), Board Member (2007-Present)
- Clinical Research Council of Associazione Italiana Oncologia Medica, Molecular and Cell Medicine Board, Committee Member (2011-Present)
- President Comitato Scientifico Associazione Italiana di Oncologia Medica (2017-Present)
- President Comitato Scientifico Lega Italiana Lotta ai Tumori (2019-2020)
- Member Consiglio Superiore di Sanità (2019-Present)

### International

- Expert Board of European Medicines Agency (EMA), Assessors Committee Member (2007-2013)
- Scientific Advisory Council, International Breast Cancer Study Group, Committee Member (2009-Present)
- St Gallen Early Breast Cancer Consensus Conference, Scientific Committee Member (2009-Present)
- International Cardio-Oncology Society, Founding Member and Scientific Secretary (2009-Present)
- European School of Oncology, Faculty Member (2009-Present)
- Scientific Advisory Council, Breast International Group (BIG), Committee Member (2011-Present)
- Institut National du Cancer, INCa, Scientific Committee Member (2010-Present)



- ❑ European Society for Medical Oncology, Metastatic Breast Cancer, Scientific Committee Member (2011-Present)
- ❑ European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Study Group, Member (2011 – present)
- ❑ Komen Scholar Scientific Peer Review Committee (2011-2012)
- ❑ Member of Breast International Group and North American Breast Cancer Group partnership under coordination of the National Cancer Institute (2009-Present)
- ❑ European Society for Medical Oncology, Metastatic Breast Cancer, Scientific Committee Chair (2014)
- ❑ European Society for Medical Oncology, IMPAKT meeting, Scientific Committee Chair (2014)
- ❑ European Society for Medical Oncology Press & Media Affairs Committee member, Official Spokesman for Breast Cancer (2014-Present)
- ❑ European Society of Medical Oncology, Women for Oncology Committee member (2014-Present)
- ❑ European Society of Medical Oncology, Global Policy Committee member (2015-Present)
- ❑ European Society of Medical Oncology, Membership Committee member (2015-Present)
- ❑ European Society of Medical Oncology, Nominating Committee member (2017-2022)
- ❑ European Society of Medical Oncology, Nominating Committee Chair (2017-2022)
- ❑ European Society of Medical Oncology, Clinical Practice Guidelines Committee Chair (2020-Present)
- ❑ St Gallen Oncology Conference on Treatment of Early Breast Cancer 2017, 2019, 2021, 2023 Conference Scientific Chair.
- ❑ ESMO Immuno-Oncology Congress 2017, Geneva, Member of the Scientific Committee
- ❑ EUSOMA (European Society of Breast Cancer Specialists), Member of the Executive Committee (2017-Present)
- ❑ ESMO 2018 Congress, Editor in Chief Daily Reporter
- ❑ ESMO Breast 2019, Conference Chair
- ❑ St Gallen 2019 Early Breast Cancer Conference, Scientific Chair
- ❑ ESMO Breast 2020, Conference Scientific Chair
- ❑ ESMO Breast 2021, Scientific Chair
- ❑ ESMO Breast 2022, Honorary Chair

- ❑ European Society of Medical Oncology, Nominating Committee Chair (2018-2021)
- ❑ European Society of Medical Oncology, Guidelines Committee Chair (2020-2022)

## CLINICAL AND SCIENTIFIC LEADERSHIP

---

Giuseppe Curigliano, MD, PhD, is head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, where besides his clinical work. He is professor of Medical Oncology at University of Milano. He is a clinician and researcher specializing in breast cancer. Dr. Curigliano earned his MD at the Università Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection. He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 5 years in the phase I unit, contributing to successful development of several targeted agents and cytotoxics. Since 2001 he is adjunct professor of Clinical Pharmacology at University of Milan, concentrating his lectures on clinical pharmacology of anticancer biologicals and cytotoxics. In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is co-chair of Division of Clinical Oncology coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). He is an active member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is founding member of/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He serves on the Clinical Research Committee of the AIOM. He serves as faculty member in the European School of Oncology (ESO). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG). He is ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference 2009, 2011 and 2013 as scientific secretary. Since October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference from 2011 to 2015. He served as Chair for the St Gallen conference 2017. Dr. Curigliano's research experiences include principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He has

been also involved as principal investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting). Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development at European Institute of Oncology. Dr. Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer (more than 490 peer reviewed article, most of them as first or last author) and several book chapters. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Institute and the European Journal of Cancer. He is member of the editorial board of Annals of Oncology, Journal of Clinical Oncology. He is associate editor of European Journal of Cancer and Co Editor in Chief of Cancer Treatment Reviews and The Breast. Prof Curigliano serves on the Executive Committee of EUSOMA (European Society of Breast Cancer Specialists) and was elected as member of the ESMO Nominating Committee in 2017.

## **TRANSLATIONAL CANCER RESEARCH**

---

There is a major trend of importance in the oncology field. The growing importance of translational science in oncology care is the actual milestone. Increasingly, our treatment decisions and therapies are being guided by advanced biological insights from molecular and cellular biology and bioinformatics. I hold an undergraduate degree in molecular biology and a PhD in Clinical Pharmacology, and I still find it challenging to stay abreast of these fantastic developments. All my early and actual working activity is within clinical trials with strong translational research. We must continue helping oncologists and clinical investigators understand the science of cancer care through scientific symposia and educational programs. The future of cutting-edge cancer treatments will depend on such understanding. Through its meetings, educational programs, grants, guidelines, publications, and online media, we must bring to the oncology community scientific insights that allow patients and clinicians to engage in 21st century oncology. I established a phase I-II Trials Unit at European Institute of Oncology using the facilities of the IEO Translational Research Campus. I obtained several research grants in clinical translational immunology (mechanisms of resistance to anti-HER2 therapies) and in translational cancer research. I am actually involved as principal investigator in a translational trial committed to develop xenograft models. The experimental plan to achieve this objective will contemplate several intermediate endpoints: i) generation of primary human breast xenografts using the above mentioned cohort of patients, ii) set up of in vivo RNAi screening using cells from primary xenografts as cancer cells in the assay, and iii) whole exome sequencing of primary tumor samples, primary xenografts and secondary tumors obtained from RNAi screening. Identification of molecular events by exome sequencing tools in tumor xenografts obtained from collected tumor tissues, may be crucial to understand molecular mechanisms inducing resistance to first line therapy. I am also committed in a national grant research protocol on stem cell research. I am also the PI of the TRANSCAN project on the prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer. The development of

surrogates for drug efficacy is becoming a major challenge in clinical research. Such surrogates could dramatically speed-up drug development by allowing quick selection of successful compounds, avoiding large adjuvant trials and identifying patients at very good outcome. In breast cancer, pathological complete response (pCR) and Ki67 drops have been proposed as surrogates for the efficacy of chemotherapy and endocrine therapy. FDA recently proposed the use of pCR for drug approval, emphasizing the need for research in this field. Preclinical studies have suggested that cytotoxic agents may partly exert their antitumor activity by inducing immune response against tumor cells. The immunogenic cell death induced by cytotoxic agents allows antigen cross-presentation, activation of dendritic cells and induction of tumor-specific cytotoxic T cells. A few studies on small breast cancer series have suggested that cytotoxic agents, including anthracyclines and taxanes, can induce tumor-specific immune response, and that exposure to such drugs could lead to the attraction of lymphocytes in the tumor bed. With the aim to identify a new potential tool for a better selection of high-risk patients eligible for postneoadjuvant investigational drugs and that could also represent a new surrogate for neoadjuvant drug efficacy for TNBC, we are evaluating whether the magnitude of lymphocytic infiltration in the residual disease after NACT could allow identifying a population of TNBC patients at good outcome. We are also assessing expression of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), the programmed death 1 (PD-1) receptor and its two known ligands, PD-L1 (also known as B7-H1 or CD274) and PD-L2 (also known as B7-DC or CD273). I'm actually the PI of the first trial on precision medicine in metastatic breast cancer (trial fully supported by Italian Association for Cancer Research).

## **VISION STATEMENT**

These are both exciting and challenging times in the fight against cancer. Advances in our knowledge of cancer are resulting in the fulfillment of the promise of precision cancer medicine for an increasing number of patients across multiple tumor types. Unprecedented advances are occurring in multiple areas including genomics, targeted therapeutics, and immunology, just to name a few. At the same time, we are facing as a field and as a community tremendous challenges including decreased research funding at a critical time when more resources are needed, the increased instability of academic careers, and the greater need to foster collaborative research and programs, to train our new generation of scientists, and to close the gap between the basic and clinical sciences.

Moving forward, cancer research globally must further expand its efforts on advancing regulatory science and policy, integrating research and patient care, fostering greater patient participation in clinical trials, and cultivating a skilled and diverse cancer research workforce. This work, together with developing partnerships with other organizations and initiatives to raise research funds, is a priority that needs to be continued and expanded. And finally, and perhaps one of the most important tasks at hand, it is the goal to continue to promote the recruitment and retention of superb talent to cancer research, to provide resources and funding to our trainees, and to facilitate access to our meetings and conferences. Most importantly, we need to continue to support a robust research agenda on multiple levels at a time when, more than ever, research is the answer to the cancer problem and pivotal

discoveries are making it possible to visualize a future when cancer will no longer be a leading cause of death.

## ORGANISATIONAL LEADERSHIP

---

### Academic

European Institute of Oncology: I played a significant role in establishing an educational program in Milan and leading its development to one of the largest and best funded academic programs in Italy. I was committed for 10 years in providing a yearly “Clinical Science in Oncology Seminars” program. Aims of the Seminars are to review developments in specific topics of oncology and to keep practicing physicians up to date with recent research and opinion. Global opinion leaders took part to these seminars.

University of Milan: In the last 7 years I was actively involved in the educational program of the Master of Clinical Pharmacology in Cancer Therapy, University of Milan, providing post-graduate

In 2014 I obtained the National Academic Qualification as Associate Professor (2013-2017)

In 2017 he won the selection as Associate Professor of Medical Oncology (MED06) at University of Milano

In University I held the role of referent for the internationalization of my department of oncology and hemato-oncology

I funded the first University Master on Artificial Intelligence in Cancer Medicine

At national level I was President of the Comitato Scientifico Associazione Italiana di Oncologia Medica (2017-Present). I was also President of the Comitato Scientifico Lega Italiana Lotta ai Tumori (2019-2020). Since 2019 I am Member Consiglio Superiore di Sanità, the only oncologist across 30 members for the national advisory council for the Ministry of Health

## INTERACTION WITH INDUSTRY

---

I have established board level links with a number of global pharmaceutical and healthcare companies which has led to significant grant funding.

IEO has an impressive record of protecting and developing its IPR and establishing spin out companies.

## INTERNATIONAL COLLABORATIONS:

---

**USA** I have established a series of collaborations with the USA's major cancer research centres (North American Breast Cancer Group, National Cancer Institute, MD Anderson, Memorial Sloan Kettering and Dana Farber, Harvard).

**INDIA** As a member of the scientific advisory board of the BIG and ESMO, I'm actively involved in the "Developing Countries Task Force", aimed to develop academic clinical research within a network of India's top cancer centres, in partnership with BIG. This collaboration will provide training opportunities for Indian investigators in Europe and will build an internationally competitive clinical research network.

**EUROPE** I had the opportunity to collaborate within the BIG network with all centres of excellence for clinical cancer research in Europe. I am in a strong position to improve standing of Medical Oncology in Europe.

**SOUTH AMERICA** I have established active collaboration with Brasil and Argentina institution training and mentoring clinician scientist that visited my institution in Milan.

**NORTH AFRICA** I have been involved in a collaborative clinical network of cancer research centres in Libia and Egypt (involving scientist with education and training in European and US countries).

## RESEARCH GRANTS RECEIVED

---

### 1994

- Toniolo Institute Grant - E 15,000.  
One year's salary for Research Assistant  
Grant Holder: G. Curigliano

### 1995-1998

- Fondazione Italiana per la Ricerca sul Cancro (FIRC) Triennial Grant – E 150,000  
Molecular biology of transitional cell bladder carcinoma. Research Grant  
Grant Holder: G. Curigliano

## **1999-2001**

- Ricerca Finalizzata Ministero della Salute Grant – E 110,000  
2 year salary for senior post-doctoral scientist for project on pharmacogenetics of transitional bladder cell carcinoma  
Grant Holder: G. Curigliano

## **2001-2009**

- Associazione Italiana Ricerca sul Cancro Grant - E 150,000  
2 year's salary for senior post-doctoral scientist for project on identification of gene signature predictive of response to bevacizumab in triple negative breast cancer Grant Holders – A. Goldhirsch, G. Curigliano
- Ricerca Finalizzata Ministero della Salute Grant - E 210,000  
Identification of Mechanisms of resistance to trastuzumab  
Grant Holders – M. Rescigno, G. Curigliano
- Cariplo Foundation Grant- E 60,000  
Eps8 gene polymorphism and toxicity from cisplatin  
Grant Holders – N. Offenhauser, G. Curigliano
- Umberto Veronesi Foundation Grant – E 120,000  
Role of cancer stem cells in anticancer drug resistance  
Grant Holder – G. Bonizzi, G. Curigliano

## **2009-2011**

- Roche Unrestricted Grant- E 300.000  
To explore activity of bevacizumab in lymphangitic breast cancer  
Grant holders – A. Goldhirsch, G. Curigliano

## **2011-2012**

- Umberto Veronesi Foundation Grant E 200,000  
Genome Remodeling in Luminal B, HER2 and Ductal Triple Negative Breast Cancer Metastasis and Xenograft: Exome sequencing analysis for identification of driver pathways to overcome resistance  
Grant holder – G. Curigliano
- Career Catalyst Research (CCR) Komen Grant E. 450.000

Measuring Estrogen Levels During Letrozole Interruption – The SOLE-EST Substudy  
Grant holders – A. Goldhirsch, G. Curigliano

- Associazione Italiana Ricerca sul Cancro (AIRC) Grant E 3,000,000  
Understanding how cancer stem cells drive breast cancer growth and how to exploit them as its Achille's heel  
Task 5 Team Leader: G Curigliano  
Optimization of available therapies: Breast cancer stem cells and drug resistance  
Grant Holders: P.P. Di Fiore, P.G. Pelicci, G. Viale and A. Goldhirsch

#### **2012-2015**

- ERA-Net on translational cancer research (TRANSCAN) E 3.000,000  
"CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer", UGI1  
Grant holder – F. André, G. Curigliano, K. Denkert

#### **2015-2017**

- AIRC funding on translational cancer research E 300.000  
"Clinical utility of a next generation sequencing-based "oncochip" for therapeutic decision in metastatic breast cancer"  
Grant holder –G. Curigliano

#### **2015-2017**

Ministero della Salute Funding Euros 360.000  
" Master protocol of precision medicine for treatment of metastatic breast cancer"  
Grant holder –G. Curigliano

#### **2016–2019**

Coordinatore WP 3 del progetto "Development of effective cancer therapies based on functional proteomics and cancer stem cell targeting". Associazione Italiana per la Ricerca sul Cancro. Finanziamento 230.733 Euro.

#### **2019-2021**

Coordinatore WP 1 "An interdisciplinary approach for the management of the elderly multimorbid patients with breast cancer therapy induced cardiac toxicity", consorzio CARDIOCARE, Horizon 2020: Finanziamento 2.500.000 Euro

#### **2021-2026**

Coordinatore WP 6 "Optimal treatment for patients with solid tumours in Europe through Artificial intelligence" Consorzio OPTIMA; Horizon 2020, Finanziamento 10.000.000 Euro



## PUBLICATIONS

---

### PUBLISHED ABSTRACTS

Over 1000 abstracts presented at national and international conferences.

### THESES and MENTORING

Dr Curigliano was committed in the last 15 years to training and mentoring medical student, residents and PhD students. He provided excellence in undergraduate, postgraduate and continuing medical education.

- |     |   |
|-----|---|
| MD  | 4-ABP DNA adducts in transitional cell carcinoma of the bladder   |
|     | dHER2 peptide vaccine ad adjuvant therapy in HER2 positive breast cancer  |
|     | Pharmacogenetic determinants of response to intravesical gemcitabine in transitional cell carcinoma of the bladder stage pT1, pT1 |
|     | Identification of a gene signature predictive of response to bevacizumab in lymphangitic breast cancer                            |
|     | Cancer testis antigens expression in triple negative breast cancer  |
| PhD | Pharmacogenetic determinants of response to intravesical gemcitabine in transitional cell carcinoma of the bladder stage pT1, pT1 |
| MD  | Xenograft models in breast cancer subtypes  |

### BIBLIOMETRIC DATA

Thompson Reuters Scopus: **H index: 76**

Number of Citations: 27.521

Google Scholar: **H index 136**

Number of Citations: 107.830

**In 2022 I was identified as Clarivate™ world's most influential researchers.**

## PEER REVIEWED PUBLICATIONS

---

Anno 1996

1) Curigliano G, Zhang YJ, Wang LY, Flamini G, Alcini A, Ratto C, Giustacchini M, Alcini E, Cittadini A, Santella RM. Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. *Carcinogenesis*. 1996 May;17(5):911-6. doi: 10.1093/carcin/17.5.911. PMID: 8640937.

2) Flamini G, Curigliano G, Ratto C, Astone A, Ferretti G, Nucera P, Sofo L, Sgambato A, Boninsegna A, Crucitti F, Cittadini A. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. *Eur J Cancer*. 1996 May;32A(5):802-6. doi: 10.1016/0959-8049(95)00625-7. PMID: 9081357.

3) Ratto C, Flamini G, Sofo L, Nucera P, Ippoliti M, Curigliano G, Ferretti G, Sgambato A, Merico M, Doglietto GB, Cittadini A, Crucitti F. Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. *Dis Colon Rectum*. 1996 Nov;39(11):1238-44. doi: 10.1007/BF02055116. PMID: 8918432.

Anno 1997

4) Flamini G, Magalini S, Curigliano G, Nanni G, Boninsegna A, Agnes S, Faticato D, Castagneto M, Cittadini A. Immunohistochemical analysis of p53 protein in transplant recipients with Kaposi's sarcoma. *J Cancer Res Clin Oncol*. 1997;123(4):240-2. doi: 10.1007/BF01240324. PMID: 9177500.

5) Romano G, Mancini R, Fedele P, Curigliano G, Flamini G, Giovagnoli MR, Malara N, Boninsegna A, Vecchione A, Santella RM, Cittadini A. Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosal cells of smokers and nonsmokers. *Anticancer Res*. 1997 Jul-Aug;17(4A):2827-30. PMID: 9252724.

Anno 1998

6) Flamini G, Romano G, Curigliano G, Chiominto A, Capelli G, Boninsegna A, Signorelli C, Ventura L, Santella RM, Sgambato A, Cittadini A. 4-Aminobiphenyl- DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study. *Carcinogenesis*. 1998 Feb;19(2):353-7. doi: 10.1093/carcin/19.2.353. PMID: 9498288.

7) Ciaparrone M, Terribile D, Curigliano G, Marra A, Sgambato A, Boninsegna A, Masetti R, Carbone A, Flamini G, Picciocchi A, Cittadini A. P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer. *Breast J*. 1998 Jul;4(4):270-6. doi: 10.1046/j.1524-4741.1998.440270.x. PMID: 21223447.

Anno 1999

8) Romano G, Sgambato A, Boninsegna A, Flamini G, Curigliano G, Yang Q, La Gioia V, Signorelli C, Ferro A, Capelli G, Santella RM, Cittadini A. Evaluation of polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral cells by an immunohistochemical assay. *Cancer Epidemiol Biomarkers Prev*. 1999 Jan;8(1):91-6. PMID: 9950245.

9) Romano G, Garagnani L, Boninsegna A, Ferrari P, Flamini G, De Gaetani C, Sgambato A, Giovanni F, Curigliano G, Ferretti G, Cittadini A, Trentini G. Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma. *Anticancer Res.* 1999 Sep-Oct;19(5C):4571-6. PMID: 10650812.

Anno 2000

10) Orlando L, Colleoni M, Nolè F, Biffi R, Rocca A, Curigliano G, Ferretti G, Peruzzotti G, de Braud F, Masci G, Goldhirsch A. Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? *Ann Oncol.* 2000 Jan;11(1):117-8. doi: 10.1023/a:1008364801718. PMID: 10690401.

11) De Pas T, Curigliano G, Catania C, Comandone A, de Braud F. Ifosfamide in the elderly: clinical considerations for a better drug management. *Crit Rev Oncol Hematol.* 2000 Feb;33(2):129-35. doi: 10.1016/s1040-8428(99)00060-8. PMID: 10737374.

12) De Pas TM, Mandalà M, Curigliano G, Peccatori F. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703. *Obstet Gynecol.* 2000 Jun;95(6 Pt 2):1030. PMID: 10808018.

13) Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabrò MG, De Pas T, Orlando L, Mandalà M, Colleoni M, Spaggiari L, Granone PL, Pagliari G, de Braud F, Fazio N, Goldhirsch A. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. *Clin Cancer Res.* 2000 Jun;6(6):2393-400. PMID: 10873091.

14) De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, del Tacca M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A, Goldhirsch A. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. *Ann Oncol.* 2000 Jul;11(7):821-7. doi: 10.1023/a:1008319923516. PMID: 10997809.

15) Colleoni M, Minchella I, Mazzarol G, Nolè F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. *Ann Oncol.* 2000 Aug;11(8):1057-9. doi: 10.1023/a:1008334404825. PMID: 11038046.

Anno 2001

16) De Pas T, de Braud F, Mandalà M, Curigliano G, Catania C, Ferretti G, Sozzi P, Solli P, Goldhirsch A. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. *Lung Cancer.* 2001 Feb-Mar;31(2-3):267-70. doi: 10.1016/s0169-5002(00)00176-8. PMID: 11165406.

17) Mandalà M, Moro C, Ferretti G, Calabro MG, Nolè F, Rocca A, Munzone E, Castro A, Curigliano G. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. *Anticancer Res.* 2001 Jan-Feb;21(1B):585-8. PMID: 11299809.

18) Lissoni P, Mandalà M, Curigliano G, Ferretti G, Moro C, Ardizzoia A, Malugani F, Tancini G, Tisi E, Arrigoni C, Barni S. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. *Oncology.* 2001;60(4):308-12. doi: 10.1159/000058525. PMID: 11408797.

19) Curigliano G, Ferretti G, Colleoni M, Marrocco E, Peruzzotti G, De Cicco C, Paganelli G, Goldhirsch A. Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms. *Ann Oncol.* 2001 May;12(5):724-5. doi: 10.1023/a:1011173806900. PMID:11432637.

- 20) Curigliano G, Ferretti G, Flamini G, Goldhirsch A, de Braud F, Calabro MG, Mandaly M, Nole F, De Pas T, D'Addessi A, Cittadini A. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. *Anticancer Res.* 2001 Jul-Aug;21(4B):3015-20. PMID: 11712804.
- 21) Fogli S, Danesi R, De Braud F, De Pas T, Curigliano G, Giovannetti G, Del Tacca M. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. *Ann Oncol.* 2001 Nov;12(11):1553-9. doi: 10.1023/a:1013133415945. PMID: 11822754.
- 22) De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabine-induced systemic capillary leak syndrome. *Ann Oncol.* 2001 Nov;12(11):1651-2. doi: 10.1023/a:1013163831194. PMID: 11822767.
- 23) Curigliano G, Ferretti G, Mandalà M, De Pas T, Calabrò MG, Solli P, Noberasco C, de Braud F. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. *Anticancer Res.* 2001 Sep-Oct;21(5):3461-9. PMID: 11848510.
- Anno 2002
- 24) De Pas T, Curigliano G, Masci G, Catania C, Comandone A, Boni C, Tucci A, Pagani O, Marrocco E, de Braud F; Italian Sarcoma Group. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. *Ann Oncol.* 2002 Jan;13(1):161-6. doi: 10.1093/annonc/mdf004. PMID: 11863099.
- 25) Curigliano G, Mandala M, Minchella I, Goldhirsch A. Mediastinal lymphadenopathy in a patient with breast cancer. *Lancet Oncol.* 2002 Mar;3(3):174. doi: 10.1016/s1470-2045(02)00681-2. PMID: 11902504.
- 26) Orlando L, Colleoni M, Curigliano G, Nolè F, Ferretti G, Masci G, Peruzzotti G, Minchella I, Intra M, Veronesi P, Viale G, Goldhirsch A. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. *Anticancer Res.* 2001 Nov-Dec;21(6A):4135-9. PMID: 11911307.
- 27) De Pas T, Pastorino U, Spaggiari L, Curigliano G, de Braud F, Robertson C. Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. *J Clin Oncol.* 2002 May 15;20(10):2603-4; author reply 2605. doi: 10.1200/JCO.2002.20.10.2603. PMID: 12011140.
- 28) Curigliano G, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, de Braud E, Robertson C, Maiorano E, Veronesi P, Nolè F, Mandalà M, Ferretti G, Viale G, Goldhirsch A. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. *Ann Oncol.* 2002 Jun;13(6):895-902. doi: 10.1093/annonc/mdf166. PMID: 12123335.
- 29) Mandalà M, Lissoni P, Ferretti G, Rocca A, Torri V, Moro C, Curigliano G, Barni S. Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients. *Oncology.* 2002;63(4):370-7. doi: 10.1159/000066228. PMID: 12417792.
- 30) Ferretti G, Mandala M, Di Cosimo S, Moro C, Curigliano G, Barni S. Catheter-related bloodstream infections, part I: pathogenesis, diagnosis, and management. *Cancer Control.* 2002 Nov-Dec;9(6):513-23. doi: 10.1177/107327480200900610. PMID: 12514569.

31) Orlando L, Curigliano G, Colleoni M, Fazio N, Nole F, Martinelli G, Cinieri S, Graffeo R, Peruzzotti G, Goldhirsch A. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. *Anticancer Res.* 2002 Sep- Oct;22(5):3057-9. PMID: 12530042.

Anno 2003

32) Veronesi G, Spaggiari L, De Pas T, Solli PG, De Braud F, Catalano GP, Curigliano G, Leo F, Pastorino U. Preoperative chemotherapy is essential for conservative surgery of Askin tumors. *J Thorac Cardiovasc Surg.* 2003 Feb;125(2):428-9. doi: 10.1067/mtc.2003.198. PMID: 12579122.

33) Ferretti G, Mandala M, Di Cosimo S, Moro C, Curigliano G, Barni S. Catheter-related bloodstream infections, part II: specific pathogens and prevention. *Cancer Control.* 2003 Jan-Feb;10(1):79-91. doi: 10.1177/107327480301000111. PMID: 12598858.

34) Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, Del Tacca M. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. *Pharmacol Rev.* 2003 Mar;55(1):57-103. doi: 10.1124/pr.55.1.4. PMID:12615954.

35) Di Cosimo S, Pistillucci G, Ferretti G, Cicchetti A, Leggio M, Silvestris N, Moro C, Mandala M, Curigliano G, Battigaglia B, Di Chio G, Cirignotta S, D'Aprile M. Palliative home care and cost savings: encouraging results from Italy. *N Z Med J.* 2003 Mar 14;116(1170):U370. PMID: 12658325.

36) Di Cosimo S, Ferretti G, Fazio N, Mandalà M, Curigliano G, Bosari S, Intra M, Latronico A, Goldhirsch A. Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. *Ann Oncol.* 2003 May;14(5):803-4. doi: 10.1093/annonc/mdg218. PMID: 12702537.

37) Solli P, Leo F, Veronesi G, Curigliano G, Martinoni A, Spaggiari L, Cipolla C, Pastorino U. Impact of limited pulmonary function on the management of resectable lung cancer. *Lung Cancer.* 2003 Jul;41(1):71-9. doi: 10.1016/s0169-5002(03)00122-3. PMID: 12826315.

38) Colleoni M, Curigliano G, Minchella I, Peruzzotti G, Nolè F, Mazzarol G, Renne G, Orlando L, Rocca A, Veronesi P, Intra M, Viale G, Sandri MT, Severi G, Goldhirsch A. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. *Ann Oncol.* 2003 Oct;14(10):1477-83. doi: 10.1093/annonc/mdg411. PMID: 14504046.

39) De Pas T, Danesi R, Catania C, Curigliano G, De Braud F; Italia Sarcoma Group. Imatinib administration in two patients with liver metastases from GIST and severe jaundice. *Br J Cancer.* 2003 Oct 20;89(8):1403-4. doi: 10.1038/sj.bjc.6601282. PMID: 14562006; PMCID: PMC2394355.

40) Mandalà M, Ferretti G, Cremonesi M, Cazzaniga M, Curigliano G, Barni S. Venous thromboembolism and cancer: new issues for an old topic. *Crit Rev Oncol Hematol.* 2003 Oct;48(1):65-80. doi: 10.1016/s1040-8428(03)00041-6. PMID: 14585484.

41) Fazio N, Orsi F, Grasso RF, Ferretti G, Medici M, Rocca A, Zampino G, Curigliano G, De Pas T, Colleoni M, Bonomo G, Marrocco E, Lunghi L, De Braud F. Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. *Anticancer Res.* 2003 Nov- Dec;23(6D):5023-30. PMID: 14981962.

Anno 2004

42) Gennari R, Curigliano G, Jereczek-Fossa BA, Zurrada S, Renne G, Intra M, Galimberti V, Luini A, Orecchia R, Viale G, Goldhirsch A, Veronesi U. Male breast cancer: a special therapeutic problem. Anything new? (Review). *Int J Oncol.* 2004 Mar;24(3):663-70. PMID: 14767551.

43) Mandalà M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with

breast cancer and a central venous catheter. *Ann Oncol.* 2004 Apr;15(4):590-3. doi: 10.1093/annonc/mdh146. PMID: 15033664.

44) Curigliano G, Cipolla C, de Braud F. Drug-induced prolongation of the QT interval. *N Engl J Med.* 2004 Jun 17;350(25):2618-21; author reply 2618-21. PMID: 15208787.

45) Curigliano G, Rigo R, Colleoni M, Braud FD, Nole F, Formica V, Orlando L, Cinieri S, Torrasi R, Cardillo A, Peruzzotti G, Medici M, Ardito R, Minchella I, Goldhirsch A. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. *Clin Breast Cancer.* 2004 Jun;5(2):125-30. doi: 10.3816/cbc.2004.n.016. PMID: 15245616.

46) Gennari R, Curigliano G, Rotmensz N, Robertson C, Colleoni M, Zurrada S, Nolè F, de Braud F, Orlando L, Leonardi MC, Galimberti V, Intra M, Veronesi P, Renne G, Cinieri S, Audisio RA, Luini A, Orecchia R, Viale G, Goldhirsch A. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. *Cancer.* 2004 Sep 15;101(6):1302-10. doi: 10.1002/cncr.20535. PMID: 15316944.

47) Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrasi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. *Clin Cancer Res.* 2004 Oct 1;10(19):6622-8. doi: 10.1158/1078-0432.CCR-04-0380. PMID: 15475452.

48) Fazio N, De Pas T, de Braud F, Spaggiari L, Mazzarol G, Biffi R, Andreoni B, Zampino M, Curigliano G, Lorizzo K, Di Meglio G, Goldhirsch A. CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. *Ann Oncol.* 2004 Dec;15(12):1850. doi: 10.1093/annonc/mdh482. PMID: 15550596.

49) De Pas T, Curigliano G, Veronesi G, Catalano G, Catania C, Jereczek-Fossa B, Orecchia R, Spaggiari L, de Braud F. Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study. *Bull Cancer.* 2004 Sep 1;91(9):E273-7. PMID: 15582897.

50) De Pas T, Pelosi G, de Braud F, Veronesi G, Curigliano G, Leon ME, Danesi R, Noberasco C, d'Aiuto M, Catalano G, Viale G, Spaggiari L. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. *J Clin Oncol.* 2004 Dec 15;22(24):4966-70. doi: 10.1200/JCO.2004.01.195. PMID: 15611511.

51) Noberasco C, De Pas T, Curigliano G, Manzoni S, Dodaro L, Pelosi G, Spaggiari L, De Braud F. Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer? *J Clin Oncol.* 2005 Feb 1;23(4):921-2; author reply 922. doi: 10.1200/JCO.2005.05.700. PMID: 15681541.

52) De Pas T, Colleoni M, Orlando L, Masci G, Rocca A, Catania C, Curigliano G, Manzoni S, Goldhirsch A, de Braud F. Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (*Ann Oncol* 2004; 15: 1543-1550): ... and in humans? *Ann Oncol.* 2005 Apr;16(4):673. doi: 10.1093/annonc/mdi101. Epub 2005 Feb 16. PMID: 15716290.

53) De Pas T, Sbanotto A, Catania C, Banfi MG, Curigliano G, Nolè F, Fazio N, Formica V, Veronesi G, de Braud F. Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. *Support Care Cancer.* 2005 Mar;13(3):194-5. doi: 10.1007/s00520-004-0706-2. Epub 2004 Nov 17. PMID: 15761704.

Anno 2005

- 54) de Braud F, De Pas T, Spaggiari L, Veronesi G, Curigliano G, Noberasco C, Pelosi G. Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst.* 2005 Mar 16;97(6):461-2; author reply 462-3. doi: 10.1093/jnci/dji076. PMID: 15770011.
- 55) Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'ó E, Colombo N. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. *J Clin Oncol.* 2005 Mar 20;23(9):1867-74. doi: 10.1200/JCO.2005.09.032. PMID: 15774779.
- 56) Orlando L, Renne G, Rocca A, Curigliano G, Colleoni M, Severi G, Peruzzotti G, Cinieri S, Viale G, Sanna G, Goldhirsch A. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. *Ann Oncol.* 2005 Jul;16(7):1094-9. doi: 10.1093/annonc/mdj213. Epub 2005 Apr 26. PMID: 15855225.
- 57) De Pas T, Putzu C, Pelosi G, Curigliano G, Noberasco C, Zampino G, Fazio N, Formica V, Spaggiari L, de Braud F. Target-treatment and patients' selection: can we still neglect the timing of tissue collection? *J Clin Oncol.* 2005 Sep 1;23(25):6274-5; author reply 6275-6. doi: 10.1200/JCO.2005.01.9174. PMID: 16135503.
- 58) Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. *Breast Cancer Res Treat.* 2005 Sep;93(1):35-40. doi: 10.1007/s10549-005-3381-1. PMID: 16184456.
- 59) Curigliano G, Colleoni M, Mandalà M, De Pas T, Spitaleri G, de Braud F, Goldhirsch A. Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. *J Clin Oncol.* 2005 Oct 1;23(28):7243-4; author reply 7244. doi: 10.1200/JCO.2005.02.1816. PMID: 16192619.
- Anno 2006
- 60) Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, Munzone E, Rocca A, Bonizzi G, Brichard V, Orlando L, Goldhirsch A. Breast cancer vaccines: a clinical reality or fairy tale? *Ann Oncol.* 2006 May;17(5):750-62. doi: 10.1093/annonc/mdj083. Epub 2005 Nov 17. PMID: 16293674.
- 61) Curigliano G, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, de Braud F, Goldhirsch A. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. *Ann Oncol.* 2006 Jul;17(7):1174-5. doi: 10.1093/annonc/mdj126. Epub 2006 Jan 12. PMID: 16410362.
- 62) Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A, Nolè F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. *Breast Cancer Res.* 2006;8(1):R4. doi: 10.1186/bcr1366. Epub 2005 Dec 7. Erratum in: *Breast Cancer Res.* 2006;8(5):407. PMID: 16417653; PMCID: PMC1413988.
- 63) Curigliano G, Magni E, Renne G, De Cobelli O, Rescigno M, Torrisi R, Spitaleri G, Pietri E, De Braud F, Goldhirsch A. "Burned out" phenomenon of the testis in retroperitoneal seminoma. *Acta Oncol.* 2006;45(3):335-6. doi: 10.1080/02841860500401175. PMID: 16644578.
- 64) Zampino MG, Verri E, Locatelli M, Curigliano G, Ascione G, Sbanotto A, Rocca A, Verweij F, Matei V, Scardino E, Decobelli O, Goldhirsch A, Nolè F. Vinorelbine-based chemotherapy in

hormone-refractory prostate cancer. *Anticancer Res.* 2006 May-Jun;26(3B):2375-80. PMID: 16821619.

65) Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. *Br J Cancer.* 2006 Aug 7;95(3):289-97. doi: 10.1038/sj.bjc.6603242. Epub 2006 Jul 25. PMID: 16868547; PMCID: PMC2360654.

66) De Pas T, Putzu C, Curigliano G, Noberasco C, Boselli S, Catania C, Orlando L, Milani A, Spaggiari L, de Braud F. A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. *Lung Cancer.* 2006 Dec;54(3):359-64. doi: 10.1016/j.lungcan.2006.08.016. Epub 2006 Oct 6. Erratum in: *Lung Cancer.* 2007 Dec;58(3):431. Sabrina, Boselli [corrected to Boselli, Sabrina]. PMID: 17028052.

67) Rocca A, Peruzzotti G, Ghisini R, Viale G, Veronesi P, Luini A, Intra M, Pietri E, Curigliano G, Giovanardi F, Maisonneuve P, Goldhirsch A, Colleoni M. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. *Anticancer Drugs.* 2006 Nov;17(10):1201-9. doi: 10.1097/01.cad.0000236306.43209.2b. PMID: 17075320.

68) Curigliano G, Spitaleri G, Zampino G. Treatment of rectal cancer. *N Engl J Med.* 2006 Dec 7;355(23):2487; author reply 2487-8. PMID: 17152682.

Anno 2007

69) Curigliano G, Pelosi G, De Pas T, Renne G, De Cobelli O, Manzotti M, Spitaleri G, de Braud F. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. *Prostate.* 2007 May 1;67(6):603-4. doi: 10.1002/pros.20530. PMID: 17290443.

70) Curigliano G, Balduzzi A, Cardillo A, Ghisini R, Peruzzotti G, Orlando L, Torrisi R, Dellapasqua S, Lunghi L, Goldhirsch A, Colleoni M. Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. *Support Care Cancer.* 2007 Oct;15(10):1213-7. doi: 10.1007/s00520-007-0277-0. Epub 2007 Jun 20. PMID: 17578607.

71) Curigliano G, Goldhirsch A. To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer. *Nat Clin Pract Oncol.* 2007 Sep;4(9):510-1. doi: 10.1038/ncponc0902. Epub 2007 Jul 10. PMID: 17622232.

72) Leo F, De Pas T, Catalano G, Piperno G, Curigliano G, Solli P, Veronesi G, Petrella F, Spaggiari L. Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer. *J Natl Cancer Inst.* 2007 Aug 1;99(15):1210; author reply 1210-1. doi: 10.1093/jnci/djm051. Epub 2007 Jul 24. PMID: 17652281.

73) De Pas T, Spitaleri G, Pruneri G, Curigliano G, Noberasco C, Luini A, Andreoni B, Testori A, de Braud F. Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. *Crit Rev Oncol Hematol.* 2008 Jan;65(1):1-7. doi: 10.1016/j.critrevonc.2007.06.003. Epub 2007 Jul 19. PMID: 17658269.

74) Curigliano G, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nolè F, Verweij F, Matei V, De Cobelli O. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. *Anticancer Drugs.* 2007 Sep;18(8):949-54. doi: 10.1097/CAD.0b013e328136c162. PMID: 17667601.



75) Curigliano G, Rescigno M, Goldhirsch A. Immunology and breast cancer: therapeutic cancer vaccines. *Breast*. 2007 Dec;16 Suppl 2:S20-6. doi: 10.1016/j.breast.2007.07.004. Epub 2007 Aug 13. PMID: 17706425.

76) Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. *Biochim Biophys Acta*. 2007 Sep;1776(1):108-23. doi: 10.1016/j.bbcan.2007.07.003. Epub 2007 Jul 17. PMID: 17720322.

77) Fazio N, Biffi R, Curigliano G, Lorizzo K, Zampino MG, de Braud F, Chiappa A, Roth A, Goldhirsch A. Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. *J Natl Cancer Inst*. 2007 Sep 5;99(17):1345-6; author reply 1346-7. doi: 10.1093/jnci/djm092. Epub 2007 Aug 28. PMID: 17728219.

78) Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. *Expert Rev Anticancer Ther*. 2007 Sep;7(9):1225-41. doi: 10.1586/14737140.7.9.1225. PMID: 17892423.

79) Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. *Eur J Cancer*. 2008 Mar;44(4):494-500. doi: 10.1016/j.ejca.2007.10.001. Epub 2007 Nov 19. PMID: 18024014.

Anno 2008

80) De Pas T, Spitaleri G, Vigna PD, Toffalorio F, Curigliano G, Gambino A, Boselli S, Catania C, de Braud F. Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. *Ecancermedicalscience*. 2008;2:102. doi: 10.3332/ecancer.2008.102. Epub 2008 Nov 24. PMID: 22275981; PMCID: PMC3234072.

81) Curigliano G, Mandalà M, Sbanotto A, Colleoni M, Ferretti G, Bucciarelli P, Peruzzotti G, de Braud F, De Pas T, Spitaleri G, Pietri E, Orsi F, Banfi MG, Goldhirsch A. Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. *Support Cancer Ther*. 2006 Jan 1;3(2):98-102. doi: 10.3816/SCT.2006.n.005. PMID: 18632446.

Anno 2009

82) Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? *International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat*. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25. PMID: 18953651; PMCID: PMC3589110.

83) De Pas T, Spitaleri G, Pelosi G, De Carlis L, Lorizzo K, Locatelli M, Curigliano G, Toffalorio F, Catania C, de Braud F. Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer. *J Thorac Oncol*. 2009 Jan;4(1):138-9. doi: 10.1097/JTO.0b013e31819151e5. PMID: 19096323.

84) Curigliano G, Spitaleri G, de Braud F, Cardinale D, Cipolla C, Civelli M, Colombo N, Colombo A, Locatelli M, Goldhirsch A. QTc prolongation assessment in anticancer drug development: clinical and methodological issues. *Ecancermedicalscience*. 2009;3:130. doi: 10.3332/ecancer.2009.130. Epub 2009 Jan 12. PMID: 22275999; PMCID: PMC3223992.

85) Spitaleri G, Matei DV, Curigliano G, Detti S, Verweij F, Zambito S, Scardino E, Rocco B, Nolè F, Ariu L, De Pas T, de Braud F, De Cobelli O. Phase II trial of estramustine phosphate and oral

- etoposide in patients with hormone-refractory prostate cancer. *Ann Oncol.* 2009 Mar;20(3):498-502. doi: 10.1093/annonc/mdn650. Epub 2009 Jan 12. PMID: 19139180.
- 86) Curigliano G, Spitaleri G, De Cobelli O, Scardino E, Sbanotto A, de Braud F. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib. *Urol Int.* 2009;82(2):196-202. doi: 10.1159/000200800. Epub 2009 Mar 19. PMID: 19322010.
- 87) Jereczek-Fossa BA, Curigliano G, Orecchia R. Systemic therapies for non- metastatic prostate cancer: review of the literature. *Onkologie.* 2009 Jun;32(6):359-63. doi: 10.1159/000215713. Epub 2009 May 14. PMID: 19521126.
- 88) Della Vigna P, Monfardini L, Bonomo G, Curigliano G, Agazzi A, Bellomi M, Orsi F. Coagulation disorders in patients with cancer: nontunneled central venous catheter placement with US guidance--a single-institution retrospective analysis. *Radiology.* 2009 Oct;253(1):249-52. doi: 10.1148/radiol.2531081963. Epub 2009 Jun 30. PMID: 19567651.
- 89) Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F, Goldhirsch A. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. *J Clin Oncol.* 2009 Dec 1;27(34):5693-9. doi: 10.1200/JCO.2009.22.0962. Epub 2009 Nov 2. PMID: 19884553.
- 90) Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. *Breast.* 2009 Oct;18 Suppl 3:S51-4. doi: 10.1016/S0960-9776(09)70273-5. PMID: 19914543.
- 91) Curigliano G, Spitaleri G, Magni E, Lorizzo K, De Cobelli O, Locatelli M, Fumagalli L, Adamoli L, Cossu Rocca M, Verri E, De Pas T, Jereczek-Fossa B, Martinelli G, Goldhirsch A, Nolè F. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. *J Chemother.* 2009 Dec;21(6):687-92. doi: 10.1179/joc.2009.21.6.687. PMID: 20071294.
- Anno 2010
- 92) Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marengi C, Curigliano G, Radice D, Adamoli L, Nolè F. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. *Breast.* 2010 Feb;19(1):33-7. doi: 10.1016/j.breast.2009.10.003. Epub 2009 Nov 1. PMID: 19884008.
- 93) Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. *Breast Cancer Res Treat.* 2010 Jul;122(1):211-7. doi: 10.1007/s10549-009-0668-7. Epub 2009 Dec 6. PMID: 19967556.
- 94) Noberasco C, Spitaleri G, Mancuso P, Zorzino L, Radice D, Milani A, Rocca A, Bertolini F, Sandri MT, Curigliano G, de Pas T, Jemos C, Omodeo Salè E, Boselli S, de Braud F. Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. *Oncology.* 2009;77(6):358-65. doi: 10.1159/000275830. Epub 2010 Jan 11. PMID: 20068365.
- 95) Orgera G, Curigliano G, Krokidis M, Bonomo G, Monfardini L, Della Vigna P, Zampino MG, Orsi F. High-intensity focused ultrasound effect in breast cancer nodal metastasis. *Cardiovasc Intervent Radiol.* 2010 Apr;33(2):447-9. doi: 10.1007/s00270-010-9824-z. PMID: 20162283.

- 96) Curigliano G. Personalizing medicine through personalized communication: individuality of the patient across borders and cultures. *J Natl Compr Canc Netw*. 2010 Mar;8(3):277-8. doi: 10.6004/jnccn.2010.0019. PMID: 20202460.
- 97) Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. *Prog Cardiovasc Dis*. 2010 Sep-Oct;53(2):94-104. doi: 10.1016/j.pcad.2010.05.006. PMID: 20728696.
- 98) Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nolè F, Rotmensz N, Goldhirsch A. Cancer-testis antigen expression in triple-negative breast cancer. *Ann Oncol*. 2011 Jan;22(1):98-103. doi: 10.1093/annonc/mdq325. Epub 2010 Jul 7. PMID: 20610479.
- 99) Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. *Eur J Cancer*. 2010 Nov;46(16):2926-35. doi: 10.1016/j.ejca.2010.07.033. Epub 2010 Aug 24. PMID: 20797845.
- 100) Munzone E, Nolè F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. *Clin Breast Cancer*. 2010 Oct 1;10(5):392-7. doi: 10.3816/CBC.2010.n.052. PMID: 20920984  
Anno 2011
- 101) Farante G, Zurrida S, Galimberti V, Veronesi P, Curigliano G, Luini A, Goldhirsch A, Veronesi U. The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. *Breast Cancer Res Treat*. 2011 Jul;128(2):369-78. doi: 10.1007/s10549-010-1124-4. Epub 2010 Aug 26. Erratum in: *Breast Cancer Res Treat*. 2011 Jul;128(2):379. Dosage error in article text. PMID: 20740312.
- 102) Petralia G, Bonello L, Summers P, Preda L, Malasevski A, Raimondi S, Di Filippi R, Locatelli M, Curigliano G, Renne G, Bellomi M. Intraobserver and interobserver variability in the calculation of apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (DW-MRI) of breast tumours. *Radiol Med*. 2011 Apr;116(3):466-76. English, Italian. doi: 10.1007/s11547-011-0616-z. Epub 2011 Jan 12. PMID: 21225368.
- 103) Lohsiriwat V, Curigliano G, Rietjens M, Goldhirsch A, Petit JY. Autologous fat transplantation in patients with breast cancer: "silencing" or "fueling" cancer recurrence? *Breast*. 2011 Aug;20(4):351-7. doi: 10.1016/j.breast.2011.01.003. Epub 2011 Feb 5. PMID: 21295982.
- 104) Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? *Ann Oncol*. 2011 Oct;22(10):2227-33. doi: 10.1093/annonc/mdq751. Epub 2011 Feb 22. PMID: 21343379.
- 105) Macedo LT, Ribeiro J, Curigliano G, Fumagalli L, Locatelli M, Carneiro JB, Quintela A, Bertelli S, De Cobelli O. Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. *Eur J Surg Oncol*. 2011 Jul;37(7):558-62. doi: 10.1016/j.ejso.2011.04.005. Epub 2011 May 8. PMID: 21555200.
- 106) Petit JY, Botteri E, Lohsiriwat V, Rietjens M, De Lorenzi F, Garusi C, Rossetto F, Martella S, Manconi A, Bertolini F, Curigliano G, Veronesi P, Santillo B, Rotmensz N. Locoregional

recurrence risk after lipofilling in breast cancer patients. *Ann Oncol.* 2012 Mar;23(3):582-588. doi: 10.1093/annonc/mdr158. Epub 2011 May 24. PMID: 21610155.

107) Petit JY, Veronesi U, Lohsiriwat V, Rey P, Curigliano G, Martella S, Garusi C, De Lorenzi F, Manconi A, Botteri E, Didier F, Orecchia R, Rietjens M. Nipple-sparing mastectomy--is it worth the risk? *Nat Rev Clin Oncol.* 2011 Oct 25;8(12):742-7. doi: 10.1038/nrclinonc.2011.159. PMID: 22024947.

108) Curigliano G. Immunity and autoimmunity: revising the concepts of response to breast cancer. *Breast.* 2011 Oct;20 Suppl 3:S71-4. doi: 10.1016/S0960-9776(11)70298-3. PMID: 22015297.

109) Curigliano G, Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer. *J Natl Cancer Inst Monogr.* 2011;2011(43):108-10. doi: 10.1093/jncimonographs/lgr038. PMID: 22043054.

110) Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). *J Natl Cancer Inst Monogr.* 2011;2011(43):147-51. doi: 10.1093/jncimonographs/lgr037. PMID: 22043063.

Anno 2012

111) Munzone E, Curigliano G, Burstein HJ, Winer EP, Goldhirsch A. CMF revisited in the 21st century. *Ann Oncol.* 2012 Feb;23(2):305-11. doi: 10.1093/annonc/mdr309. Epub 2011 Jun 29. PMID: 21715566.

112) Curigliano G. New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. *Cancer Treat Rev.* 2012 Jun;38(4):303-10. doi: 10.1016/j.ctrv.2011.06.006. Epub 2011 Jul 18. PMID: 21764517.

113) Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L, Locatelli M, Dalton M, Quintela A, Carvalheira JBC, Manunta S, Mazzarella L, Brollo J, Goldhirsch A. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? *Ann Oncol.* 2012 Mar;23(3):547-555. doi: 10.1093/annonc/mdr382. Epub 2011 Sep 6. PMID: 21896541.

114) Orgera G, Krokidis M, Monfardini L, Arnone P, Bonomo G, Della Vigna P, Curigliano G, Orsi F. Ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in pancreatic metastasis from renal cell carcinoma. *Cardiovasc Intervent Radiol.* 2012 Oct;35(5):1258-61. doi: 10.1007/s00270-011-0291-y. PMID: 22011784.

115) Botteri E, Disalvatore D, Curigliano G, Brollo J, Bagnardi V, Viale G, Orsi F, Goldhirsch A, Rotmensz N. Biopsy of liver metastasis for women with breast cancer: impact on survival. *Breast.* 2012 Jun;21(3):284-8. doi: 10.1016/j.breast.2011.12.014. Epub 2011 Dec 31. PMID: 22212746.

116) Curigliano G, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolé F, Criscitiello C, Goldhirsch A. Targeting the subtypes of breast cancer: rethinking investigational drugs. *Expert Opin Investig Drugs.* 2012 Feb;21(2):191-204. doi: 10.1517/13543784.2012.651456. Epub 2012 Jan 10. PMID: 22229343.

117) Petit JY, Veronesi U, Orecchia R, Curigliano G, Rey PC, Botteri E, Rotmensz N, Lohsiriwat V, Cassilha Kneubil M, Rietjens M. Risk factors associated with recurrence after nipple-sparing

mastectomy for invasive and intraepithelial neoplasia. *Ann Oncol.* 2012 Aug;23(8):2053-2058. doi: 10.1093/annonc/mdr566. Epub 2012 Jan 9. PMID: 22231025.

118) Peccatori FA, Giovannetti E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, Curigliano G, Azim HA Jr, Goldhirsch A, Peters GJ. "The only thing I know is that I know nothing": 5-fluorouracil in human milk. *Ann Oncol.* 2012 Feb;23(2):543-4. doi: 10.1093/annonc/mdr582. PMID: 22275286.

119) Munzone E, Botteri E, Sciandivasci A, Curigliano G, Nolè F, Mastropasqua M, Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. *Breast Cancer Res Treat.* 2012 Jul;134(1):277-82. doi: 10.1007/s10549-012-2040-6. Epub 2012 Apr 1. PMID: 22467243.

120) Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, Pruneri G, Rotmensz N, Curigliano G, Adamoli L, Bocciolone L, Goldhirsch A, Nolè F. Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. *Ann Oncol.* 2012 Nov;23(11):2884-2890. doi: 10.1093/annonc/mds098. Epub 2012 Apr 29. PMID: 22547541.

121) Kneubil MC, Lohsiriwat V, Curigliano G, Brollo J, Botteri E, Rotmensz N, Martella S, Mastropasqua MG, Iera M, Coelho MB, Intra M, Orecchia R, Rey P, Rietjens M, Petit JY. Risk of locoregional recurrence in patients with false-negative frozen section or close margins of retroareolar specimen in nipple-sparing mastectomy. *Ann Surg Oncol.* 2012 Dec;19(13):4117-23. doi: 10.1245/s10434-012-2514-0. Epub 2012 Jul 21. PMID: 22820937.

122) Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, Curigliano G, Colleoni M, Goldhirsch A, Nolè F. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. *Breast J.* 2012 Sep;18(5):470-4. doi: 10.1111/j.1524-4741.2012.01278.x. Epub 2012 Jul 25. PMID: 22827581.

123) Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. *Clin Breast Cancer.* 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001. PMID: 23040002.

124) Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2012 Oct;23 Suppl 7:vii155-66. doi: 10.1093/annonc/mds293. PMID: 22997448.

Anno 2013

125) Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. *Cancer Treat Rev.* 2013 Feb;39(1):44-50. doi:10.1016/j.ctrv.2012.03.009. Epub 2012 Apr 27. PMID: 22541668.

126) Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. *Clin Cancer Res.* 2013 Jan 1;19(1):28-33. doi: 10.1158/1078-0432.CCR-11-2701. Epub 2012 Dec 20. PMID: 23258741.

- 127) Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensch N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. *Eur J Surg Oncol*. 2013 Mar;39(3):260-5. doi: 10.1016/j.ejso.2012.12.004. Epub 2013 Jan 10. PMID: 23313014.
- 128) Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. *Acta Oncol*. 2013 Nov;52(8):1649-56. doi: 10.3109/0284186X.2012.754990. Epub 2013 Jan 17. PMID: 23327413.
- 129) Petit JY, Rietjens M, Botteri E, Rotmensch N, Bertolini F, Curigliano G, Rey P, Garusi C, De Lorenzi F, Martella S, Manconi A, Barbieri B, Veronesi P, Intra M, Brambullo T, Gottardi A, Sommario M, Lomeo G, Iera M, Giovinazzo V, Lohsiriwat V. Evaluation of fat grafting safety in patients with intraepithelial neoplasia: a matched-cohort study. *Ann Oncol*. 2013 Jun;24(6):1479-84. doi: 10.1093/annonc/mds660. Epub 2013 Feb 7. PMID: 23393126.
- 130) Criscitiello C, Curigliano G. HER2 signaling pathway and trastuzumab cardiotoxicity. *Future Oncol*. 2013 Feb;9(2):179-81. doi: 10.2217/fon.12.193. PMID: 23414468.
- 131) Curigliano G. A review of the CTRC-AACR San Antonio Breast Cancer Symposium 2012. *Ecancermedalscience*. 2013;7:291. doi: 10.3332/ecancer.2013.291. Epub 2013 Feb 11. PMID: 23441137; PMCID: PMC3575200.
- 132) Ferri N, Cazzaniga S, Mazzarella L, Curigliano G, Lucchini G, Zerla D, Gandolfi R, Facchetti G, Pellizzoni M, Rimoldi I. Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in Pt(II) complexes on human carcinoma cell lines: a comparative study with cisplatin. *Bioorg Med Chem*. 2013 Apr 15;21(8):2379-2386. doi: 10.1016/j.bmc.2013.01.063. Epub 2013 Feb 5. PMID: 23462712.
- 133) Curigliano G, Criscitiello C, Andrè F, Colleoni M, Di Leo A. Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? *Ecancermedalscience*. 2013 Mar 26;7:299. doi: 10.3332/ecancer.2013.299. PMID: 23589728; PMCID: PMC3622446.
- 134) Brollo J, Kneubil MC, Botteri E, Rotmensch N, Duso BA, Fumagalli L, Locatelli MA, Criscitiello C, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, Curigliano G. Locoregional recurrence in patients with HER2 positive breast cancer. *Breast*. 2013 Oct;22(5):856-62. doi: 10.1016/j.breast.2013.03.010. Epub 2013 May 1. PMID: 23642529.
- 135) Gelao L, Criscitiello C, Fumagalli L, Locatelli M, Manunta S, Esposito A, Minchella I, Goldhirsch A, Curigliano G. Tumour dormancy and clinical implications in breast cancer. *Ecancermedalscience*. 2013 May 21;7:320. doi: 10.3332/ecancer.2013.320. PMID: 23717341; PMCID: PMC3660156.
- 136) Zurrida S, Bagnardi V, Curigliano G, Mastropasqua MG, Orecchia R, Disalvatore D, Greco M, Cataliotti L, D'Aiuto G, Talakhadze N, Goldhirsch A, Viale G. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. *Eur J Cancer*. 2013 Oct;49(15):3083-92. doi: 10.1016/j.ejca.2013.05.007. Epub 2013 Jun 15. PMID: 23777741.
- 137) Curigliano G, Criscitiello C, Gelao L, Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). *Clin Cancer Res*. 2013 Oct 15;19(20):5564-71. doi: 10.1158/1078-0432.CCR-12-3697. Epub 2013 Jul 29. PMID: 23897901.
- 138) Dubsy PC, Curigliano G. Immunotherapy in breast cancer - towards a new understanding of both tumor and host. *Breast Care (Basel)*. 2012 Aug;7(4):258-60. doi: 10.1159/000342629. PMID: 23904826; PMCID: PMC3515787.

- 139) Munzone E, Curigliano G, Colleoni M. Tailoring adjuvant treatments for the individual patient with luminal breast cancer. *Hematol Oncol Clin North Am.* 2013 Aug;27(4):703-14, vii-viii. doi: 10.1016/j.hoc.2013.05.012. Epub 2013 Jun 18. PMID: 23915740.
- 140) Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol.* 2013 Sep;24(9):2206-23. doi: 10.1093/annonc/mdt303. Epub 2013 Aug 4. PMID: 23917950; PMCID: PMC3755334.
- 141) Mazarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S, Curigliano G, Pelicci PG. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. *Eur J Cancer.* 2013 Nov;49(17):3588-97. doi: 10.1016/j.ejca.2013.07.016. Epub 2013 Aug 15. PMID: 23953055.
- 142) Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. *Breast.* 2013 Oct;22(5):650-6. doi: 10.1016/j.breast.2013.07.037. Epub 2013 Aug 17. PMID: 23958375.
- 144) Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. *Lancet Oncol.* 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8. Epub 2013 Aug 19. PMID: 23965225.
- 144) Curigliano G, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Best management of locally advanced inoperable breast cancer. *EJC Suppl.* 2013 Sep;11(2):289-90. doi: 10.1016/j.ejcsup.2013.07.052. PMID: 26217148; PMCID: PMC4041552.
- 145) Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, Curigliano G, Extermann M, Lichtman SM, Ballman K, Cohen HJ, Muss H, Wedding U. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology-- International Society Of Geriatric Oncology position article. *J Clin Oncol.* 2013 Oct 10;31(29):3711-8. doi: 10.1200/JCO.2013.49.6125. Epub 2013 Sep 9. PMID: 24019549.
- 146) Curigliano G, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. *Breast.* 2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. PMID: 24074802.
- 147) Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. *Curr Opin Oncol.* 2013 Nov;25(6):602-8. doi: 10.1097/CCO.000000000000020. PMID: 24076578.
- Anno 2014
- 148) Criscitiello C, Disalvatore D, Santangelo M, Rotmensz N, Bazolli B, Maisonneuve P, Goldhirsch A, Curigliano G. No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis. *Cancer Epidemiol Biomarkers Prev.* 2014 Jan;23(1):215-7. doi: 10.1158/1055-9965.EPI-13-1041. Epub 2013 Oct 28. PMID: 24165579.
- 149) Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A, Curigliano G. Monitoring tumor-derived cell-free DNA in patients with solid

tumors: clinical perspectives and research opportunities. *Cancer Treat Rev.* 2014 Jun;40(5):648-55. doi: 10.1016/j.ctrv.2013.10.003. Epub 2013 Oct 23. PMID: 24184333.

150) Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. A meta- analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. *Eur J Cancer.* 2014 Jan;50(2):277-89. doi: 10.1016/j.ejca.2013.10.004. Epub 2013 Nov 21. PMID: 24269135.

151) Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. *Breast.* 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4. PMID: 24314620.

152) Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Adamoli L, Goldhirsch A, Curigliano G. Immune approaches to the treatment of breast cancer, around the corner? *Breast Cancer Res.* 2014 Feb 25;16(1):204. doi: 10.1186/bcr3620. PMID: 25774617; PMCID: PMC3978442.

153) Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor- infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol.* 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: *Ann Oncol.* 2015 Jul;26(7):1518. PMID: 24401929; PMCID: PMC3933248.

154) Ballman KV, Mauer M, Wedding U, Mohile SG, Muss H, Extermann M, Luciani A, Cohen HJ, Hurria A, Lichtman SM, Curigliano G, Wildiers H. Reply to L.K. Mell et al. *J Clin Oncol.* 2014 Apr 1;32(10):1090-1. doi: 10.1200/JCO.2013.54.5236. Epub 2014 Feb 18. PMID: 24550420.

155) Cortés J, Curigliano G, Diéras V. Expert perspectives on biosimilar monoclonal antibodies in breast cancer. *Breast Cancer Res Treat.* 2014 Apr;144(2):233-9. doi: 10.1007/s10549-014-2879-9. Epub 2014 Feb 23. PMID: 24562824; PMCID: PMC3949011.

156) Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". *Toxins (Basel).* 2014 Mar 3;6(3):914-33. doi: 10.3390/toxins6030914. PMID: 24594636; PMCID: PMC3968368.

157) Criscitiello C, Gelao L, Viale G, Esposito A, Curigliano G. Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. *Expert Opin Investig Drugs.* 2014 May;23(5):599-610. doi: 10.1517/13543784.2014.895323. Epub 2014 Mar 5. PMID: 24597540.

158) Curigliano G, Criscitiello C. Successes and limitations of targeted cancer therapy in breast cancer. *Prog Tumor Res.* 2014;41:15-35. doi: 10.1159/000355896. Epub 2014 Feb 17. PMID: 24727984.

159) Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, Curigliano G. Dendritic cell-based vaccines: clinical applications in breast cancer. *Immunotherapy.* 2014;6(3):349-60. doi: 10.2217/imt.13.169. PMID: 24762078.

160) Leighl NB, Curigliano G. Early-stage lung cancer--what do the experts recommend? *Ann Oncol.* 2014 Aug;25(8):1451-3. doi: 10.1093/annonc/mdu220. Epub 2014 Jun 11. PMID: 24920789.



- 161) Curigliano G, Perez EA. Immunoscoring breast cancer: TILs remember what they target. *Ann Oncol*. 2014 Aug;25(8):1455-6. doi: 10.1093/annonc/mdu227. Epub 2014 Jun 20. PMID: 24950980.
- 162) Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, Pruneri G, Mastropasqua MG, Luini A, Bassi F, Pagani G, Viale G, Goldhirsch A. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. *Breast Cancer Res*. 2014 Jun 20;16(3):R65. doi: 10.1186/bcr3679. PMID: 24951027; PMCID: PMC4095689.
- 163) Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. *Breast Cancer Res*. 2014;16(2):205. doi: 10.1186/bcr3630. PMID: 25032257; PMCID: PMC4052940.
- 164) Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. *Ann Oncol*. 2014 Oct;25(10):1979-1987. doi: 10.1093/annonc/mdu364. Epub 2014 Jul 28. PMID: 25070545.
- 165) Esposito A, Criscitiello C, Salè EO, Curigliano G. Optimal adjuvant chemotherapy in breast cancer: selection of agents. *Expert Rev Clin Pharmacol*. 2014 Sep;7(5):605-11. doi: 10.1586/17512433.2014.945429. Epub 2014 Aug 1. PMID: 25080998.
- 166) Criscitiello C, Viale G, Esposito A, Curigliano G. Dinaciclib for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2014 Sep;23(9):1305-12. doi: 10.1517/13543784.2014.948152. Epub 2014 Aug 8. PMID: 25107301.
- 167) Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stërba J, Villalba M, Bertolini F. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. *Ecanermedicalscience*. 2014 Sep 9;8:463. doi: 10.3332/ecancer.2014.463. PMID: 25228919; PMCID: PMC4162678.
- 168) Lammers P, Criscitiello C, Curigliano G, Jacobs I. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. *Pharmaceuticals (Basel)*. 2014 Sep 17;7(9):943-53. doi: 10.3390/ph7090943. PMID: 25232798; PMCID: PMC4190498.
- 169) Curigliano G. 'Tu quoque Brute fili mihi!' (Julius Caesar, Ides of March, 44 BC): role of tumor microenvironment and immune system in breast cancer progression. *Curr Opin Oncol*. 2014 Nov;26(6):543-4. doi: 10.1097/CCO.000000000000123. PMID: 25279960.
- 170) Criscitiello C, Esposito A, Curigliano G. Tumor-stroma crosstalk: targeting stroma in breast cancer. *Curr Opin Oncol*. 2014 Nov;26(6):551-5. doi: 10.1097/CCO.000000000000122. PMID: 25279962.
- 171) Aurilio G, Bagnardi V, Graffeo R, Nolè F, Petit JY, Locatelli M, Martella S, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer? *Anticancer Res*. 2014 Nov;34(11):6677-83. PMID: 25368274.
- 172) Curigliano G. From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014.

Ecancermedalscience. 2014 Oct 16;8:472. doi: 10.3332/ecancer.2014.472. PMID: 25374620; PMCID: PMC4203474.

Anno 2015

173) Locatelli M, Criscitiello C, Esposito A, Minchella I, Goldhirsch A, Cipolla C, Curigliano G. QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. *Target Oncol.* 2015 Mar;10(1):27-43. doi: 10.1007/s11523-014-0325-x. Epub 2014 Jun 27. PMID: 24970120.

174) Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, Curigliano G. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. *Cancer Treat Rev.* 2015 Feb;41(2):61-8. doi: 10.1016/j.ctrv.2014.12.001. Epub 2014 Dec 8. PMID: 25499997.

175) Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. *Ann Oncol.* 2015 Apr;26(4):682-687. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18. PMID: 25600567.

176) Socinski MA, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D. Clinical considerations for the development of biosimilars in oncology. *MAbs.* 2015;7(2):286-93. doi: 10.1080/19420862.2015.1008346. PMID: 25621390; PMCID: PMC4623533.

177) Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, Criscitiello C, Viale G, Goldhirsch A. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. *Breast.* 2015 Jun;24(3):263-71. doi: 10.1016/j.breast.2015.02.036. Epub 2015 Mar 12. PMID: 25772326.

178) Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart M. New approaches for improving outcomes in breast cancer in Europe. *Breast.* 2015 Aug;24(4):321-30. doi: 10.1016/j.breast.2015.03.001. Epub 2015 Mar 31. PMID: 25840656.

179) Ferri N, Facchetti G, Pellegrino S, Ricci C, Curigliano G, Pini E, Rimoldi I. Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. *Bioorg Med Chem.* 2015 May 15;23(10):2538-47. doi: 10.1016/j.bmc.2015.03.044. Epub 2015 Mar 25. PMID: 25865132.

180) Aurilio G, Bagnardi V, Nolè F, Pruneri G, Graffeo R, Petit JY, Cullurà D, Martella S, Locatelli M, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. *Clin Breast Cancer.* 2015 Oct;15(5):e237-41. doi: 10.1016/j.clbc.2015.03.009. Epub 2015 Mar 24. PMID: 25908443.

181) Esposito A, Criscitiello C, Curigliano G. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. *Ecancermedalscience.* 2015 Mar 31;9:518. doi: 10.3332/ecancer.2015.518. PMID: 25932042; PMCID: PMC4404037.

182) Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol.* 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4. PMID: 25939896;

PMCID: PMC4511219.

183) Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation*. 2015 Jun 2;131(22):1981-8. doi: 10.1161/CIRCULATION.AHA.114.013777. Epub 2015 May 6. PMID: 25948538.

184) Curigliano G, Goldhirsch A. De-escalation attempts for adjuvant trastuzumab: longer beats shorter. *Ann Oncol*. 2015 Jul;26(7):1275-6. doi: 10.1093/annonc/mdv247. Epub 2015 May 22. PMID: 26002609.

185) Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG- NABCG collaboration. *Ann Oncol*. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. PMID: 26019189; PMCID: PMC4804123.

186) Esposito A, Criscitiello C, Curigliano G. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. *J Natl Cancer Inst Monogr*. 2015 May;2015(51):51-5. doi: 10.1093/jncimonographs/lgv012. PMID: 26063887.

187) Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). *J Natl Cancer Inst Monogr*. 2015 May;2015(51):90-6. doi: 10.1093/jncimonographs/lgv023. PMID: 26063896; PMCID: PMC5009414.

188) Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. Erratum for: *Ann Oncol*. 2014 Mar;25(3):611-8. PMID: 26109735; PMCID: PMC5266091.

189) Santangelo ML, Criscitiello C, Renda A, Federico S, Curigliano G, Dodaro C, Scotti A, Tammaro V, Calogero A, Riccio E, Pisani A, Carlomagno N. Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. *Biomed Res Int*. 2015;2015:183523. doi: 10.1155/2015/183523. Epub 2015 Jun 22. PMID: 26185750; PMCID: PMC4491567.

190) Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Mod Pathol*. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24. PMID: 26205180.

- 191) Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? *Eur J Surg Oncol*. 2015 Oct;41(10):1288-92. doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. PMID: 26238477.
- 192) Nailor A, Dejana E, Reynolds AR, Punwani S, Curigliano G, Bertolini F, Shah M, Danesi R, Kerbel R, McVie G. Lessons from the first ecancer symposium on angiogenesis in gastric cancer. *Ecancermedalscience*. 2015 Jul 21;9:553. doi: 10.3332/ecancer.2015.553. PMID: 26284117; PMCID: PMC4531128.
- 193) Criscitiello C, Curigliano G. Immunotherapy of Breast Cancer. *Prog Tumor Res*. 2015;42:30-43. doi: 10.1159/000437183. Epub 2015 Sep 4. PMID: 26377084.
- 194) Esposito A, Criscitiello C, Gelao L, Pravettoni G, Locatelli M, Minchella I, Di Leo M, Liuzzi R, Milani A, Massaro M, Curigliano G. Mechanisms of anorexia-cachexia syndrome and rationale for treatment with selective ghrelin receptor agonist. *Cancer Treat Rev*. 2015 Nov;41(9):793-7. doi: 10.1016/j.ctrv.2015.09.002. Epub 2015 Sep 11. PMID: 26386985.
- 195) Criscitiello C, Esposito A, De Placido S, Curigliano G. Targeting fibroblast growth factor receptor pathway in breast cancer. *Curr Opin Oncol*. 2015 Nov;27(6):452-6. doi: 10.1097/CCO.0000000000000224. PMID: 26397764.
- 196) Esposito A, Criscitiello C, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. *Curr Opin Oncol*. 2015 Nov;27(6):445-51. doi: 10.1097/CCO.0000000000000225. PMID: 26447875.
- Anno 2016
- 197) Curigliano G, Valagussa P, Veronesi U, Gianni L. The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine. *Ann Oncol*. 2016 Jan;27(1):6-8. doi: 10.1093/annonc/mdv565. Epub 2015 Nov 23. PMID: 26598541.
- 198) Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. *Pharmacol Ther*. 2016 Jan;157:120-4. doi: 10.1016/j.pharmthera.2015.11.007. Epub 2015 Nov 23. PMID: 26615782.
- 199) Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Civelli M, Lamantia G, Colombo N, Cipolla CM, Veglia F, Fiorentini C, Curigliano G. Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy". *Circulation*. 2016 Jan 26;133(4):e363. doi: 10.1161/CIRCULATIONAHA.115.018780. PMID: 26811280.
- 200) Pravettoni G, Mazzocco K, Gorini A, Curigliano G. Understanding cognitive processes behind acceptance or refusal of phase I trials. *Crit Rev Oncol Hematol*. 2016 Apr;100:69-73. doi: 10.1016/j.critrevonc.2016.01.023. Epub 2016 Jan 23. PMID: 26852078.
- 201) Cairns L, Curigliano G. Highlights from the 38th SABCS annual meeting, 8th-12th December 2015, San Antonio, USA. *Ecancermedalscience*. 2016 Feb 2;10:618. doi: 10.3332/ecancer.2016.618. PMID: 26913069; PMCID: PMC4754120.
- 202) Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA Cancer J Clin*. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. PMID: 26919165.
- 203) Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. *Breast*

- Cancer Res Treat. 2016 Apr;156(2):301-10. doi: 10.1007/s10549-016-3750-y. Epub 2016 Mar 14. PMID: 26975189.
- 204) Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. *Breast Cancer Res Treat.* 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18. PMID: 26993131.
- 205) Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J. Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. *J Card Fail.* 2016 Jun;22(6):465-71. doi: 10.1016/j.cardfail.2016.03.012. Epub 2016 Mar 30. PMID: 27038642.
- 206) Criscitiello C, Bagnardi V, Esposito A, Gelao L, Santillo B, Viale G, Rotmensz N, Goldhirsch A, Curigliano G. Impact of autoimmune diseases on outcome of patients with early breast cancer. *Oncotarget.* 2016 Aug 9;7(32):51184-51192. doi: 10.18632/oncotarget.9966. PMID: 27323400; PMCID: PMC5239468.
- 207) Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. *Breast.* 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. Epub 2016 Jun 20. PMID: 27336726.
- 208) Curigliano G, O'Connor DP, Rosenberg JA, Jacobs I. Biosimilars: Extrapolation for oncology. *Crit Rev Oncol Hematol.* 2016 Aug;104:131-7. doi: 10.1016/j.critrevonc.2016.06.002. Epub 2016 Jun 15. PMID: 27354233.
- 209) Criscitiello C, Bagnardi V, Viale G, Disalvatore D, Rotmensz N, Esposito A, Goldhirsch A, Curigliano G. HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. *Anticancer Res.* 2016 Jul;36(7):3537-40. PMID: 27354620.
- 210) Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancellato G, Munzone E, Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat.* 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2. PMID: 27372069; PMCID: PMC4977583.
- 211) Tsiatas M, Mountzios G, Curigliano G. Future perspectives in cancer immunotherapy. *Ann Transl Med.* 2016 Jul;4(14):273. doi: 10.21037/atm.2016.07.14. PMID: 27563660; PMCID: PMC4971381.
- 212) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Barón-Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee

for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur J Heart Fail.* 2017 Jan;19(1):9-42. doi: 10.1002/ejhf.654. Epub 2016 Aug 27. PMID: 27565769.

213) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J.* 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211. Epub 2016 Aug 26. Erratum in: *Eur Heart J.* 2016 Dec 24;: PMID: 27567406.

214) Migali C, Milano M, Trapani D, Criscitiello C, Esposito A, Locatelli M, Minchella I, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Ther Adv Med Oncol.* 2016 Sep;8(5):360-74. doi: 10.1177/1758834016658423. Epub 2016 Jul 10. PMID: 27583028; PMCID: PMC4981297.

215) Curigliano G. Being more precise in assessing the value of precision medicine in breast cancer. *Breast.* 2016 Oct;29:186-7. doi: 10.1016/j.breast.2016.08.010. PMID: 27600532.

216) Criscitiello C, Esposito A, Trapani D, Curigliano G. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev.* 2016 Nov;50:205-207. doi: 10.1016/j.ctrv.2016.09.019. Epub 2016 Oct 6. PMID: 27744144.

217) D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, Criscitiello C, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfrancone L. RNAi screens identify CHD4 as an essential gene in breast cancer growth. *Oncotarget.* 2016 Dec 6;7(49):80901-80915. doi: 10.18632/oncotarget.12646. PMID: 27779108; PMCID: PMC5348363.

218) Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? *Eur J Surg Oncol.* 2016 Dec;42(12):1780-1786. doi: 10.1016/j.ejso.2016.10.011. Epub 2016 Oct 29. PMID: 27825710. Anno 2017

219) Toesca A, Peradze N, Manconi A, Galimberti V, Intra M, Colleoni M, Bonanni B, Curigliano G, Rietjens M, Viale G, Sacchini V, Veronesi P. Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. *Breast.* 2017 Feb;31:51-56. doi: 10.1016/j.breast.2016.10.009. Epub 2016 Nov 2. PMID: 27810700; PMCID: PMC5278881.

220) Curigliano G, Criscitiello C, Esposito A, Pruneri G. Over-using chemotherapy in the adjuvant setting. *Breast.* 2017 Feb;31:303-308. doi: 10.1016/j.breast.2016.11.011. Epub 2016 Nov 17. PMID: 27866835.

221) Curigliano G, Cardoso F, Costa A, Galimberti V, Goldhirsch A, Pelicci PG, Veronesi P, Viale G, Orecchia R. From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. *Breast.* 2017 Feb;31:241-243. doi: 10.1016/j.breast.2016.11.013. Epub 2016 Nov 19. PMID: 27876474.

222) Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. *Oncotarget.* 2017 Jan 10;8(2):2320-2328. doi: 10.18632/oncotarget.13727. PMID: 27906684; PMCID: PMC5356802.

223) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N,

Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). *Breast*. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5. Erratum in: *Breast*. 2017 Apr;32:269-270. PMID: 27927580.

224) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [*Breast* 31 (February 2017) 244-259]. *Breast*. 2017 Apr;32:269-270. doi: 10.1016/j.breast.2017.01.001. Epub 2017 Jan 18. Erratum for: *Breast*. 2017 Feb;31:244-259. PMID: 28109648.

225) Esposito A, Criscitiello C, Trapani D, Curigliano G. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. *Curr Oncol Rep*. 2017 Jan;19(1):1. doi: 10.1007/s11912-017-0564-y. PMID: 28110461.

226) Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching PA, Campone M, Bachelot T, Krivorotko P, Chan S, Ferro A, Schwartzberg L, Gillet M, De Sousa Alves PM, Wascotte V, Lehmann FF, Goss P. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. *Breast Cancer Res Treat*. 2017 Apr;162(3):479-488. doi: 10.1007/s10549-017-4130-y. Epub 2017 Feb 7. PMID: 28176175; PMCID: PMC5332485.

227) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Ann Oncol*. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. Erratum in: *Ann Oncol*. 2017 Dec 1;28(12):3111. PMID: 28177437; PMCID: PMC5378224.

228) Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R, Generali D. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. *Eur J Cancer*. 2017 Apr;75:245-258. doi: 10.1016/j.ejca.2017.01.026. Epub 2017 Feb 24. PMID: 28242502.

229) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Ann Oncol*. 2017 Dec 1;28(12):3111. doi:

10.1093/annonc/mdx036. Erratum for: *Ann Oncol*. 2017 Jan 1;28(1):16-33. PMID: 28327998; PMCID: PMC5834023.

230) Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. *Oncoimmunology*. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. PMID: 28344865; PMCID: PMC5353940.

231) Meattini I, Curigliano G, Terziani F, Becherini C, Airoidi M, Allegrini G, Amoroso D, Barni S, Bengala C, Guarneri V, Marchetti P, Martella F, Piovano P, Vannini A, Desideri I, Tarquini R, Galanti G, Barletta G, Livi L. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. *Med Oncol*. 2017 May;34(5):75. doi: 10.1007/s12032-017-0938-x. Epub 2017 Mar 31. PMID: 28364270.

232) Curigliano G, Criscitiello C, Esposito A, Intra M, Minucci S. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. *Expert Opin Drug Metab Toxicol*. 2017 May;13(5):575-581. doi: 10.1080/17425255.2017.1318848. Epub 2017 Apr 21. PMID: 28395543.

233) Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensch N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. *Ann Oncol*. 2017 Feb 1;28(2):321-328. doi: 10.1093/annonc/mdw623. PMID: 28426105.

234) Curigliano G, Goldhirsch A. Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection. *Ann Oncol*. 2017 Mar 1;28(3):441-443. doi: 10.1093/annonc/mdx016. PMID: 28426119.

235) Gligorov J, Curigliano G, Müller V, Knoop A, Jenkins V, Verma S, Osborne S, Lauer S, Machackova Z, Fallowfield L, Pivot X. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. *Breast*. 2017 Aug;34:89-95. doi: 10.1016/j.breast.2017.05.004. Epub 2017 May 23. PMID: 28549309.

236) Curigliano G, Criscitiello C. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. *J Clin Oncol*. 2017 Aug 10;35(23):2600-2603. doi: 10.1200/JCO.2017.72.5960. Epub 2017 Jun 29. PMID: 28661760.

237) Trapani D, Esposito A, Criscitiello C, Mazzarella L, Locatelli M, Minchella I, Minucci S, Curigliano G. Entinostat for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2017 Aug;26(8):965-971. doi: 10.1080/13543784.2017.1353077. Epub 2017 Jul 24. PMID: 28718331.

238) Curigliano G, Cardoso F. Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe! *Breast*. 2017 Dec;36:86-88. doi: 10.1016/j.breast.2017.07.010. Epub 2017 Jul 19. PMID: 28734762.

239) Viale G, Trapani D, Curigliano G. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. *Biomed Res Int*. 2017;2017:4719194. doi: 10.1155/2017/4719194. Epub 2017 Jul 10. PMID: 28770222; PMCID: PMC5523547.

240) Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik



S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Adv Anat Pathol*. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.000000000000162. PMID: 28777142; PMCID: PMC5564448.

241) Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. *Adv Anat Pathol*. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.000000000000161. PMID: 28777143; PMCID: PMC5638696.

242) Curigliano G. How to Achieve Optimal Care in Early Breast Cancer with 'Less' or 'More' Treatment. *Breast Care (Basel)*. 2017 Jul;12(3):136-137. doi: 10.1159/000478652. Epub 2017 Jun 27. PMID: 28785179; PMCID: PMC5527166.

243) Locatelli MA, Curigliano G, Eniu A. Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. *Breast Care (Basel)*. 2017 Jul;12(3):152-158. doi: 10.1159/000478087. Epub 2017 Jun 27. PMID: 28785182; PMCID: PMC5527164.

244) Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Paganì O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the

Primary Therapy of Early Breast Cancer 2017. *Ann Oncol.* 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308. Erratum in: *Ann Oncol.* 2018 Oct 1;29(10):2153. Erratum in: *Ann Oncol.* 2019 Jan 9;: Erratum in: *Ann Oncol.* 2019 Jul;30(7):1181. PMID: 28838210; PMCID: PMC6246241.

245) Criscitiello C, Viale G, Curigliano G. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. *Curr Opin Oncol.* 2017 Nov;29(6):428-433. doi: 10.1097/CCO.0000000000000401. PMID: 28872469.

246) Locatelli M, Curigliano G. Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures. *Curr Opin Oncol.* 2017 Nov;29(6):411-427. doi: 10.1097/CCO.0000000000000406. PMID: 28914645.

247) Bellomi M, De Piano F, Ancona E, Lodigiani AF, Curigliano G, Raimondi S, Preda L. Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases. *Eur J Radiol.* 2017 Oct;95:96-101. doi: 10.1016/j.ejrad.2017.08.001. Epub 2017 Aug 4. PMID: 28987705.

248) Roviello G, Andre F, Venturini S, Pistilli B, Curigliano G, Cristofanilli M, Rosellini P, Generali D. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. *Eur J Cancer.* 2017 Nov;86:257-265. doi: 10.1016/j.ejca.2017.09.018. Epub 2017 Oct 19. PMID: 29055841.

249) de Melo Gagliato D, Cortes J, Curigliano G, Loi S, Denkert C, Perez-Garcia J, Holgado E. Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. *Biochim Biophys Acta Rev Cancer.* 2017 Dec;1868(2):527-537. doi: 10.1016/j.bbcan.2017.10.003. Epub 2017 Oct 20. PMID: 29061314.

250) Criscitiello C, Bagnardi V, Pruneri G, Vingiani A, Esposito A, Rotmensz N, Curigliano G. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. *Eur J Cancer.* 2017 Dec;87:164-171. doi: 10.1016/j.ejca.2017.10.011. Epub 2017 Nov 15. PMID: 29154173.

Anno 2018

251) Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. *Ann Oncol.* 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. PMID: 29045519; PMCID: PMC6246427.

252) Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. *Ann Oncol.* 2018 Jan 1;29(1):162-169. doi: 10.1093/annonc/mdx691. PMID: 29077781.

253) Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume

BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja E. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive

breast cancer: Results from Neo-ALTTO. *Eur J Cancer*. 2018 Jan;89:42-48. doi: 10.1016/j.ejca.2017.10.036. Epub 2017 Dec 8. PMID: 29227816; PMCID: PMC5777154.

254) Botteri E, Krendyukov A, Curigliano G. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients. *Eur J Cancer*. 2018 Jan;89:49-55. doi: 10.1016/j.ejca.2017.10.034. Epub 2017 Dec 8. PMID: 29227817.

255) Duso BA, Trapani D, Viale G, Criscitiello C, D'Amico P, Belli C, Mazzarella L, Locatelli M, Minchella I, Curigliano G. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. *Expert Opin Pharmacother*. 2018 Feb;19(3):299-305. doi: 10.1080/14656566.2018.1429407. Epub 2018 Jan 22. PMID: 29355400.

256) Cardoso F, Curigliano G. A rude awakening from tumour cells. *Nature*. 2018 Feb;554(7690):35-36. doi: 10.1038/d41586-018-01140-z. PMID: 32094835.

257) Cardoso F, Curigliano G. A rude awakening from tumour cells. *Nature*. 2018 Feb 1;554(7690):35-36. doi: 10.1038/d41586-018-01140-z. PMID: 29388969.

258) Mazzarella L, Curigliano G. A new approach to assess drug sensitivity in cells for novel drug discovery. *Expert Opin Drug Discov*. 2018 Apr;13(4):339-346. doi: 10.1080/17460441.2018.1437136. Epub 2018 Feb 7. PMID: 29415581.

259) Criscitiello C, Viale G, Curigliano G, Goldhirsch A. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. *Breast Cancer (Dove Med Press)*. 2018 Jan 30;10:23-29. doi: 10.2147/BCTT.S134641. Erratum in: *Breast Cancer (Dove Med Press)*. 2018 Mar 16;10 :51. PMID: 29430197; PMCID: PMC5796458.

260) Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. *Lancet Oncol*. 2018 Mar;19(3):323-336. doi: 10.1016/S1470-2045(18)30083-4. Epub 2018 Feb 9. PMID: 29433963.

261) Curigliano G. Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care? *Lancet Oncol*. 2018 Apr;19(4):434-436. doi: 10.1016/S1470-2045(18)30129-3. Epub 2018 Feb 28. Erratum in: *Lancet Oncol*. 2018 Apr;19(4):e184. PMID: 29501365.

262) Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F, Curigliano G. Targeting the microenvironment in solid tumors. *Cancer Treat Rev*. 2018 Apr;65:22-32. doi: 10.1016/j.ctrv.2018.02.004. Epub 2018 Feb 22. PMID: 29502037.

263) Mazzarella L, Guida A, Curigliano G. Cetuximab for treating non-small cell lung cancer. *Expert Opin Biol Ther*. 2018 Apr;18(4):483-493. doi: 10.1080/14712598.2018.1452906. PMID: 29534625.

264) Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM; ICOS-ONE Study Investigators. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding

prevention with enalapril: The International CardioOncology Society- one trial. *Eur J Cancer*. 2018 May;94:126-137. doi: 10.1016/j.ejca.2018.02.005. Epub 2018 Mar 20. PMID: 29567630.

265) Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Paganì O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol*. 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. Erratum for: *Ann Oncol*. 2017 Aug 1;28(8):1700-1712. PMID: 29733336; PMCID: PMC6887963.

266) Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. *Eur J Cancer*. 2018 Jul;97:1-6. doi: 10.1016/j.ejca.2018.03.023. Epub 2018 May 17. PMID: 29734046.

267) Curigliano G. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. *Semin Cancer Biol*. 2018 Oct;52(Pt 2):253-258. doi: 10.1016/j.semcancer.2018.05.004. Epub 2018 May 27. PMID: 29775688.

268) Cardoso F, Curigliano G. The PROMISE to increase precision in adjuvant therapy for early breast cancer: To "Type" or to "Print"? *NPJ Breast Cancer*. 2018 May 22;4:12. doi: 10.1038/s41523-018-0064-8. PMID: 29845111; PMCID: PMC5964184.

269) Janjigian YY, Bissig M, Curigliano G, Coppola J, Latymer M. Talking to patients about biosimilars. *Future Oncol*. 2018 Oct;14(23):2403-2414. doi: 10.2217/fon-2018-0044. Epub 2018 Jun 1. PMID: 29856243.

270) Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor- positive, HER2-negative metastatic breast cancer: TREN trial. *Ann Oncol*. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214. PMID: 29893790; PMCID: PMC6454527.

271) Calabrò MG, Curigliano G. Edoxaban for Cancer-Associated Venous Thromboembolism. *N Engl J Med*. 2018 Jul 5;379(1):93. doi: 10.1056/NEJMc1806646. PMID: 29975029.

272) Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghier NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Paganì O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)<sup>+</sup>. *Ann Oncol*. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. PMID: 30032243; PMCID: PMC7360146.

273) Curigliano G. Inflammatory breast cancer and chest wall disease: The oncologist perspective. *Eur J Surg Oncol*. 2018 Aug;44(8):1142-1147. doi: 10.1016/j.ejso.2018.05.019. Epub 2018 May 22. PMID: 30032791.

- 274) Rubio IT, Wyld L, Cardoso F, Curigliano G, Kovacs T, Poortmans P, Cortes J. Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back? *Breast*. 2018 Oct;41:133-135. doi: 10.1016/j.breast.2018.07.008. Epub 2018 Jul 23. PMID: 30056250.
- 275) Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. *Oncotarget*. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. PMID: 30167089; PMCID: PMC6114962.
- 276) Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, Del Mastro L, Paluch-Shimon S, Loibl S, Partridge AH, Demeestere I, Azim HA Jr, Peccatori FA. The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. *Breast*. 2018 Dec;42:41-49. doi: 10.1016/j.breast.2018.08.099. Epub 2018 Aug 22. PMID: 30170202.
- 277) Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A; International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol*. 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sep 5. PMID: 30196031.
- 278) Hofstädter-Thalmann E, Dafni U, Allen T, Arnold D, Banerjee S, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Report on the status of women occupying leadership roles in oncology. *ESMO Open*. 2018 Sep 21;3(6):e000423. doi: 10.1136/esmoopen-2018-000423. PMID: 30273418; PMCID: PMC6157529.
- 279) Banerjee S, Dafni U, Allen T, Arnold D, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Hofstädter-Thalmann E, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. *ESMO Open*. 2018 Sep 21;3(6):e000422. doi: 10.1136/esmoopen-2018-000422. PMID: 30273420; PMCID: PMC6157518.
- 280) Curigliano G. Targeting DNA Repair. *Handb Exp Pharmacol*. 2018;249:161-180. doi: 10.1007/164\_2017\_31. PMID: 30341723.
- 281) Curigliano G. Cancer Evolution as the New Frontier of Precision Medicine. *Handb Exp Pharmacol*. 2018;249:289-297. doi: 10.1007/164\_2018\_147. PMID: 30406442.
- 282) Belli C, Zuin M, Mazzarella L, Trapani D, D'Amico P, Guerini-Rocco E, Achutti Duso B, Curigliano G. Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. *Crit Rev Oncol Hematol*. 2018 Dec;132:125-129. doi: 10.1016/j.critrevonc.2018.09.019. Epub 2018 Oct 3. PMID: 30447917.
- Anno 2019
- 283) Esposito A, Viale G, Criscitiello C, Curigliano G. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. *Expert Rev Clin Pharmacol*. 2019 Jan;12(1):9-16. doi: 10.1080/17512433.2019.1552134. Epub 2018 Dec 4. PMID: 30466330.
- 284) Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. *Ann Oncol*. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517. PMID: 30475950.

- 285) Zucchetti B, Shimada AK, Katz A, Curigliano G. The role of histone deacetylase inhibitors in metastatic breast cancer. *Breast*. 2019 Feb;43:130-134. doi: 10.1016/j.breast.2018.12.001. Epub 2018 Dec 6. PMID: 30553187.
- 286) Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. *Ann Oncol*. 2019 Feb 1;30(2):236-242. doi: 10.1093/annonc/mdy547. PMID: 30590484.
- 287) Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol*. 2019 Jul 1;30(7):1181. doi: 10.1093/annonc/mdy537. Erratum for: *Ann Oncol*. 2017 Aug 1;28(8):1700-1712. PMID: 30624592; PMCID: PMC6637369.
- 288) Shah RR, Curigliano G. Safety of Novel Targeted Therapies in Oncology. *Drug Saf*. 2019 Feb;42(2):157-158. doi: 10.1007/s40264-018-0770-z. PMID: 30649739.
- 289) Curigliano G, Shah RR. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. *Drug Saf*. 2019 Feb;42(2):247-262. doi: 10.1007/s40264-018-0778-4. PMID: 30649751.
- 290) Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. *Crit Rev Oncol Hematol*. 2019 Jan;133:171-182. doi: 10.1016/j.critrevonc.2018.11.008. Epub 2018 Nov 26. PMID: 30661654.
- 291) Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R. Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. *Cancer Treat Rev*. 2019 Mar;74:21-28. doi: 10.1016/j.ctrv.2019.01.006. Epub 2019 Jan 19. Erratum in: *Cancer Treat Rev*. 2019 Dec;81:101913. PMID: 30685576.
- 292) Cardoso MJ, Wyld L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Biganzoli L. EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. *Breast*. 2019 Apr;44:90-93. doi: 10.1016/j.breast.2019.01.011. Epub 2019 Jan 26. Erratum in: *Breast*. 2019 Dec;48:102. PMID: 30703669.
- 293) Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. *Lancet Oncol*. 2019 Mar;20(3):371-382. doi: 10.1016/S1473-2045(18)30812-X. Epub 2019 Feb 11. PMID: 30765258.
- 294) Criscitiello C, Viale G, Curigliano G. Peptide vaccines in early breast cancer. *Breast*. 2019 Apr;44:128-134. doi: 10.1016/j.breast.2019.02.003. Epub 2019 Feb 7. PMID: 30769238.
- 295) Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with

trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). *Ann Oncol.* 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. PMID: 30796821.

296) Belli C, Duso BA, Ferraro E, Curigliano G. Homologous recombination deficiency in triple negative breast cancer. *Breast.* 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20. PMID: 30818144.

297) Tarantino P, Curigliano G. Defining the immunogram of breast cancer: a focus on clinical trials. *Expert Opin Biol Ther.* 2019 May;19(5):383-385. doi: 10.1080/14712598.2019.1598372. Epub 2019 Apr 1. PMID: 30892954.

298) Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I. Knowledge, attitudes and practice of physicians towards fertility and pregnancy- related issues in youngBRCA-mutated breast cancer patients. *Reprod Biomed Online.* 2019 May;38(5):835-844. doi: 10.1016/j.rbmo.2018.11.031. Epub 2019 Jan 10. PMID: 30914152.

299) Esposito A, Viale G, Curigliano G. Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review. *JAMA Oncol.* 2019 Sep 1;5(9):1347-1354. doi: 10.1001/jamaoncol.2019.0034. PMID: 30920609.

300) Marra A, Curigliano G. T-cell bispecific antibodies to bypass MHC class I loss in breast cancer. *Ann Oncol.* 2019 Jun 1;30(6):877-879. doi: 10.1093/annonc/mdz115. PMID: 30938431.

301) Elgendy M, Cirò M, Hosseini A, Weizmann J, Mazzarella L, Ferrari E, Cazzoli R, Curigliano G, DeCensi A, Bonanni B, Budillon A, Pelicci PG, Janssens V, Ogris M, Baccarini M, Lanfrancone L, Weckwerth W, Foiani M, Minucci S. Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3 $\beta$ -MCL-1 Axis. *Cancer Cell.* 2019 May 13;35(5):798-815.e5. doi: 10.1016/j.ccell.2019.03.007. Epub 2019 Apr 25. PMID: 31031016.

302) Curigliano G, de Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM. Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. *Oncologist.* 2019 Nov;24(11):e1034-e1043. doi: 10.1634/theoncologist.2018-0773. Epub 2019 May 7. PMID: 31064888; PMCID: PMC6853111.

303) Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. *BMC Med.* 2019 May 9;17(1):90. doi: 10.1186/s12916-019-1326-5. PMID: 31068190; PMCID: PMC6507064.

304) Cardoso MJ, Biganzoli L, Rubio IT, M L, G C, B C, L M, Kovacs T, Wyld L. About the French prohibition of textured breast implants: is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position. *Breast.* 2019 Aug;46:95-96. doi: 10.1016/j.breast.2019.05.005. Epub 2019 May 3. Erratum in: *Breast.* 2019 Dec;48:103. PMID: 31125932.

305) Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L. Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReEnd trial. *Breast Cancer Res.* 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5. PMID: 31142370; PMCID: PMC6542028.

306) Punzi S, Meliksetian M, Riva L, Marocchi F, Pruneri G, Criscitiello C, Orsi F, Spaggiari L, Casiraghi M, Della Vigna P, Luzi L, Curigliano G, Pelicci PG, Lanfrancone L. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and

Chemotherapy-Resistant Breast Cancer PDXs. *Cells*. 2019 Jun 18;8(6):605. doi: 10.3390/cells8060605. PMID: 31216647; PMCID: PMC6627522.

307) Criscitiello C, Curigliano G. Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? *Eur J Cancer*. 2019 Aug;117:1-4. doi: 10.1016/j.ejca.2019.04.028. Epub 2019 Jun 21. PMID: 31229945.

308) Mazzarella L, Duso BA, Trapani D, Belli C, D'Amico P, Ferraro E, Viale G, Curigliano G. The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review. *Eur J Cancer*. 2019 Aug;117:14-31. doi: 10.1016/j.ejca.2019.04.035. Epub 2019 Jun 21. PMID: 31229946.

309) Migliavacca Zucchetti B, Nicolò E, Curigliano G. Biosimilars for breast cancer. *Expert Opin Biol Ther*. 2019 Oct;19(10):1015-1021. doi: 10.1080/14712598.2019.1638362. Epub 2019 Jul 10. PMID: 31248290.

310) Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. *Eur J Cancer*. 2019 Sep;118:41-48. doi: 10.1016/j.ejca.2019.05.014. Epub 2019 Jul 11. PMID: 31302586.

311) Burstein HJ, Curigliano G, Loibl S, Dubsy P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B; Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol*. 2019 Oct 1;30(10):1541-1557. doi: 10.1093/annonc/mdz235. PMID: 31373601.

312) Pivot X, Pegram M, Cortes J, Lüftner D, Lyman GH, Curigliano G, Bondarenko I, Yoon YC, Kim Y, Kim C. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. *Eur J Cancer*. 2019 Oct;120:1-9. doi: 10.1016/j.ejca.2019.07.015. Epub 2019 Aug 21. PMID: 31445454.

313) Viale G, Morganti S, Ferraro E, Zagami P, Marra A, Curigliano G. What therapies are on the horizon for HER2 positive breast cancer? *Expert Rev Anticancer Ther*. 2019 Sep;19(9):811-822. doi: 10.1080/14737140.2019.1660164. Epub 2019 Aug 28. PMID: 31448640.

314) Morganti S, Curigliano G. Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better? *Curr Opin Oncol*. 2019 Nov;31(6):469-471. doi: 10.1097/CCO.0000000000000582. PMID: 31464761.

315) Marra A, Curigliano G. Are all cyclin-dependent kinases 4/6 inhibitors created equal? *NPJ Breast Cancer*. 2019 Aug 29;5:27. doi: 10.1038/s41523-019-0121-y. PMID: 31482107; PMCID: PMC6715721.

316) Ferraro E, Trapani D, Marrucci E, Curigliano G. Evaluating triptorelin as a treatment option for breast cancer. *Expert Opin Pharmacother*. 2019 Oct;20(15):1809-1818. doi: 10.1080/14656566.2019.1650020. Epub 2019 Sep 9. PMID: 31500470.

319) Zinzani PL, Dreyling M, Gradishar W, Andre M, Esteva FJ, Boulos S, González Barca E, Curigliano G. Are Biosimilars the Future of Oncology and Haematology? *Drugs*. 2019 Oct;79(15):1609-1624. doi: 10.1007/s40265-019-01193-y. PMID: 31541401.

318) Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, Curigliano G, André F, Michiels S. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Ann Oncol*. 2019 Dec 1;30(12):1941-1949. doi: 10.1093/annonc/mdz395. PMID: 31566659.



- 319) Criscitiello C, Viale G, Curigliano G. Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. *Curr Opin Oncol.* 2019 Nov;31(6):472-479. doi: 10.1097/CCO.0000000000000570. PMID: 31593974.
- 320) Abdel-Aziz AK, Saadeldin MK, D'Amico P, Orecchioni S, Bertolini F, Curigliano G, Minucci S. Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. *Eur J Cancer.* 2019 Nov;122:22-41. doi: 10.1016/j.ejca.2019.08.013. Epub 2019 Oct 10. PMID: 31606656.
- 321) Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G. Lucitanib for the Treatment of HR positive/HER2 negative Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. *Clin Cancer Res.* 2020 Jan 15;26(2):354-363. doi: 10.1158/1078-0432.CCR-19-1164. Epub 2019 Oct 16. PMID: 31619444.
- 322) Cardoso MJ, Wyld L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Biganzoli L. Corrigendum to "EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants" [*Breast* 44 (April 2019) 90-93]. *Breast.* 2019 Dec;48:102. doi: 10.1016/j.breast.2019.10.005. Erratum for: *Breast.* 2019 Apr;44:90-93. PMID: 31706463.
- 323) Cardoso MJ, Biganzoli L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Kovacs T, Wyld L. Corrigendum to "About the French prohibition of textured breast implants: Is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position" [*Breast* 46 (August 2019) 95-96]. *Breast.* 2019 Dec;48:103. doi: 10.1016/j.breast.2019.10.010. Erratum for: *Breast.* 2019 Aug;46:95-96. PMID: 31706464.
- 324) Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R. Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [*Cancer Treatm. Rev.* 74 (2019) 21-28]. *Cancer Treat Rev.* 2019 Dec;81:101913. doi: 10.1016/j.ctrv.2019.101913. Epub 2019 Nov 6. Erratum for: *Cancer Treat Rev.* 2019 Mar;74:21-28. PMID: 31706687.
- 325) Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. *Adv Exp Med Biol.* 2019;1168:9-30. doi: 10.1007/978-3-030-24100-1\_2. PMID: 31713162.
- 326) Punzi S, Balestrieri C, D'Alesio C, Bossi D, Dellino GI, Gatti E, Pruneri G, Criscitiello C, Lovati G, Meliksetyan M, Carugo A, Curigliano G, Natoli G, Pelicci PG, Lanfranccone L. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. *Breast Cancer Res.* 2019 Nov 21;21(1):123. doi: 10.1186/s13058-019-1216-y. PMID: 31752957; PMCID: PMC6873410.
- Anno 2020
- 327) Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort- Expansion Clinical Trial. *JAMA Oncol.* 2020 Jan 1;6(1):100-107. doi: 10.1001/jamaoncol.2019.3848. PMID: 31697308; PMCID: PMC6865300.
- 328) Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes

- J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. *N Engl J Med*. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. PMID: 31825192; PMCID: PMC7458671.
- 329) Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. *N Engl J Med*. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. Erratum in: *N Engl J Med*. 2020 Feb 6;382(6):586. PMID: 31825569.
- 330) Curigliano G, Loibl S. CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. *Lancet Oncol*. 2020 Feb;21(2):191-192. doi: 10.1016/S1470-2045(19)30808-3. Epub 2019 Dec 16. PMID: 31859247.
- 331) Curigliano G, Bagnardi V, Ghioni M, Louahed J, Brichard V, Lehmann FF, Marra A, Trapani D, Criscitiello C, Viale G. Expression of tumor-associated antigens in breast cancer subtypes. *Breast*. 2020 Feb;49:202-209. doi: 10.1016/j.breast.2019.12.002. Epub 2019 Dec 12. PMID: 31869767; PMCID:PMC7375652.
- 332) Biganzoli L, Marotti L, Cardoso MJ, Cataliotti L, Curigliano G, Cuzick J, Goldhirsch A, Leidenius M, Mansel R, Markopoulos C, Wyld L, Rubio IT. European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. *Breast Care (Basel)*. 2019 Dec;14(6):359-365. doi: 10.1159/000503603. Epub 2019 Oct 16. PMID: 31933581; PMCID: PMC6940462.
- 333) Trapani D, Curigliano G, Eniu A. Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. *Breast Care (Basel)*. 2019 Dec;14(6):373-381. doi: 10.1159/000502637. Epub 2019 Sep 24. PMID: 31933583; PMCID: PMC6940432.
- 334) McCartney A, Bonechi M, De Luca F, Biagioni C, Curigliano G, Moretti E, Minisini AM, Bergqvist M, Benelli M, Migliaccio I, Galardi F, Risi E, De Santo I, Romagnoli D, Biganzoli L, Di Leo A, Malorni L. Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TReND Trial. *Clin Cancer Res*. 2020 May 1;26(9):2131-2139. doi: 10.1158/1078-0432.CCR-19-3271. Epub 2020 Jan 14. PMID: 31937617.
- 335) Marra A, Viale G, Pileri SA, Pravettoni G, Viale G, De Lorenzi F, Nolè F, Veronesi P, Curigliano G. Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. *Cancer Treat Rev*. 2020 Mar;84:101963. doi: 10.1016/j.ctrv.2020.101963. Epub 2020 Jan 13. PMID: 31958739.
- 336) Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol*. 2020 Feb;31(2):171-190. doi: 10.1016/j.annonc.2019.10.023. PMID: 31959335; PMCID: PMC8019325.
- 337) Criscitiello C, Curigliano G. Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA- like tumours. *Eur J Cancer*. 2020 Mar;127:236-239. doi: 10.1016/j.ejca.2019.12.004. Epub 2020 Jan 20. PMID: 31973961.

- 338) Triberti S, Durosini I, Curigliano G, Pravettoni G. Is Explanation a Marketing Problem? The Quest for Trust in Artificial Intelligence and Two Conflicting Solutions. *Public Health Genomics*. 2020;23(1-2):2-5. doi: 10.1159/000506014. Epub 2020 Jan 28. PMID: 31991406.
- 339) Stebbing J, Mainwaring PN, Curigliano G, Pegram M, Latymer M, Bair AH, Rugo HS. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. *J Clin Oncol*. 2020 Apr 1;38(10):1070-1080. doi: 10.1200/JCO.19.02953. Epub 2020 Feb 14. PMID: 32058846; PMCID: PMC7106981.
- 340) Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S, Roman J, Harbeck N, Eniu A, Kaufman PA, Tabernero J, García-Estévez L, Schmid P, Arribas J. Enhancing global access to cancer medicines. *CA Cancer J Clin*. 2020 Mar;70(2):105-124. doi: 10.3322/caac.21597. Epub 2020 Feb 18. PMID: 32068901.
- 341) Kovacs T, Rubio IT, Markopoulos C, Audisio RA, Knox S, Kühn T, Mansel R, Matrai Z, Meani F, Nava M, Wyld L; BRESO Structure Working Group. Theoretical and practical knowledge curriculum for European Breast Surgeons. *Eur J Surg Oncol*. 2020 Apr;46(4 Pt B):717-736. doi: 10.1016/j.ejso.2020.01.027. Epub 2020 Feb 8. PMID: 32075718.
- 342) Aurilio G, Verri E, Frassoni S, Bagnardi V, Cossu Rocca M, Cullurà D, Milani M, Mascia R, Curigliano G, Orsi F, Jereczek-Fossa BA, Musi G, Omodeo Salè E, De Cobelli O, Nolè F. Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center. *Am J Clin Oncol*. 2020 Jun;43(6):381-387. doi: 10.1097/COC.0000000000000679. PMID: 32079853.
- 343) Passaro A, Mackenzie G, Lambertini M, Morgan G, Zimmermann S, Garrido P, Curigliano G, Trapani D. European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows. *ESMO Open*. 2020 Feb;5(1):e000598. doi: 10.1136/esmoopen-2019-000598. Epub 2020 Feb 5. Erratum in: *ESMO Open*. 2020 Mar;5(2): PMID: 32133983; PMCID: PMC7046424.
- 344) Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA Jr, Bianchi- Micheli G, Cardoso MJ, Curigliano G, Gelmon KA, Harbeck N, Merschdorf J, Poortmans P, Pruneri G, Senkus E, Spanic T, Stearns V, Wengström Y, Peccatori F, Pagni O. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). *Ann Oncol*. 2020 Jun;31(6):674-696. doi: 10.1016/j.annonc.2020.03.284. Epub 2020 Mar 19. PMID: 32199930.
- 345) Gelber RD, Coates AS, Gelber S, Orecchia R, Veronesi P, Di Leo A, Colleoni M, Winer EP, Burstein HJ, Viale G, Senn HJ, Piccart M, Curigliano G. The legacy of Professor Aron Goldhirsch. *Ann Oncol*. 2020 Jun;31(6):671-673. doi: 10.1016/j.annonc.2020.03.288. Epub 2020 Mar 23. PMID: 32217075.
- 346) Oliveri S, Ongaro G, Durosini I, Curigliano G, Pravettoni G. Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support. *Breast Cancer Res Treat*. 2020 May;181(1):221-224. doi: 10.1007/s10549-020-05601-w. Epub 2020 Mar 31. PMID: 32232699.
- 347) Mazzeo L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, Curigliano G. Master protocols in immuno-oncology: do novel drugs deserve novel designs? *J Immunother Cancer*. 2020 Mar;8(1):e000475. doi: 10.1136/jitc-2019-000475. PMID: 32238471; PMCID: PMC7174064.
- 348) File D, Curigliano G, Carey LA. Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. *Am Soc Clin Oncol Educ Book*. 2020 Mar;40:1-11. doi: 10.1200/EDBK\_100023. PMID: 32239987.

- 349) Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanha M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. *Oncologist*. 2020 Jun;25(6):e936-e945. Doi: 10.1634/theoncologist.2020-0213. Epub 2020 Apr 27. PMID: 32243668; PMCID: PMC7288661.
- 350) Tarantino P, Morganti S, Curigliano G. Biologic therapy for advanced breast cancer: recent advances and future directions. *Expert Opin Biol Ther*. 2020 Sep;20(9):1009-1024. doi: 10.1080/14712598.2020.1752176. Epub 2020 Apr 21. PMID: 32255704.
- 351) Curigliano G. How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience. *Oncologist*. 2020 Jun;25(6):463-467. doi: 10.1634/theoncologist.2020-0267. Epub 2020 Apr 27. PMID: 32298029; PMCID: PMC7262348.
- 352) Trapani D, Curigliano G. How can biosimilars change the trajectory of breast cancer therapy? *Expert Rev Anticancer Ther*. 2020 May;20(5):325-328. doi: 10.1080/14737140.2020.1757438. Epub 2020 Apr 28. PMID: 32298188.
- 353) Tarantino P, Trapani D, Curigliano G. Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2)-related disease pandemic. *Eur J Cancer*. 2020 Jun;132:8-10. doi: 10.1016/j.ejca.2020.03.023. Epub 2020 Apr 6. PMID: 32305011; PMCID: PMC7136890.
- 354) Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, André F, Curigliano G. HER2-Low Breast Cancer: Pathological and Clinical Landscape. *J Clin Oncol*. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. PMID: 32330069.
- 355) Curigliano G, Cardoso MJ, Poortmans P, Gentilini O, Pravettoni G, Mazzocco K, Houssami N, Pagani O, Senkus E, Cardoso F; editorial board of *The Breast*. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. *Breast*. 2020 Aug;52:8-16. doi: 10.1016/j.breast.2020.04.006. Epub 2020 Apr 16. PMID: 32334323; PMCID: PMC7162626.
- 356) Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, Saini ML, Verma S, Leone M, Aftimos P, Curigliano G. Effect of the COVID-19 pandemic on cancer treatment and research. *Lancet Haematol*. 2020 Jun;7(6):e432-e435. doi: 10.1016/S2352-3026(20)30123-X. Epub 2020 Apr 24. PMID: 32339482; PMCID: PMC7195053.
- 357) Meessen JMTA, Cardinale D, Ciceri F, Sandri MT, Civelli M, Bottazzi B, Cucchi G, Menatti E, Mangiavacchi M, Condorelli G, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Pastori P, Ghisoni F, Bianchi A, Falci C, Cortesi P, Farolfi A, Monopoli A, Milandri C, Bregni M, Malossi A, Nassiacos D, Verusio C, Staszewsky L, Leone R, Novelli D, Balconi G, Nicolis EB, Franzosi MG, Masson S, Garlanda C, Mantovani A, Cipolla CM, Latini R; ICOS-ONE Study Investigators. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. *ESC Heart Fail*. 2020 Aug;7(4):1452-1466. doi: 10.1002/ehf2.12695. Epub 2020 May 1. PMID: 32358917; PMCID: PMC7373944.
- 358) Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease

Burden. *Oncologist*. 2020 Sep;25(9):803-809. doi: 10.1634/theoncologist.2020-0014. Epub 2020 May 20. PMID: 32369650; PMCID: PMC7485362.

359) Roelands J, Hendrickx W, Zoppoli G, Mall R, Saad M, Halliwill K, Curigliano G, Rinchai D, Decock J, Delogu LG, Turan T, Samayoa J, Chouchane L, Ballestrero A, Wang E, Finetti P, Bertucci F, Miller LD, Galon J, Marincola FM, Kuppen PJK, Ceccarelli M, Bedognetti D. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. *J Immunother Cancer*. 2020 Apr;8(1):e000617. doi: 10.1136/jitc-2020-000617. Erratum in: *J Immunother Cancer*. 2020 Jun;8(1): PMID: 32376723; PMCID: PMC7223637.

360) Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhurairi A, Chemaly RF, Almuhanha M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. In Reply. *Oncologist*. 2020 Aug;25(8):e1252-e1253. doi: 10.1634/theoncologist.2020-0329. Epub 2020 May 27. PMID: 32378772; PMCID: PMC7267302.

361) Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. *Eur J Cancer*. 2020 Jun;132:199-206. doi: 10.1016/j.ejca.2020.04.017. Epub 2020 Apr 29. PMID: 32380430; PMCID: PMC7188643.

362) Di Tano M, Raucci F, Vernieri C, Caffa I, Buono R, Fanti M, Brandhorst S, Curigliano G, Nencioni A, de Braud F, Longo VD. Synergistic effect of fasting- mimicking diet and vitamin C against KRAS mutated cancers. *Nat Commun*. 2020 May 11;11(1):2332. doi: 10.1038/s41467-020-16243-3. PMID: 32393788; PMCID: PMC7214421.

363) Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez- Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. *NPJ Breast Cancer*. 2020 May 12;6:16. doi: 10.1038/s41523-020-0154-2. PMID: 32411818; PMCID: PMC7217824.

364) Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klausen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *NPJ Breast Cancer*. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. PMID: 32411819; PMCID: PMC7217863.

- 365) Roberto M, Basta F, Mazzuca F, Curigliano G, Marchetti P. Risk of coronavirus disease 2019 in patients treated for cancer: An immune response- based hypothesis. *Eur J Cancer*. 2020 Jul;134:6-8. doi: 10.1016/j.ejca.2020.05.003. Epub 2020 May 18. PMID: 32425367; PMCID: PMC7231735.
- 366) Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *NPJ Breast Cancer*. 2020 May 12;6:15. doi: 10.1038/s41523-020-0155-1. PMID: 32436923; PMCID: PMC7217941.
- 367) de Azambuja E, Trapani D, Loibl S, Delalogue S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. *ESMO Open*. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmooopen-2020-000793. PMID: 32439716; PMCID: PMC7295852.
- 368) Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. *J Clin Oncol*. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29. PMID: 32468955; PMCID: PMC7403000.
- 369) Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzarella L, Criscitiello C, Esposito A, Curigliano G. Pharmacological management of male breast cancer. *Expert Opin Pharmacother*. 2020 Aug;21(12):1493-1504. doi: 10.1080/14656566.2020.1763305. Epub 2020 Jun 4. PMID: 32496137.
- 370) Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. Evolution of Cancer Care in Response to the COVID-19 Pandemic. *Oncologist*. 2020 Sep;25(9):e1426-e1427. doi: 10.1634/theoncologist.2020-0451. Epub 2020 Jul 7. PMID: 32536024; PMCID: PMC7323244.
- 371) Di Cosimo S, Malfettone A, Pérez-García JM, Llombart-Cussac A, Miceli R, Curigliano G, Cortés J. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. *Eur J Cancer*. 2020 Aug;135:62-65. doi: 10.1016/j.ejca.2020.05.026. Epub 2020 Jun 4. PMID: 32544799; PMCID: PMC7269953.
- 372) Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. *Br J Cancer*. 2020 Sep;123(5):694-697. doi: 10.1038/s41416-020-0948-x. Epub 2020 Jun 22. PMID: 32572174; PMCID: PMC7307309.
- 373) Criscitiello C, Vingiani A, Maisonneuve P, Viale G, Viale G, Curigliano G. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. *Breast Cancer Res Treat*. 2020 Sep;183(2):347-354. doi: 10.1007/s10549-020-05771-7. Epub 2020 Jul 3. PMID: 32621251.
- 374) Nicolò E, Zagami P, Curigliano G. Antibody-drug conjugates in breast cancer: the chemotherapy of the future? *Curr Opin Oncol*. 2020 Sep;32(5):494-502. doi: 10.1097/CCO.0000000000000656. PMID: 32657795.

- 375) Belli C, Anand S, Gainor JF, Penault-Llorca F, Subbiah V, Drilon A, André F, Curigliano G. Progresses Toward Precision Medicine in RET-altered Solid Tumors. *Clin Cancer Res*. 2020 Dec 1;26(23):6102-6111. doi: 10.1158/1078-0432.CCR-20-1587. Epub 2020 Jul 14. PMID: 32665298.
- 376) Curigliano G. Cancer Patients and Risk of Mortality for COVID-19. *Cancer Cell*. 2020 Aug 10;38(2):161-163. doi: 10.1016/j.ccell.2020.07.006. Epub 2020 Jul 25. PMID: 32710820; PMCID: PMC7381394.
- 377) Trapani D, Curigliano G, Alexandru E, Sternberg CN. The global landscape of drug development for kidney cancer. *Cancer Treat Rev*. 2020 Sep;89:102061. doi: 10.1016/j.ctrv.2020.102061. Epub 2020 Jun 23. PMID: 32738737.
- 378) Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol*. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31. PMID: 32745693; PMCID: PMC7836806.
- 379) Passaro A, Attili I, Morganti S, Del Signore E, Gianoncelli L, Spitaleri G, Stati V, Catania C, Curigliano G, de Marinis F. Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. *Cancer Treat Rev*. 2020 Sep;89:102085. doi: 10.1016/j.ctrv.2020.102085. Epub 2020 Jul 22. PMID: 32771858.
- 380) Criscitiello C, Marra A, Morganti S, Zagami P, Viale G, Esposito A, Curigliano G. Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. *Oncologist*. 2020 Nov;25(11):e1732-e1742. doi: 10.1634/theoncologist.2020-0518. Epub 2020 Sep 18. PMID: 32785940; PMCID: PMC7648370.
- 381) Tarantino P, Curigliano G. Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. *N Engl J Med*. 2020 Aug 13;383(7):694-695. doi: 10.1056/NEJMc2021840. PMID: 32786200.
- 382) Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. *Lancet Oncol*. 2020 Sep;21(9):1234-1243. doi: 10.1016/S1470-2045(20)30321-1. Epub 2020 Aug 17. PMID: 32818466.
- 383) Trapani D, Curigliano G. How to treat lobular cancer in the adjuvant setting? *Curr Opin Oncol*. 2020 Nov;32(6):561-567. doi: 10.1097/CCO.0000000000000674. PMID: 32826487.
- 384) Corti C, Crimini E, Criscitiello C, Trapani D, Curigliano G. Adjuvant treatment of early male breast cancer. *Curr Opin Oncol*. 2020 Nov;32(6):594-602. doi: 10.1097/CCO.0000000000000678. PMID: 32852309.
- 385) Venetis K, Invernizzi M, Sajjadi E, Curigliano G, Fusco N. Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. *Cancer Treat Rev*. 2020 Nov;90:102089. doi: 10.1016/j.ctrv.2020.102089. Epub 2020 Aug 14. PMID: 32889360.
- 386) Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A. Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. *JCO Glob Oncol*. 2020 Sep;6:1357-1362. doi: 10.1200/GO.20.00346. PMID: 32897732; PMCID: PMC7529519.

- 387) Trapani D, Zagami P, Nicolò E, Pravettoni G, Curigliano G. Management of Cardiac Toxicity Induced by Chemotherapy. *J Clin Med*. 2020 Sep 7;9(9):2885. doi: 10.3390/jcm9092885. PMID: 32906611; PMCID: PMC7565686.
- 388) Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockerl-Goldstein K, Blaes A, Lyon AR, Ganatra S, López-Fernández T, O'Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, Curigliano G, Neilan TG, Herrmann J. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. *CA Cancer J Clin*. 2020 Nov;70(6):480-504. doi: 10.3322/caac.21635. Epub 2020 Sep 10. PMID: 32910493; PMCID: PMC7934086.
- 389) Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, Curigliano G, de Azambuja E. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. *Eur J Cancer*. 2020 Nov;139:43-50. doi: 10.1016/j.ejca.2020.08.011. Epub 2020 Sep 2. PMID: 32971510; PMCID: PMC7467090.
- 390) Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Paganì O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). *Ann Oncol*. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23. PMID: 32979513; PMCID: PMC7510449.
- 391) Tarantino P, Marra A, Gandini S, Minotti M, Pricolo P, Signorelli G, Criscitiello C, Locatelli M, Belli C, Bellomi M, Curigliano G. Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. *Eur J Cancer*. 2020 Nov;139:92-98. doi: 10.1016/j.ejca.2020.08.026. Epub 2020 Sep 24. PMID: 32979647.
- 392) Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, Mula-Hussain L, Errihani H, Khattak A, De Guzman RB, Mathias C, Alkaiyat MOF, Jradi H, Rolfo C; International Research Network on COVID-19 Impact on Cancer Care. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. *JCO Glob Oncol*. 2020 Sep;6:1428-1438. doi: 10.1200/GO.20.00351. PMID: 32986516; PMCID: PMC7529504.
- 393) Jazieh AR, Chan SL, Curigliano G, Dickson N, Eaton V, Garcia-Foncillas J, Gilmore T, Horn L, Kerr DJ, Lee J, Mathias C, Nogueira-Rodrigues A, Pierce L, Rogado A, Schilsky RL, Soria JC, Warner JL, Yoshida K. Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. *JCO Glob Oncol*. 2020 Sep;6:1461-1471. doi: 10.1200/GO.20.00423. PMID: 32997537; PMCID: PMC7529523.
- 394) Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. *Clin Cancer Res*. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12. PMID: 33046517.
- 395) Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and



- novel therapies. *NPJ Breast Cancer*. 2020 Oct 16;6:54. doi: 10.1038/s41523-020-00197-2. PMID: 33088912; PMCID: PMC7568552.
- 396) Tagliabue M, Maffini F, Fumagalli C, Gandini S, Lepanto D, Corso F, Cacciola S, Ranghiero A, Rappa A, Vacirca D, Cossu Rocca M, Alterio D, Guerini Rocco E, Cattaneo A, Chu F, Zorzi S, Curigliano G, Chiocca S, Barberis M, Viale G, Ansarin M. A role for the immune system in advanced laryngeal cancer. *Sci Rep*. 2020 Oct 27;10(1):18327. doi: 10.1038/s41598-020-73747-0. Erratum in: *Sci Rep*. 2021 May 3;11(1):9760. PMID: 33110100; PMCID: PMC7591515.
- 397) El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S. Repurposing anticancer drugs for the management of COVID-19. *Eur J Cancer*. 2020 Dec;141:40-61. doi: 10.1016/j.ejca.2020.09.014. Epub 2020 Sep 22. PMID: 33125946; PMCID: PMC7508523.
- 398) Marchetti P, Botticelli A, Ascierto AP, Curigliano G, Giannarelli D. Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. *J Transl Med*. 2020 Nov 25;18(1):446. doi: 10.1186/s12967-020-02588-2. PMID: 33239030; PMCID: PMC7688006.
- 399) Sessa C, Colombo N, Creutzberg CL, Concin N, Wimberger P, Curigliano G, Marinoni K, Douillard JY, Pentheroudakis G, Torri V, Rauh S. Implementing clinical practice guidelines: time to assess it. *ESMO Open*. 2020 Nov;5(6):e001130. doi: 10.1136/esmoopen-2020-001130. PMID: 33239316; PMCID: PMC7689583.
- 400) Bono P, Massard C, Peltola KJ, Azaro A, Italiano A, Kristeleit RS, Curigliano G, Lassen U, Arkenau HT, Hakulinen P, Garratt C, Ikonen T, Mustonen MVJ, Rodon JA. Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. *ESMO Open*. 2020 Dec;5(6):e001081. doi: 10.1136/esmoopen-2020-001081. PMID: 33262202; PMCID: PMC7709506.
- 401) Curigliano G, Pravettoni G. Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer. *Lancet Oncol*. 2020 Dec;21(12):1543-1545. doi: 10.1016/S1470-2045(20)30694-X. PMID: 33271084.
- 402) Grande E, Giovannini M, Marriere E, Pultar P, Quinlan M, Chen X, Rahmanzadeh G, Curigliano G, Cui X. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. *Br J Clin Pharmacol*. 2020 Dec 9. doi: 10.1111/bcp.14697. Epub ahead of print. PMID: 33300203.
- Anno 2021-2022
- 403) Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, Morganti S, Passerini R, Orecchia R, Curigliano G. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. *Ann Oncol*. 2021 Jan;32(1):113-119. doi: 10.1016/j.annonc.2020.10.473. Epub 2020 Oct 21. PMID: 33098994; PMCID: PMC7577226.
- 404) Tarantino P, Prat A, Curigliano G. New anti-HER2 agents for brain metastasis: histology-agnostic weapons? *Breast Cancer Res Treat*. 2021 Feb;185(3):879-881. doi: 10.1007/s10549-020-05982-y. Epub 2020 Oct 30. PMID: 33128191.
- 405) Mazzarella L, Giugliano S, D'Amico P, Belli C, Duso BA, Rescigno M, Curigliano G. Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. *Eur J Cancer*. 2020 Dec;141:218-224. doi: 10.1016/j.ejca.2020.10.006. Epub 2020 Nov 10. PMID: 33186857.
- 406) Curigliano G. CDK4/6 inhibitors for HR+/HER2- early stage breast cancer - when to escalate treatment? *Nat Rev Clin Oncol*. 2021 Feb;18(2):67-68. doi: 10.1038/s41571-020-00453-1. PMID: 33235325.

- 407) Tarantino P, Morganti S, Uliano J, Giugliano F, Crimini E, Curigliano G. Margetuximab for the treatment of HER2-positive metastatic breast cancer. *Expert Opin Biol Ther.* 2021 Feb;21(2):127-133. doi: 10.1080/14712598.2021.1856812. Epub 2020 Dec 14. PMID: 33238772.
- 408) Tarantino P, Prat A, Cortes J, Cardoso F, Curigliano G. Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. *Biochim Biophys Acta Rev Cancer.* 2021 Jan;1875(1):188487. doi: 10.1016/j.bbcan.2020.188487. Epub 2020 Nov 28. PMID: 33259892.
- 409) Conforti F, Tarantino P, Trillo P, Pala L, Zagami P, Pirola S, Di Venosa B, Catania C, Queirolo P, Pennacchioli E, Della Vigna P, Curigliano G, De Pas TM. Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. *Cancer Treat Rev.* 2021 Jan;92:102133. doi: 10.1016/j.ctrv.2020.102133. Epub 2020 Dec 3. PMID: 33296826.
- 410) Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G, Gentilini O, Gnant M, Günthert A, Hauser N, Heil J, Knauer M, Knotek-Roggenbauer M, Knox S, Kovacs T, Kuerer HM, Loibl S, Mannhart M, Meattini I, Penault-Llorca F, Radosevic-Robin N, Sager P, Španić T, Steyerova P, Tausch C, Peeters MTFDV, Weber WP, Cardoso MJ, Poortmans P. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. *Lancet Oncol.* 2021 Jan;22(1):e18-e28. doi: 10.1016/S1470-2045(20)30580-5. PMID: 33387500.
- 411) Corti C, Curigliano G. Commentary: SARS-CoV-2 vaccines and cancer patients. *Ann Oncol.* 2021 Apr;32(4):569-571. doi: 10.1016/j.annonc.2020.12.019. Epub 2021 Jan 12. PMID: 33450404; PMCID: PMC7831848.
- 412) Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, Reis-Filho JS, Subbiah V, Gainor JF, Endris V, Repetto M, Drilon A, Scarpa A, André F, Douillard JY, Curigliano G. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. *Ann Oncol.* 2021 Mar;32(3):337-350. doi: 10.1016/j.annonc.2020.11.021. Epub 2021 Jan 14. PMID: 33455880.
- 413) Marra A, Curigliano G. Adjuvant and Neoadjuvant Treatment of Triple- Negative Breast Cancer With Chemotherapy. *Cancer J.* 2021 Jan-Feb 01;27(1):41-49. doi: 10.1097/PPO.0000000000000498. PMID: 33475292.
- 414) Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2021 Apr 1;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932. PMID: 33480963; PMCID: PMC7823434.
- 415) Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol.* 2021 Mar;159:103223. doi: 10.1016/j.critrevonc.2021.103223. Epub 2021 Jan 19. PMID: 33482345.
- 416) Esposito A, Marra A, Bagnardi V, Frassoni S, Morganti S, Viale G, Zagami P, Varano GM, Buccimazza G, Orsi F, Venetis K, Mazzarella L, Viale G, Fusco N, Criscitiello C, Curigliano G. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in

patients treated with immunotherapy: A multi-parametric analysis. *Eur J Cancer*. 2021 Mar;145:197-209. doi: 10.1016/j.ejca.2020.12.028. Epub 2021 Jan 22. PMID: 33493979.

417) Trapani D, Yves Douillard J, Winer EP, Burstein H, Anne Carey L, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G, Ilbawi AM. The global landscape of treatment standards for breast cancer. *J Natl Cancer Inst*. 2021 Jan 27:djab011. doi: 10.1093/jnci/djab011. Epub ahead of print. PMID: 33502535.

418) Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. *J Hematol Oncol*. 2021 Jan 28;14(1):20. doi: 10.1186/s13045-021-01035-z. PMID: 33509252; PMCID: PMC7844898.

419) Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Puztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. *JCO Glob Oncol*. 2021 Feb;7:162-172. doi: 10.1200/GO.20.00589. PMID: 33529077; PMCID: PMC8081548.

420) Horgan D, Ciliberto G, Conte P, Curigliano G, Seijo L, Montuenga LM, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Riegman P, Kerr K, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Koeva-Balabanova J, Paradiso A, Maravic Z, Fotaki V, Malats N, Bernini C, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeek J, Duffy M, Jagielska B, Capoluongo E. Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. *Cancers (Basel)*. 2021 Feb 2;13(3):583. doi: 10.3390/cancers13030583. PMID: 33540773; PMCID: PMC7867284.

421) Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Capoluongo E, Banerjee S, Riegman P, Kerr K, Horbach B, Büttner R, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gutiérrez-Ibarluzea I, Gannon B, Mastris K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeek J, Duffy M, Sarnowska E, Jagielska B, Mee S, Curigliano G. Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. *Biomed Hub*. 2020 Sep 14;5(3):182-223. doi: 10.1159/000511209. PMID: 33564664; PMCID: PMC7841733.

422) Morganti S, Curigliano G. Combinations using checkpoint blockade to overcome resistance. *Ecanermediscience*. 2020 Dec 3;14:1148. doi: 10.3332/ecancer.2020.1148. PMID: 33574893; PMCID: PMC7864692.

423) Tarantino P, Curigliano G. Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. *Breast Cancer Res Treat*. 2021 Apr;186(3):885-886. doi: 10.1007/s10549-021-06150-6. Epub 2021 Feb 25. PMID: 33634418.

424) Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, Wrangle JM, Curigliano G, Greillier L, Johnson ML, Ready N, Robinet G, Lally S, Maag D, Valenzuela R, Blot V, Besse B. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. *J Thorac Oncol*. 2021 Feb 27:S1556-0864(21)01745-7. doi: 10.1016/j.jtho.2021.02.022. Epub ahead of print. PMID: 33652156.

425) Tarantino P, Mazzarella L, Marra A, Trapani D, Curigliano G. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality.

Cancer Treat Rev. 2021 Mar;94:102169. doi: 10.1016/j.ctrv.2021.102169. Epub 2021 Feb 20. PMID: 33652262.

426) Meattini I, Poortmans PM, Aznar MC, Becherini C, Bonzano E, Cardinale D, Lenihan DJ, Marrazzo L, Curigliano G, Livi L. Association of Breast Cancer Irradiation With Cardiac Toxic Effects: A Narrative Review. *JAMA Oncol.* 2021 Jun 1;7(6):924-932. doi: 10.1001/jamaoncol.2020.7468. PMID: 33662107.

427) Attili I, Tarantino P, Passaro A, Stati V, Curigliano G, de Marinis F. Strategies to overcome resistance to immune checkpoint blockade in lung cancer. *Lung Cancer.* 2021 Apr;154:151-160. doi: 10.1016/j.lungcan.2021.02.035. Epub 2021 Mar 3. PMID: 33684660.

428) Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol.* 2021 May;18(5):313-319. doi: 10.1038/s41571-021-00487-z. Epub 2021 Mar 15. Erratum in: *Nat Rev Clin Oncol.* 2021 Mar 23;: PMID: 33723371; PMCID: PMC7957448.

429) Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R, Schmid P, Curigliano G, Muñoz-Couselo E, Perez-García J, Marti M, Blanco-Heredia J, Anjos CD, Vazquez M, De Mattos-Arruda L, Cortés J. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. *Eur J Cancer.* 2021 May;148:134-145. doi: 10.1016/j.ejca.2021.01.037. Epub 2021 Mar 17. PMID: 33743482.

430) Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol.* 2021 May;18(5):320. doi: 10.1038/s41571-021-00503-2. Erratum for: *Nat Rev Clin Oncol.* 2021 May;18(5):313-319. PMID: 33758378; PMCID: PMC7985918.

431) Galardi F, De Luca F, Biagioni C, Migliaccio I, Curigliano G, Minisini AM, Bonechi M, Moretti E, Risi E, McCartney A, Benelli M, Romagnoli D, Cappadona S, Gabellini S, Guarducci C, Conti V, Biganzoli L, Di Leo A, Malorni L. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TReND trial. *Breast Cancer Res.* 2021 Mar 24;23(1):38. doi: 10.1186/s13058-021-01415-w. PMID: 33761970; PMCID: PMC7992319.

432) Campanale A, Di Napoli A, Ventimiglia M, Pileri S, Minella D, Curigliano G, Martelli M, De Vita R, Di Giulio P, Montorsi M, Veronesi P, Giordano S, Iachino A, Lispi L. Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients. *Eur J Cancer.* 2021 May;148:277-286. doi: 10.1016/j.ejca.2021.01.041. Epub 2021 Mar 23. PMID: 33765512.

433) Corti C, Crimini E, Tarantino P, Pravettoni G, Eggermont AMM, Delalogue S, Curigliano G. SARS-CoV-2 vaccines for cancer patients: a call to action. *Eur J Cancer.* 2021 May;148:316-327. doi: 10.1016/j.ejca.2021.01.046. Epub 2021 Feb 25. PMID: 33770576; PMCID: PMC7904467.

434) Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A,

Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccamese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). *Clin Cancer Res*. 2021 Jun 15;27(12):3443-3455. doi: 10.1158/1078-0432.CCR-20-4928. Epub 2021 Mar 30. PMID: 33785482.

435) Pérez-García JM, Llombart-Cussac A, G Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L, Carañana V, de la Cruz Sánchez S, M Vázquez R, Prat A, R Borrego M, Sampayo-Cordero M, Seguí-Palmer MÁ, Soberino J, Malfettone A, Schmid P, Cortés J. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial. *Eur J Cancer*. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. Epub 2021 Mar 29. PMID: 33794440.

436) Park K, Chang GC, Curigliano G, Lim WT, Soo RA, Molina-Vila MA, Cattan V, Darville H, Gandossi E, Smutna V, Sudey I, Viteri S. Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. *Lung Cancer*. 2021 May;155:127-135. doi: 10.1016/j.lungcan.2021.03.012. Epub 2021 Mar 13. PMID: 33798902.

437) Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. *Lancet*. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1. Erratum in: *Lancet*. 2021 May 8;397(10286):1710. PMID: 33812473.

438) Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, Morano F, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, Curigliano G, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, Pietrantonio F. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite

instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. *J Immunother Cancer*. 2021 Apr;9(4):e002501. doi: 10.1136/jitc-2021-002501. PMID: 33849927; PMCID: PMC8051394.

439) Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. *Eur J Cancer*. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. PMID: 33862496.

440) de Guillebon E, Jimenez M, Mazzarella L, Betsou F, Stadler P, Peták I, Jeannot E, Chanas L, Servant N, Marret G, Duso BA, Legrand F, Kornerup KN, Bernhart SH, Balogh G, Dóczi R, Filotás P, Curigliano G, Bièche I, Guérin J, Dirner A, Neuzillet C, Girard N, Borcoman E, Larbi Chérif L, Tresca P, Roufai DB, Dupain C, Scholl S, André F, Fernandez X, Filleron T, Kamal M, Le Tourneau C. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. *ESMO Open*. 2021 Jun;6(3):100106. doi: 10.1016/j.esmoop.2021.100106. Epub 2021 Apr 14. PMID: 33865192; PMCID: PMC8066350.

441) Trapani D, Gandini S, Corti C, Crimini E, Bellerba F, Minchella I, Criscitiello C, Tarantino P, Curigliano G. Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. *Cancer Treat Rev*. 2021 Jun;97:102205. doi: 10.1016/j.ctrv.2021.102205. Epub 2021 Apr 9. PMID: 33878560.

- 442) Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spaltalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. *Clin Cancer Res*. 2021 Apr 21. doi: 10.1158/1078-0432.CCR-20-4746. Epub ahead of print. PMID: 33883177.
- 443) Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. *ESMO Open*. 2021 Jun;6(3):100117. doi: 10.1016/j.esmooop.2021.100117. Epub 2021 Apr 20. PMID: 33887690; PMCID: PMC8086024.
- 444) Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, Borelli B, Brambilla M, Prete AA, Quarà V, Antista M, Fassan M, Morano F, Spallanzani A, Ambrosini M, Curigliano G, de Braud F, Zagonel V, Fucà G, Pietrantonio F. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. *Eur J Cancer*. 2021 Jun;150:155-167. doi: 10.1016/j.ejca.2021.03.043. Epub 2021 Apr 24. PMID: 33901794.
- 445) Tagliabue M, Maffini F, Fumagalli C, Gandini S, Lepanto D, Corso F, Cacciola S, Ranghiero A, Rappa A, Vacirca D, Cossu Rocca M, Alterio D, Guerini Rocco E, Cattaneo A, Chu F, Zorzi S, Curigliano G, Chiocca S, Barberis M, Viale G, Ansarin M. Author Correction: A role for the immune system in advanced laryngeal cancer. *Sci Rep*. 2021 May 3;11(1):9760. doi: 10.1038/s41598-021-89174-8. Erratum for: *Sci Rep*. 2020 Oct 27;10(1):18327. PMID: 33941821; PMCID: PMC8093299.
- 446) Curigliano G, Martin M, Jhaveri K, Beck JT, Tortora G, Fazio N, Maur M, Hubner RA, Lahner H, Donnet V, Ajipa O, Li Z, Blumenstein L, Andre F. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. *Eur J Cancer*. 2021 Jul;151:49-62. doi: 10.1016/j.ejca.2021.03.042. Epub 2021 May 5. PMID: 33964572.
- 447) Criscitiello C, Corti C, Pravettoni G, Curigliano G. Managing side effects of immune checkpoint inhibitors in breast cancer. *Crit Rev Oncol Hematol*. 2021 Jun;162:103354. doi: 10.1016/j.critrevonc.2021.103354. Epub 2021 May 21. PMID: 34029683.
- 448) Trapani D, Giugliano F, Uliano J, Zia VAA, Marra A, Viale G, Ferraro E, Esposito A, Criscitiello C, D'amico P, Curigliano G. Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. *Breast Cancer Res Treat*. 2021 Jun;187(2):323-337. doi: 10.1007/s10549-021-06259-8. Epub 2021 May 27. PMID: 34043122.
- 449) Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G. Precision medicine in breast cancer: From clinical trials to clinical practice. *Cancer Treat Rev*. 2021 Jul;98:102223. doi: 10.1016/j.ctrv.2021.102223. Epub 2021 May 12. PMID: 34049187.
- 450) Tarantino P, Trapani D, Curigliano G. Mastering the Use of Novel Anti-HER2 Treatment Options. *JCO Oncol Pract*. 2021 Jun 2:OP2100216. doi: 10.1200/OP.21.00216. Epub ahead of print. PMID: 34077256.

- 451) Trapani D, Curigliano G. COVID-19 vaccines in patients with cancer. *Lancet Oncol*. 2021 Jun;22(6):738-739. doi: 10.1016/S1470-2045(21)00250-3. PMID: 34087120; PMCID: PMC8169039.
- 452) Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol*. 2021 Jun 9:S1470-2045(21)00247-3. doi: 10.1016/S1470-2045(21)00247-3. Epub ahead of print. PMID: 34118197.
- 453) Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Lebloulloux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. *Lancet Diabetes Endocrinol*. 2021 Jun 9:S2213-8587(21)00120-0. doi: 10.1016/S2213-8587(21)00120-0. Epub ahead of print. PMID: 34118198.
- 454) Yekedüz E, Trapani D, Xu W, de Vries EG, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, Curigliano G, Choueiri TK, Ürün Y. Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors. *Int J Cancer*. 2021 Jun 14. doi: 10.1002/ijc.33708. Epub ahead of print. PMID: 34124786.
- 455) Esposito I, Calabria S, Piccinni C, Addesi A, Dondi L, Ronconi G, Pedrini A, Maggioni AP, Curigliano G, Listi A, Righi L, Novello S, Buglioni S, Ciliberto G, Pruneri G, Martini N. L'oncologia mutazionale del carcinoma polmonare: marcatori molecolari, farmaci, condizioni negoziali ed esperienze in centri di riferimento nazionale [Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.]. *Recenti Prog Med*. 2021 Jun;112(6):419-437. Italian. doi: 10.1701/3620.36025. PMID: 34128934.
- 456) Saini KS, Martins-Branco D, Tagliamento M, Vidal L, Singh N, Punie K, Saini ML, Chico I, Curigliano G, de Azambuja E, Lambertini M. Emerging issues related to COVID-19 vaccination in patients with cancer. *Oncol Ther*. 2021 Jun 16. doi: 10.1007/s40487-021-00157-1. Epub ahead of print. PMID: 34137014.
- 457) Curigliano G, Eggermont AMM. Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen! *Eur J Cancer*. 2021 May 24:S0959-8049(21)00311-7. doi: 10.1016/j.ejca.2021.05.007. Epub ahead of print. PMID: 34147290.
- 458) Saini KS, Martins-Branco D, Tagliamento M, Vidal L, Singh N, Punie K, Saini ML, Chico I, Curigliano G, de Azambuja E, Lambertini M. Emerging issues related to COVID-19 vaccination in patients with cancer. *Oncol Ther*. 2021 Jun 16:1-11. doi: 10.1007/s40487-021-00157-1. Epub ahead of print. PMID: 34155481; PMCID: PMC8208766.
- 459) Repetto M, Conforti F, Pirola S, Calvello M, Pala L, Bonanni B, Catania C, Curigliano G, De Pas T. Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. *Eur J Cancer*. 2021 Jun 20;153:162-167. doi: 10.1016/j.ejca.2021.05.029. Epub ahead of print. PMID: 34161910.
- 460) Giugliano F, Crimini E, Tarantino P, Zagami P, Uliano J, Corti C, Trapani D, Curigliano G, Ascierto PA, First line treatment of BRAF mutated advanced melanoma: Does one size fit all?, *Cancer Treatment Reviews*, Volume 99, 2021, 102253, ISSN 0305-7372, <https://doi.org/10.1016/j.ctrv.2021.102253>.

- 461) Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdottir A, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Lasa Montoya M, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. *Cancer Discov.* 2021 Jun 28:candisc.1647.2020. doi: 10.1158/2159-8290.CD-20-1647. Epub ahead of print. PMID: 34183353.
- 462) Corti C, Giugliano F, Nicolò E, Ascione L, Curigliano G. Antibody-Drug Conjugates for the Treatment of Breast Cancer. *Cancers (Basel).* 2021 Jun 9;13(12):2898. doi: 10.3390/cancers13122898. PMID: 34207890; PMCID: PMC8229763.
- 463) Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Harder Brix E, Brenner A, Crouzet L, Ferrario C, Muñoz-Mateu M, Arkenau HT, Iqbal N, Aithal S, Block M, Cold S, Cancel M, Hahn O, Poosarla T, Stringer-Reasor E, Colleoni M, Cameron D, Curigliano G, Siadak M, DeBusk K, Ramos J, Feng W, Gelmon K. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). *Eur J Cancer.* 2021 Aug;153:223-233. doi: 10.1016/j.ejca.2021.05.025. Epub 2021 Jun 29. PMID: 34214937.
- 464) Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. *Ann Oncol.* 2021 Jul 2:S0923-7534(21)02105-0. doi: 10.1016/j.annonc.2021.06.024. Epub ahead of print. PMID: 34224826.
- 465) Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M; Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Ann Oncol.* 2021 Jul 6:S0923-7534(21)02104-9. doi: 10.1016/j.annonc.2021.06.023. Epub ahead of print. PMID: 34242744.
- 466) Le Du F, Diéras V, Curigliano G. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. *Eur J Cancer.* 2021 Sep;154:175-189. doi: 10.1016/j.ejca.2021.06.026. Epub 2021 Jul 16. PMID: 34280871.
- 467) Trillo Aliaga P, Spada F, Peveri G, Bagnardi V, Fumagalli C, Laffi A, Rubino M, Gervaso L, Guerini Rocco E, Pisa E, Curigliano G, Fazio N. Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. *Cancer Treat Rev.* 2021 Sep;99:102261. doi: 10.1016/j.ctrv.2021.102261. Epub 2021 Jul 22. PMID: 34332293.
- 468) Tarantino P, Tolaney SM, Harbeck N, Cortes J, Curigliano G. Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? *J Clin Oncol.* 2021 Aug 18:JCO2101059. doi: 10.1200/JCO.21.01059. Epub ahead of print. PMID: 34406849.



- 469) Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I, Chee CE, Yeh KH, Lin PC, Chua C, Hasbullah HH, Lee MA, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. *Ann Oncol*. 2021 Aug 16;S0923-7534(21)03982-X. doi: 10.1016/j.annonc.2021.08.1752. Epub ahead of print. PMID: 34411693.
- 470) Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia JL, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. *ESMO Open*. 2021 Jul 24;6(5):100237. doi: 10.1016/j.esmoop.2021.100237. Epub ahead of print. PMID: 34411971; PMCID: PMC8302832.
- 471) Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. *J Immunother Cancer*. 2021 Aug;9(8):e003370. doi: 10.1136/jitc-2021-003370. PMID: 34429334.
- 472) Jhaveri K, Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. *Clin Cancer Res*. 2021 Aug 25;clinres.1095.2021. doi: 10.1158/1078-0432.CCR-21-1095. Epub ahead of print. PMID: 34433648.
- 473) Criscitiello C, Marra A, Morganti S, Zagami P, Gandini S, Esposito A, Curigliano G. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. *Eur J Cancer*. 2021 Aug 30;157:40-49. doi: 10.1016/j.ejca.2021.07.037. Epub ahead of print. PMID: 34474219.
- 474) Antonarelli G, Corti C, Tarantino P, Ascione L, Cortes J, Romero P, Mittendorf EA, Disis ML, Curigliano G. Therapeutic Cancer Vaccines Revamping: Technology Advancements and Pitfalls. *Ann Oncol*. 2021 Sep 6;S0923-7534(21)04457-4. doi: 10.1016/j.annonc.2021.08.2153. Epub ahead of print. PMID: 34500046; PMCID: PMC8420263.
- 475) Nicolò E, Trapani D, Berton Giachetti PPM, Zagami P, Curigliano G. Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. *Cancer Treat Rev*. 2021 Aug 18;100:102281. doi: 10.1016/j.ctrv.2021.102281. Epub ahead of print. PMID: 34500366.
- 476) Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De Placido S, Martín M, Jerusalem G, Venturini S, Curigliano G, Generali D. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. *Cancers (Basel)*. 2021 Sep 1;13(17):4421. doi: 10.3390/cancers13174421. PMID: 34503231; PMCID: PMC8430783.
- 477) Tarantino P, Antonarelli G, Ascione L, Curigliano G. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. *Expert Opin Investig Drugs*. 2021 Sep 26:1-15. doi: .1080/13543784.2021.1972968. Epub ahead of print. PMID: 34569405.

34569405.

478) Antonarelli G, Giugliano F, Corti C, Repetto M, Tarantino P, Curigliano G. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. *Pharmaceuticals (Basel)*. 2021 Aug 31;14(9):884. doi: 10.3390/ph14090884. PMID: 34577584; PMCID: PMC8468026.

479) Alcalay M, Jereczek-Fossa BA, Pepa M, Volpe S, Zaffaroni M, Fiore F, Marvaso G, Pravettoni G, Curigliano G, Santaguida S, Pelicci PG. Biomedical omics: first insights of a new MSc degree of the University of Milan. *Tumori*. 2022 Feb;108(1):6-11. doi: 10.1177/03008916211047268. Epub 2021 Sep 29. PMID: 34585604.

480) Tarantino P, Uliano J, Morganti S, Giugliano F, Crimini E, Curigliano G. Clinical development and current role of margetuximab for the treatment of breast cancer. *Drugs Today (Barc)*. 2021 Sep;57(9):551-558. doi: 10.1358/dot.2021.57.9.3319148. PMID: 34586103.

481) Valenza C, Porta FM, Rappa A, Guerini-Rocco E, Viale G, Barberis M, de Marinis F, Curigliano G, Catania C. Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. *Curr Oncol*. 2021 Aug 31;28(5):3384-3392. doi: 10.3390/currncol28050292. PMID: 34590588; PMCID: PMC8482094.

482) Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. *Expert Rev Clin Pharmacol*. 2021 Oct;14(10):1233-1252. doi: 10.1080/17512433.2021.1947246. PMID: 34591728.

483) Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS. Phase I/IIa Trial of BMS-986148, an Anti- mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2022 Jan 1;28(1):95-105. doi: 10.1158/1078-0432.CCR-21-1181. Epub 2021 Oct 6. PMID: 34615718.

484) Tarantino P, Modi S, Tolaney SM, Cortés J, Hamilton EP, Kim SB, Toi M, André F, Curigliano G. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. *JAMA Oncol*. 2021 Dec 1;7(12):1873-1881. doi: 10.1001/jamaoncol.2021.3595. PMID: 34647966.

485) Duggan C, Trapani D, Ilbawi AM, Fidarova E, Laversanne M, Curigliano G, Bray F, Anderson BO. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. *Lancet Oncol*. 2021 Nov;22(11):1632-1642. doi: 10.1016/S1470-2045(21)00462-9. Epub 2021 Oct 13. PMID: 34653370.

486) Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. *Ann Oncol*. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19. PMID: 34678411.

487) Corti C, Antonarelli G, Scotté F, Spano JP, Barrière J, Michot JM, André F, Curigliano G. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic

review. *Ann Oncol.* 2022 Feb;33(2):158-168. doi: 10.1016/j.annonc.2021.10.014. Epub 2021 Oct 28. PMID: 34718117; PMCID: PMC8552625.

488) Eggermont A, Geoerger B, Curigliano G. Precision Cancer Medicine: Large Studies Indicate Steady Progress. *Cancer Discov.* 2021 Nov;11(11):2677-2678. doi: 10.1158/2159-8290.CD-21-1069. PMID: 34725088.

489) Trapani D, Murthy SS, Boniol M, Booth C, Simensen VC, Kasumba MK, Giuliani R, Curigliano G, Ilbawi AM. Distribution of the workforce involved in cancer care: a systematic review of the literature. *ESMO Open.* 2021 Dec;6(6):100292. doi: 10.1016/j.esmoop.2021.100292. Epub 2021 Nov 8. PMID: 34763251; PMCID: PMC8591344.

490) Corti C, Nicolò E, Curigliano G. Novel immune targets for the treatment of triple-negative breast cancer. *Expert Opin Ther Targets.* 2021 Oct;25(10):815-834. doi: 10.1080/14728222.2021.2006187. Epub 2021 Nov 25. PMID: 34763593.

491) Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolane SM, Cortes J, Soria JC, Curigliano G. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. *CA Cancer J Clin.* 2021 Nov 12. doi: 10.3322/caac.21705. Epub ahead of print. PMID: 34767258.

492) González-Martínez S, Pizarro D, Pérez-Mies B, Caniego-Casas T, Curigliano G, Cortés J, Palacios J. Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. *Cancers (Basel).* 2021 Oct 28;13(21):5416. doi: 10.3390/cancers13215416. PMID: 34771579; PMCID: PMC8582578.

493) Farante G, Toesca A, Magnoni F, Lissidini G, Vila J, Mastropasqua M, Viale G, Penco S, Cassano E, Lazzeroni M, Bonanni B, Leonardi MC, Ripoll-Orts F, Curigliano G, Orecchia R, Galimberti V, Veronesi P. Advances and controversies in management of breast ductal carcinoma in situ (DCIS). *Eur J Surg Oncol.* 2021 Nov 9:S0748-7983(21)00780-0. doi: 10.1016/j.ejso.2021.10.030. Epub ahead of print. PMID: 34772587.

494) Corti C, Giachetti PPMB, Eggermont AMM, Delaloge S, Curigliano G. Therapeutic vaccines for breast cancer: Has the time finally come? *Eur J Cancer.* 2022 Jan;160:150-174. doi: 10.1016/j.ejca.2021.10.027. Epub 2021 Nov 22. PMID: 34823982; PMCID: PMC8608270.

495) Darwich A, Silvestri A, Benmebarek MR, Mouriès J, Cadilha B, Melacarne A, Morelli L, Supino D, Taleb A, Obeck H, Sustmann C, Losurdo A, Masci G, Curigliano G, Kobold S, Penna G, Rescigno M. Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1. *J Immunother Cancer.* 2021 Nov;9(11):e003224. doi: 10.1136/jitc-2021-003224. PMID: 34824159; PMCID: PMC8627417.

496) Trillo Aliaga P, Trapani D, Sandoval JL, Crimini E, Antonarelli G, Vivanet G, Morganti S, Corti C, Tarantino P, Friedlaender A, Belli C, Minchella I, Locatelli M, Esposito A, Criscitiello C, Curigliano G. Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. *Cancers (Basel).* 2021 Nov 20;13(22):5829. doi: 10.3390/cancers13225829. PMID: 34830983; PMCID: PMC8616209.

497) Keam B, Machiels JP, Kim HR, Licitra L, Golusinski W, Gregoire V, Lee YG, Belka C, Guo Y, Rajappa SJ, Tahara M, Azrif M, Ang MK, Yang MH, Wang CH, Ng QS, Wan Zamaniah WI, Kiyota N, Babu S, Yang K, Curigliano G, Peters S, Kim TW, Yoshino T, Pentheroudakis G. Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. *ESMO Open.* 2021 Dec;6(6):100309. doi: 10.1016/j.esmoop.2021.100309. Epub 2021 Nov 26. PMID: 34844180; PMCID: PMC8710460.

498) El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW,

Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno- Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. *NPJ Breast Cancer*. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. PMID: 34853355; PMCID: PMC8636568.

499) Kanavarar R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. *ESMO Open*. 2021 Dec;6(6):100304. doi: 10.1016/j.esmoop.2021.100304. Epub 2021 Dec 1. PMID: 34864348; PMCID: PMC8645910.

500) Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. *Eur Heart J*. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674. PMID: 34904661; PMCID: PMC8803367.

501) Tarantino P, Barroso-Sousa R, Garrido-Castro AC, McAllister SS, Guerriero JL, Mittendorf E, Curigliano G, Tolaney SM. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. *Expert Rev Anticancer Ther*. 2022 Feb;22(2):141-153. doi: 10.1080/14737140.2022.2020650. Epub 2021 Dec 28. PMID: 34919490.

502) Trapani D, Curigliano G. Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021. *Breast*. 2021 Dec 13:S0960-9776(21)01018-3. doi: 10.1016/j.breast.2021.12.012. Epub ahead of print. PMID: 34920925.

503) Giugliano F, Antonarelli G, Tarantino P, Cortes J, Rugo HS, Curigliano G. Harmonizing PD-L1 testing in metastatic triple negative breast cancer. *Expert Opin Biol Ther*. 2022 Mar;22(3):345-348. doi: 10.1080/14712598.2022.2021180. Epub 2021 Dec 29. PMID: 34930070.

504) Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, Hamilton EP, Hurvitz SA, Rugo HS, Curigliano G, Tolaney SM. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? *Ann Oncol*. 2022 Mar;33(3):234-238. doi: 10.1016/j.annonc.2021.12.004. Epub 2021 Dec 20. PMID: 34942341.

505) Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. *Cancer Treat Rev*. 2022 Feb;103:102324. doi: 10.1016/j.ctrv.2021.102324. Epub 2021 Dec 16. PMID: 34953200.

506) Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without

brain metastases (HER2CLIMB): final overall survival analysis. *Ann Oncol.* 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23. PMID: 34954044.

507) Crimini E, Corti C, Repetto M, Giugliano F, Antonarelli G, Tarantino P, Zagami P, Morganti S, Nicolò E, Uliano J, Curigliano G. Systemic Treatment of Ductal Carcinoma In Situ of the Breast. *Chirurgia (Bucur).* 2021 Dec;116(500):S97-S104. doi: 10.21614/chirurgia.116.5.suppl.S97. PMID: 34967317.

508) D'Amico P, Reduzzi C, Qiang W, Zhang Y, Gerratana L, Zhang Q, Davis AA, Shah AN, Manai M, Curigliano G, Cristofanilli M. Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer. *Cancers (Basel).* 2021 Dec 24;14(1):79. doi: 10.3390/cancers14010079. PMID: 35008244; PMCID: PMC8750036.

509) Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. *J Immunother Cancer.* 2022 Jan;10(1):e003231. doi: 10.1136/jitc-2021-003231. PMID: 35022192; PMCID: PMC8756278.

510) Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolane SM. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. *JAMA Oncol.* 2022 Jan 13. doi: 10.1001/jamaoncol.2021.6597. Epub ahead of print. PMID: 35024766.

511) Pentheroudakis G, Curigliano G, Zielinski C. ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit. *ESMO Open.* 2022 Jan 10;7(1):100344. doi: 10.1016/j.esmoop.2021.100344. Epub ahead of print. PMID: 35026722; PMCID: PMC8760392.

512) Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivinet G, Bellerba F, Trapani D, Marra A, Esposito A, Criscitiello C, Viale G, Curigliano G. Evolution of low HER2 expression between early and advanced-stage breast cancer. *Eur J Cancer.* 2022 Mar;163:35-43. doi: 10.1016/j.ejca.2021.12.022. Epub 2022 Jan 13. PMID: 35032815.

513) Horgan D, Curigliano G, Rieß O, Hofman P, Büttner R, Conte P, Cufer T, Gallagher WM, Georges N, Kerr K, Penault-Llorca F, Mastris K, Pinto C, Van Meerbeeck J, Munzone E, Thomas M, Ujupan S, Vainer GW, Velthaus JL, André F. Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. *J Pers Med.* 2022 Jan 8;12(1):72. doi: 10.3390/jpm12010072. PMID: 35055387; PMCID: PMC8780351.

514) Trapani D, Ginsburg O, Fadelu T, Lin NU, Hasset M, Ilbawi AM, Anderson BO, Curigliano G. Global challenges and policy solutions in breast cancer control. *Cancer Treat Rev.* 2022 Jan 19;104:102339. doi: 10.1016/j.ctrv.2022.102339. Epub ahead of print. PMID: 35074727.

515) Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H. Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. *J Geriatr Oncol.* 2022 Jan 28:S1879-4068(22)00010-8. doi: 10.1016/j.jgo.2022.01.009. Epub ahead of print. PMID: 35101364.

516) Fucà G, Cohen R, Lonardi S, Shitara K, Elez ME, Fakhri M, Chao J, Klempner SJ, Emmett M, Jayachandran P, Bergamo F, García MD, Mazzoli G, Provenzano L, Colle R, Svrcek M, Ambrosini M, Randon G, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, Corti F, Cremolini C, Overman M, Andre T, Pietrantonio F. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. *J Immunother Cancer.* 2022 Feb;10(2):e004001. doi: 10.1136/jitc-2021-004001. PMID: 35110358; PMCID: PMC8811606.

- 517) Morganti S, Marra A, Crimini E, D'Amico P, Zagami P, Curigliano G. Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? *Breast Cancer Res Treat.* 2022 Feb 6. doi: 10.1007/s10549-022-06535-1. Epub ahead of print. PMID: 35124720.
- 518) Tan AC, Tan SH, Zhou S, Peters S, Curigliano G, Tan DSW. Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. *Cancer Treat Rev.* 2022 Feb 3;104:102354. doi: 10.1016/j.ctrv.2022.102354. Epub ahead of print. PMID: 35134620.
- 519) Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. *Ann Oncol.* 2022 Feb 14:S0923-7534(22)00112-0. doi: 10.1016/j.annonc.2022.02.003. Epub ahead of print. PMID: 35176458.
- 520) Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, André F, Curigliano G. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. *NPJ Breast Cancer.* 2022 Feb 18;8(1):23. doi: 10.1038/s41523-022-00386-1. PMID: 35181659.
- 521) Antonarelli G, Valenza C, Mayer EL, Loibl S, Curigliano G. Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? *Lancet Oncol.* 2022 Mar;23(3):325-328. doi: 10.1016/S1470-2045(21)00756-7. PMID: 35240079.
- 522) González-Martínez S, Pizarro D, Pérez-Mies B, Caniego-Casas T, Rodríguez- Peralto JL, Curigliano G, Cortés A, Gión M, Cortés J, Palacios J. Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. *Cancers (Basel).* 2022 Feb 23;14(5):1151. doi: 10.3390/cancers14051151. PMID: 35267459; PMCID: PMC8909188.
- 523) Morganti S, Bianchini G, Giordano A, Giuliano M, Curigliano G, Criscitiello C. How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? *ESMO Open.* 2022 Apr;7(2):100428. doi: 10.1016/j.esmoop.2022.100428. Epub 2022 Mar 7. PMID: 35272131; PMCID: PMC8908056.
- 524) Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. *Cancer Chemother Pharmacol.* 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. Epub 2022 Mar 17. PMID: 35298698; PMCID: PMC8956549.
- 525) Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? *Curr Oncol Rep.* 2022 Jul;24(7):809-817. doi: 10.1007/s11912-022-01266-4. Epub 2022 Mar 19. PMID: 35305211.
- 526) Giugliano F, Zucali PA, Galli G, Ballatore Z, Corti C, Aliaga PT, Uliano J, Vivinet G, Curigliano G, Conforti F, Queirolo P, Berardi R, Manglaviti S, Apollonio G, Perrino M, Borea F, D'Antonio F, Garassino MC, De Pas T. SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. *Eur J Cancer.* 2022 May;166:202-207. doi: 10.1016/j.ejca.2022.02.011. Epub 2022 Feb 25. PMID: 35306318; PMCID: PMC8872961.

- 527) Passalacqua MI, Rizzo G, Santarpià M, Curigliano G. 'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research'. *Expert Opin Investig Drugs*. 2022 Dec 25:1-20. doi: 10.1080/13543784.2022.2159805. Epub ahead of print. PMID: 36522800.
- 528) Longo B, Di Napoli A, Curigliano G, Veronesi P, Pileri S, Martelli M, De Vita R, Felici N, Cirillo P, Bernardi C, D'orsi G, Giacalone M, Storti G, Cervelli V. Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL. *Breast*. 2022 Dec;66:332-341. doi: 10.1016/j.breast.2022.11.009. Epub 2022 Dec 3. PMID: 36502569; PMCID: PMC9763507.
- 529) Nicosia L, Bozzini AC, Ballerini D, Palma S, Pesapane F, Raimondi S, Gaeta A, Bellerba F, Origgi D, De Marco P, Castiglione Minischetti G, Sangalli C, Meneghetti L, Curigliano G, Cassano E. Radiomic Features Applied to Contrast Enhancement Spectral Mammography: Possibility to Predict Breast Cancer Molecular Subtypes in a Non-Invasive Manner. *Int J Mol Sci*. 2022 Dec 5;23(23):15322. doi: 10.3390/ijms232315322. PMID: 36499648; PMCID: PMC9740943.
- 530) Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaq S, Cortés J. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. *Lancet*. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420-5. Epub ahead of print. PMID: 36495879.
- 531) Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. *JAMA Oncol*. 2022 Dec 1:e225610. doi: 10.1001/jamaoncol.2022.5610. Epub ahead of print. PMID: 36454580; PMCID: PMC9716438.
- 532) Nicolò E, Tarantino P, Curigliano G. Biology and Treatment of HER2-Low Breast Cancer. *Hematol Oncol Clin North Am*. 2023 Feb;37(1):117-132. doi: 10.1016/j.hoc.2022.08.013. PMID: 36435605.
- 533) Taurelli Salimbeni B, Corvaja C, Valenza C, Zagami P, Curigliano G. The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. *Expert Opin Investig Drugs*. 2022 Nov;31(11):1203-1226. doi: 10.1080/13543784.2022.2151433. Epub 2022 Dec 22. PMID: 36413823.
- 534) Nicolò E, Repetto M, Boscolo Bielo L, Tarantino P, Curigliano G. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2? *Cancer J*. 2022 Nov-Dec 01;28(6):436-445. doi: 10.1097/PPO.0000000000000629. PMID: 36383906.
- 535) Spitaleri G, Trillo Aliaga P, Catania C, Signore ED, Attili I, Santoro C, Giugliano F, Berton Giachetti PPM, Curigliano G, Passaro A, de Marinis F. Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers. *Clin Lung Cancer*. 2023 Jan;24(1):e19-e26. doi: 10.1016/j.clc.2022.10.004. Epub 2022 Oct 21. PMID: 36372676; PMCID: PMC9584758.
- 536) Tarantino P, Nicolò E, Curigliano G. Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer". *Eur J Cancer*. 2022 Nov

9:S0959-8049(22)00802-4. doi:10.1016/j.ejca.2022.10.008. Epub ahead of print. PMID: 36371304.

537) Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. *Br J Cancer*. 2022 Nov 5. doi: 10.1038/s41416-022-02025-9. Epub ahead of print. PMID: 36335217.

538) van Dam P, Tomatis M, Ponti A, Marotti L, Aristei C, Biganzoli L, Cardoso MJ, Cheung KL, Curigliano G, De Vries J, Santini D, Sardanelli F, Rubio IT; Eusoma Working Group. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres. *Eur J Cancer*. 2022 Dec;177:72-79. doi: 10.1016/j.ejca.2022.09.027. Epub 2022 Oct 12. PMID: 36332437; PMCID: PMC9554010.

539) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR 3rd, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Kaufman PA, Ashley EJ, Perez-Olle R, Hong S, Rosales MK, Gradishar WJ; SOPHIA Study Group. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. *J Clin Oncol*. 2022 Nov 4;JCO 2102937. doi: 10.1200/JCO.21.02937. Epub ahead of print. PMID: 36332179.

540) Uliano J, Nicolò E, Corvaja C, Taurelli Salimbeni B, Trapani D, Curigliano G. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. *Expert Rev Clin Pharmacol*. 2022 Dec;15(12):1399-1413. doi: 10.1080/17512433.2022.2142559. Epub 2022 Nov 8. PMID: 36317756.

541) Lee GA, Aktaa S, Baker E, Gale CP, Yaseen IF, Gulati G, Asteggiano R, Szmít S, Cohen-Solal A, Abdin A, Jurczak W, Garrido Lopez P, Sverdlov AL, Tocchetti CG, Barac A, Parrini I, Zamorano P, Iakobishvili Z, Pudil R, Badimon L, Kirby AM, Blaes AH, Farmakis D, Curigliano G, Stephens R, Lyon AR, Lopez-Fernandez T. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. *Eur Heart J Qual Care Clin Outcomes*. 2022 Dec 13;9(1):1-7. doi: 10.1093/ehjqcco/qcac070. PMID: 36316010; PMCID: PMC9745663.

542) Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Paluch-Shimon S; ESMO Guidelines Committee. *Ann Oncol*. 2022 Oct 25:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print. PMID: 36307055.

543) Aapro M, Cardoso F, Curigliano G, Eniu A, Gligorov J, Harbeck N, Mueller A, Pagani O, Paluch-Shimon S, Senkus E, Thürlimann B, Zaman K. Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. *Breast*. 2022 Dec;66:145-156. doi: 10.1016/j.breast.2022.07.011. Epub 2022 Jul 31. PMID: 36279803; PMCID: PMC9597182.

544) Corvaja C, Taurelli Salimbeni B, Nicolò E, Puglisi F, Curigliano G. Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance. *Expert Opin Pharmacother*. 2022 Nov;23(16):1765-1770. doi: 10.1080/14656566.2022.2139176. Epub 2022 Nov 3. PMID: 36268855.



- 545) Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, Baldassarre G, Curigliano G, Delmonte A, De Luca A, Fiorentino M, Gregorc V, Ibrahim T, Lazzari C, Mastronuzzi A, Pronzato P, Santoro A, Scambia G, Tommasi S, Vingiani A, Giacomini P, De Maria R. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer. *J Exp Clin Cancer Res.* 2022 Oct 17;41(1):305. doi: 10.1186/s13046-022-02512-0. PMID: 36245005; PMCID: PMC9575294.
- 546) Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. *NPJ Breast Cancer.* 2022 Oct 11;8(1):114. doi: 10.1038/s41523-022-00479-x. PMID: 36220852; PMCID: PMC9553912.
- 547) Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. *Cancer Treat Rev.* 2022 Dec;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub 2022 Sep 28. PMID: 36202026.
- 548) Albanell J, Pérez-García JM, Gil-Gil M, Curigliano G, Ruíz Borrego M, Comerma L, Gibert J, Bellet M, Bermejo B, Calvo L, de la Haba J, Espinosa E, Minisini AMM, Quiroga V, Santaballa Bertran A, Mina L, Bellosillo B, Rojo F, Menéndez S, Sampayo-Cordero M, Popa C, Malfettone A, Cortés J, Llombart-Cussac A. Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. *Clin Cancer Res.* 2022 Sep 27:CCR-22-1281. doi: 10.1158/1078-0432.CCR-22-1281. Epub ahead of print. PMID: 36165912.
- 549) Fabi A, Buono G, Bria E, Bianchini G, Curigliano G, De Laurentiis M, De Placido S, Del Mastro L, Guarneri V, Generali D, Livi L, Lorusso V, Montemurro F, Puglisi F, Vigneri P, Zambelli A, Arpino G. Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach. *Front Oncol.* 2022 Sep 9;12:950861. doi: 10.3389/fonc.2022.950861. PMID: 36158652; PMCID: PMC9501706.
- 550) Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, Higham CE, Lupi I, Paschou SA, Toth M, van der Kooij M, Dekkers OM. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. *Eur J Endocrinol.* 2022 Oct 25;187(6):G1-G21. doi: 10.1530/EJE-22-0689. PMID: 36149449; PMCID: PMC9641795.
- 551) Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, Nakhli F, Bellon JR, Parker T, Strauss S, Jin Q, King TA, Overmoyer BA, Curigliano G, Regan MM, Tolaney SM, Lynce F. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. *Eur J Cancer.* 2022 Oct;174:277-286. doi: 10.1016/j.ejca.2022.07.001. PMID: 36116830.
- 552) Franzoi MA, Trapani D, Jezdic S, Regan MM, Curigliano G, Andre F. Reply to the Letter to the Editor 'Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification' by Hannoun-Levi et al. *Ann Oncol.* 2022 Dec;33(12):1331-1333. doi: 10.1016/j.annonc.2022.09.154. Epub 2022 Sep 15. PMID: 36115609.
- 553) Prat A, Bardia A, Curigliano G, Hammond MEH, Loibl S, Tolaney SM, Viale G. An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2

Amplification (HER2-Low). *JAMA Oncol.* 2022 Sep 15. doi:10.1001/jamaoncol.2022.4175. Epub ahead of print. PMID: 36107417.

554) Swami N, Corti C, Curigliano G, Celi LA, Dee EC. Exploring biases in predictive modelling across diverse populations. *Lancet Healthy Longev.* 2022 Feb;3(2):e88. doi: 10.1016/S2666-7568(21)00307-X. PMID: 36098328.

555) Valenza C, Trapani D, Curigliano G. Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer. *Curr Opin Oncol.* 2022 Nov 1;34(6):595-605. doi: 10.1097/CCO.0000000000000905. Epub 2022 Sep 7. PMID: 36083118.

556) Belli C, Antonarelli G, Repetto M, Boscolo Bielo L, Crimini E, Curigliano G. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies. *Cancers (Basel).* 2022 Sep 1;14(17):4278. doi: 10.3390/cancers14174278. PMID: 36077813; PMCID: PMC9454727.

557) Brown C, Mantzaris M, Nicolaou E, Karanasiou G, Papageorgiou E, Curigliano G, Cardinale D, Filippatos G, Memos N, Naka KK, Papakostantinou A, Vogazianos P, Ioulianou E, Shammas C, Constantinidou A, Tozzi F, Fotiadis DI, Antoniadis A. A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research. *Cardiooncology.* 2022 Sep 7;8(1):16. doi: 10.1186/s40959-022-00142-1. PMID: 36071532; PMCID: PMC9450324.

558) Horgan D, Spanic T, Apostolidis K, Curigliano G, Chorostowska-Wynimko J, Dauben HP, Lal JA, Dziadziuszko R, Mayer-Nicolai C, Kozaric M, Jönsson B, Gutierrez-Ibarluzea I, Fandel MH, Lopert R. Towards Better Pharmaceutical Provision in Europe-Who Decides the Future? *Healthcare (Basel).* 2022 Aug 22;10(8):1594. doi: 10.3390/healthcare10081594. PMID: 36011250; PMCID: PMC9408332.

559) Trapani D, Tay-Teo K, Tesch ME, Roitberg F, Sengar M, Altuna SC, Hassett MJ, Genazzani AA, Kesselheim AS, Curigliano G. Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. *Curr Oncol.* 2022 Aug 16;29(8):5774-5791. doi: 10.3390/curroncol29080455. PMID: 36005193; PMCID: PMC9406873.

560) Bonadio RC, Tarantino P, Testa L, Punie K, Pernas S, Barrios C, Curigliano G, Tolaney SM, Barroso-Sousa R. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences? *Cancer Treat Rev.* 2022 Nov;110:102459. doi: 10.1016/j.ctrv.2022.102459. Epub 2022 Aug 18. PMID: 35998514.

561) Trapani D, Ferraro E, Giugliano F, Boscolo Bielo L, Curigliano G, Burstein HJ. Postneoadjuvant treatment for triple-negative breast cancer. *Curr Opin Oncol.* 2022 Nov 1;34(6):623-634. doi: 10.1097/CCO.0000000000000893. Epub 2022 Aug 19. PMID: 35993306.

562) Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. *Ann Oncol.* 2022 Nov;33(11):1168-1178. doi: 10.1016/j.annonc.2022.08.002. Epub 2022 Aug 13. PMID: 35973665.

564) Antonarelli G, Corti C, Zucali PA, Perrino M, Manglaviti S, Lo Russo G, Varano GM, Salvini P, Curigliano G, Catania C, Conforti F, De Pas T. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic

MalignanciEs (TYME) Italian collaborative group. *Eur J Cancer*. 2022 Oct;174:31-36. doi: 10.1016/j.ejca.2022.07.009. Epub 2022 Aug 12. PMID: 35970033.

565) Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, Felip E, Ferreira AR, Ganz PA, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge AH, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. *Ann Oncol*. 2022 Nov;33(11):1119-1133. doi: 10.1016/j.annonc.2022.07.1941. Epub 2022 Aug 10. PMID: 35963481.

566) Shuman AG, Aapro MS, Anderson B, Arbour K, Barata PC, Bardia A, Bruera E, Chabner BA, Chen H, Choy E, Conte P, Curigliano G, Dizon D, O'Reilly E, Tito Fojo A, Gelderblom H, Graubert TA, Gurtler JS, Hall E, Hirsch FR, Idbaih A, Ilson DH, Kelley M, La Vecchia C, Ludwig H, Moy B, Muss H, Opdam F, Pentz RD, Posner MR, Ross JS, Sacher A, Senan S, Perez de Celis ES, Tanabe KK, Vermorken JB, Wehrenberg-Klee E, Bates SE. Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization. *Oncologist*. 2022 Aug 13;27(9):711-3. doi:10.1093/oncolo/oyac165. Epub ahead of print. PMID: 35962750; PMCID: PMC9438903.

567) Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase ½ ARROW trial. *Nat Med*. 2022 Aug;28(8):1640-1645. doi: 10.1038/s41591-022-01931-y. Epub 2022 Aug 12. PMID: 35962206; PMCID: PMC9388374.

568) Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi- Micheli G, Cardoso MJ, Curigliano G, Gelmon KA, Gentilini O, Harbeck N, Kaufman B, Kim SB, Liu Q, Merschdorf J, Poortmans P, Pruneri G, Senkus E, Sirohi B, Spanic T, Sulosaari V, Peccatori F, Paganì O. ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). *Ann Oncol*. 2022 Nov;33(11):1097-1118. doi: 10.1016/j.annonc.2022.07.007. Epub 2022 Aug 4. PMID: 35934170.

569) De Rose F, Meduri B, De Santis MC, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delalogue S, Cortes J, Curigliano G. Rethinking breast cancer follow-up based on individual risk and recurrence management. *Cancer Treat Rev*. 2022 Sep;109:102434. doi: 10.1016/j.ctrv.2022.102434. Epub 2022 Jul 1. PMID: 35933845.

570) Tarantino P, Curigliano G, Tolaney SM. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. *Cancer Discov*. 2022 Sep 2;12(9):2026-2030. doi: 10.1158/2159-8290.CD-22-0703. PMID: 35856622.

571) Corti C, Conforti F, Pala L, Catania C, Coccorocchio E, Ferrucci PF, Curigliano G, Queirolo P, de Pas T. Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. *Eur J Cancer*. 2022 Sep;172:332-339. doi: 10.1016/j.ejca.2022.06.015. Epub 2022 Jul 9. PMID: 35820244.

572) Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. Epub 2022 Jul 6. PMID: 35809752.

- 573) Crimini E, Repetto M, Tarantino P, Ascione L, Antonarelli G, Rocco EG, Barberis M, Mazzearella L, Curigliano G. Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. *Cancers (Basel)*. 2022 Jun 29;14(13):3193. doi: 10.3390/cancers14133193. PMID: 35804968; PMCID: PMC9264928.
- 574) Kanesvaran R, Castro E, Wong A, Fizazi K, Chua MLK, Zhu Y, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Prabhash K, Zou Q, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. *ESMO Open*. 2022 Aug;7(4):100518. doi: 10.1016/j.esmoop.2022.100518. Epub 2022 Jul 4. PMID: 35797737; PMCID: PMC9434138.
- 575) Giugliano F, Valenza C, Tarantino P, Curigliano G. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced? *Expert Opin Investig Drugs*. 2022 Aug;31(8):855-874. doi: 10.1080/13543784.2022.2095260. Epub 2022 Jul 6. PMID: 35762248.
- 576) Tini G, Trapani D, Duso BA, Beria P, Curigliano G, Pelicci PG, Mazzearella L. Quantifying geographical accessibility to cancer clinical trials in different income landscapes. *ESMO Open*. 2022 Jun;7(3):100515. doi: 10.1016/j.esmoop.2022.100515. Epub 2022 Jun 21. PMID: 35738201; PMCID: PMC9271515.
- 577) Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. *Cancer*. 2022 Sep 1;128(17):3185-3195. doi: 10.1002/cncr.34366. Epub 2022 Jun 23. PMID: 35737639; PMCID: PMC9540525.
- 578) Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. *JAMA Oncol*. 2022 Aug 1;8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286. PMID: 35737367; PMCID: PMC9227690.
- 579) Moss P, Berenbaum F, Curigliano G, Grupper A, Berg T, Pather S. Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. *Vaccine*. 2022 Jul 30;40(32):4348-4360. doi: 10.1016/j.vaccine.2022.05.067. Epub 2022 May 27. PMID: 35718592; PMCID: PMC9135663.
- 580) Corti C, Antonarelli G, Valenza C, Nicolò E, Rugo H, Cortés J, Harbeck N, Carey LA, Criscitiello C, Curigliano G. Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? *Eur J Cancer*. 2022 Aug;171:25-42. doi: 10.1016/j.ejca.2022.04.039. Epub 2022 Jun 11. PMID: 35696887.
- 581) Gion M, Trapani D, Cortés A, Valenza C, Lin N, Cortés J, Curigliano G. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. *Am Soc Clin Oncol Educ Book*. 2022 Apr;42:1-11. doi: 10.1200/EDBK\_351222. PMID: 35671434.
- 582) Wildiers H, Meyskens T, Marréaud S, Lago LD, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Meulemans B, Sousa B, Poncet C, Brain E. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. *Breast*. 2022 Aug;64:100-111. doi: 10.1016/j.breast.2022.05.004. Epub 2022 May 20. PMID: 35636341; PMCID: PMC9157551.

- 583) Valenza C, Antonarelli G, Giugliano F, Aurilio G, Verri E, Briganti A, Curigliano G, Necchi A. Emerging treatment landscape of non-muscle invasive bladder cancer. *Expert Opin Biol Ther.* 2022 Jun;22(6):717-734. doi: 10.1080/14712598.2022.2082869. Epub 2022 May 31. PMID: 35634893.
- 584) Repetto M, Crimini E, Ascione L, Boscolo Bielo L, Belli C, Curigliano G. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046. *Invest New Drugs.* 2022 Oct;40(5):1133-1136. doi: 10.1007/s10637-022-01259-x. Epub 2022 May 25. PMID: 35612671.
- 585) Corti C, Cobanaj M, Marian F, Dee EC, Lloyd MR, Marcu S, Dombrowschi A, Biondetti GP, Batalini F, Celi LA, Curigliano G. Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias. *Cancer Treat Rev.* 2022 Jul;108:102410. doi: 10.1016/j.ctrv.2022.102410. Epub 2022 May 19. PMID: 35609495.
- 586) Trapani D, Curigliano G. The global landscape of drug development of trastuzumab biosimilars. *J Cancer Policy.* 2021 Jun;28:100273. doi: 10.1016/j.jcpo.2021.100273. Epub 2021 Feb 9. PMID: 35559916.
- 587) Trapani D, Lengyel CG, Habeeb BS, Altuna SC, Petrillo A, El Bairi K, Hussain S, Mazher SA, Elfaham EM, Curigliano G, Khan SZ. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. *J Cancer Policy.* 2021 Jun;28:100285. doi: 10.1016/j.jcpo.2021.100285. Epub 2021 Apr 26. PMID: 35559914.
- 588) Trapani D, Franzoi MA, Burstein HJ, Carey LA, Delaloge S, Harbeck N, Hayes DF, Kalinsky K, Puzstai L, Regan MM, Sestak I, Spanic T, Sparano J, Jezdic S, Cherny N, Curigliano G, Andre F. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. *Ann Oncol.* 2022 Jul;33(7):702-712. doi: 10.1016/j.annonc.2022.03.273. Epub 2022 May 9. PMID: 35550723.
- 589) Tarantino P, Jin Q, Mittendorf EA, King TA, Curigliano G, Tolaney SM. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib. *Ann Oncol.* 2022 Aug;33(8):845-847. doi: 10.1016/j.annonc.2022.04.069. Epub 2022 May 4. PMID: 35525374.
- 590) Pagano D, Home P, Irs A, Ledermann J, Curigliano G, Iwatani T, Mandrola J, Freemantle N. The path for medical associations to sponsor trustworthy guidelines: is it feasible? *J R Soc Med.* 2022 Jul;115(7):252-256. doi: 10.1177/01410768221095240. Epub 2022 Apr 29. PMID: 35485430; PMCID: PMC9234889.
- 591) Gnant M, Curigliano G, Senn H, Thürlimann B, Weber WP. Customizing early breast cancer therapies - The 2021 St. Gallen International Breast Cancer Consensus Conference. *Breast.* 2022 Mar;62 Suppl 1(Suppl 1):S2. doi: 10.1016/j.breast.2022.03.009. Epub 2022 Mar 16. PMID: 35473638; PMCID: PMC9097795.
- 592) Nicolò E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, Cristofanilli M, Curigliano G. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. *Cancer Treat Rev.* 2022 May;106:102395. doi: 10.1016/j.ctrv.2022.102395. Epub 2022 Apr 18. PMID: 35468539.
- 593) Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, Molinelli C, Adamo V, Bianchini G, Biganzoli L, Curigliano G, De Laurentiis M, Fabi A, Frassoldati A, Gennari A, Marchiò C, Perrone F, Viale G, Zamagni C, Zambelli A, Del Mastro L, De Placido S, Guarneri V, Marchetti P, Puglisi F. Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. *Cancers (Basel).* 2022 Apr 9;14(8):1898. doi: 10.3390/cancers14081898. PMID: 35454806; PMCID: PMC9029479.

- 594) Aran A, Garrigós L, Curigliano G, Cortés J, Martí M. Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality? *Cancers (Basel)*. 2022 Mar 31;14(7):1771. doi: 10.3390/cancers14071771. PMID: 35406543; PMCID: PMC8996954.
- 595) Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, Curigliano G, Criscitiello C, Fusco N. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. *Front Mol Biosci*. 2022 Mar 15;9:834651. doi: 10.3389/fmolb.2022.834651. PMID: 35372498; PMCID: PMC8965450.
- 596) Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G, Fusco N. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. *Expert Opin Investig Drugs*. 2022 Jun;31(6):593-605. doi: 10.1080/13543784.2022.2054326. Epub 2022 Mar 24. PMID: 35311430.
- 597) Corti C, Cobanaj M, Dee EC, Criscitiello C, Tolaney SM, Celi LA, Curigliano G. Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. *Cancer Treat Rev*. 2022 Dec 11;112:102498. doi: 10.1016/j.ctrv.2022.102498. Epub ahead of print. PMID: 36527795.

## PUBLISHED BOOK CHAPTERS

---

1. D. Bossi, F. Wolf, G. Calviello, L. Lauro, **G. Curigliano**, A. Romito and A. Cittadini. Magnesium in the regulation of ascites tumor cell energy metabolism. *Molecular Oncology And Clinical Application (Birkhauser, Basel)*. Edited by A. Cittadini, R. Baserga, H.M. Pinedo, T. Galeotti and D. Corda (1993).
2. **G. Curigliano** and G. Ferretti. *Oncogenesi. Trattato di Radioterapia (2000)*
3. **G. Curigliano**. *I sarcomi dei tessuti molli. Trattato di Chirurgia. Sabiston (Italian Edition 2003)*
4. U. Veronesi, F. Bertolini and **G. Curigliano**. *Oncologia. Enciclopedia Treccani, Edizione 2004*
5. **G. Curigliano** et. Al. *Il carcinoma della mammella. Zanussi. Trattato di Medicina Interna. 2007*
6. **G. Curigliano** et. Al. *Il carcinoma del testicolo. Zanussi. Trattato di Medicina Interna. 2007*
7. **G. Curigliano** et. Al. *Le sindromi paraneoplastiche. Zanussi. Trattato di Medicina Interna. 2007*
8. **G. Curigliano**. *Sarcomas of bone and soft tissue. Greenfield Surgery di Mulholland, Lippincott Williams & Wilkins. 2010*
9. F. Bertolini, **G. Curigliano** and U. Veronesi, and. *Oncologia. Enciclopedia Treccani, Edizione 2010*
10. **G. Curigliano**, Janaina Brollo, Maximiliano Cassilha Kneubil. *Systemic Impact of Breast Reconstruction. Reconstructive Breast cancer Surgery. Mario Rietjens and Cicero Urban Editors. Springer 2012*
11. **G. Curigliano**, C. Criscitiello. *Successes and Limitations of Targeted Cancer Therapy in Breast Cancer. Peters S, Stahel RA (eds): Successes and Limitations of Targeted Cancer Therapy. Prog Tumor Res. Basel, Karger, 2014, vol 41, pp 15–35*
12. Angela Esposito, Lucia Gelao, Carmen Criscitiello and **Giuseppe Curigliano**. *Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment. The Heart and Toxins. Elsevier 2015*

13. Giuseppe Curigliano and Marzia Locatelli. Arrhythmias and QTc Prolongation. Hot Topics in Medicine and Surgery. Elsevier 2016.

#### **SELECTED INTERNATIONAL CONFERENCES ATTENDED AS FACULTY**

- 1992 International Conference on Cancer: Molecular Oncology and Clinical Application, Roma, Italia.
- 1993 4th World Congress International Gastro-Surgical Club, Madrid, Spain.
- 1995 5th Congress of the European Council of Coloproctology, Barcellona, Spain.
- 1995 First International Congress "Colorectal Cancer: from Gene to Cure", Amsterdam, Netherland.
- 1995 Research Forum 94° Annual Convention of American Society of Colon and Rectal Surgeons, Montreal, Canada.
- 1996 American Association for Cancer Research 87th Annual Meeting, Washington, USA.
- 1996 AARC and IARC Joint Conference "Carcinogenesis from environmental pollution: Assessment of human risk and strategies for prevention", Budapest, Hungary.
- 1996 2nd International Symposium on Predictive Oncology and Therapy "Impact of cancer biotechnology on diagnostic and prognostic indicators in predictive oncology and therapy", Nice, France.
- 1998 European Association for Cancer Research, XV meeting, Stockholm, Sweden.
- 1998 4th International Symposium on Predictive Oncology and Therapy "Impact of biotechnology on cancer: Diagnostic and Prognostic Indicators", Nice, France.
- 2000 2nd Milan Breast Conference, Milan, Italy
- 2000 25th European Society of Medical Oncology Congress, Hamburg, Germany.
- 2000 37th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, USA
- 2001 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, USA
- 2001 Molecular Targets and Cancer Therapeutics. AACR-NCI-EORTC International Conference, Miami, USA

2002 4th Milan Breast Conference, Milan, Italy

2003 5th Milan Breast Conference, Milan, Italy

2003 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA

2004 6th Milan Breast Conference, Milan, Italy

2004 Molecular Targets and Cancer Therapeutics. AACR-NCI-EORTC International Conference, Geneva, Switzerland

2004 40th Annual Meeting of American Society of Clinical Oncology, New Orleans, USA

2005 41th Annual Meeting of American Society of Clinical Oncology, Orlando, USA

2005 7th Milan Breast Conference, Milan, Italy

2005 96th American Association for Cancer research Annual Meeting Anaheim/Orange County, USA, CA, 2005

2006 42th Annual Meeting of American Society of Clinical Oncology, Atlanta, USA

2006 8th Milan Breast Cancer Conference

2006 97th American Association for Cancer research Annual Meeting Washington, USA, 2006

2006 Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland

2007 98th American Association for Cancer Research Annual Meeting, Los Angeles, USA

2007 43th Annual Meeting of American Society of Clinical Oncology, Chicago, USA

2007 9th Milan Breast Cancer Conference

2008 10th Milan Breast Cancer Conference

2008 Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland

2008 Annual Meeting of American Society of Clinical Oncology, Orlando, USA

2008 San Antonio, Breast Cancer Symposium, San Antonio, Texas, USA

2009 Annual Meeting of American Society of Clinical Oncology, Orlando, USA

2009 San Antonio, Breast Cancer Symposium, San Antonio, Texas, USA

2010 ASCO Annual Meeting, Chicago

2010 IMPAKT Breast Cancer Conference, Brussels, Belgium

2011 Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland

2011 IMPAKT Breast Cancer Conference, Brussels, Belgium



2011 Milan Breast Cancer Conference

2012 IMPAKT Breast Cancer Conference, Brussels, Belgium

2012 ESMO Meeting, Vienna, Invited Speaker and Faculty Member

2013 Saint Gallen Breast Cancer Conference, St Gallen, Switzerland

2013 ECCO Cancer Meeting, Amsterdam

2013 ASCO Annual Meeting, Chicago

2013 Russian Society of Medical Oncology, Moscow

2013 ESTRO annual meeting, Porto

2013 ESSO annual meeting, Amsterdam

2013 San Antonio Breast Cancer Conference

2014 ESMO 2014 Meeting, Madrid, Scientific Chair

2014 IMPAKT Breast Cancer Meeting, Brussels, Scientific Chair

2015 Russian Society of Medical Oncology, Moscow

2015 ESTRO annual meeting, Vienna

2015 ESSO annual meeting, Liverpool

2015 San Antonio Breast Cancer Conference

2015 ECCO 2015 Meeting, Vienna, Invited Speaker

2015 IMPAKT Breast Cancer Meeting, Brussels, Invited Speaker

2015 ABC 3, Advanced Breast Cancer Meeting, Lisboa, Invited Speaker

2016 ESMO Immuno-Oncology Preceptorship, Siena, Invited Speaker

2016 UK Breast Cancer Research Symposium, London, UK, Invited Speaker

2016 Forum in Oncology, St Petersburg, Russia, Invited Speaker

2016 ESO-ESMO Masterclass in Medical Oncology, Wolfsberg, Switzerland, Invited Speaker

2016 ESO-ESMO Masterclass in Medical Oncology, Moscow, Russia, Invited Speaker

2016 ESO-ESMO Masterclass in Medical Oncology, Bogotá, Colombia, Invited Speaker

2016 Global Forum in Oncology, New York, USA, Invited Speaker

2016 Workshop in Clinical Oncology, Dubai, United Emirates States, Invited Speaker

2016 UK, Breast Cancer Research Symposium, London, United Kingdom

2016 ESMO Academy, August 26<sup>th</sup> -28<sup>th</sup> Oxford, United Kingdom

2016 2<sup>nd</sup> World Congress on Controversies in Breast Cancer, September 8-11, Barcelona, Spain

2016 ESMO Immuno-Oncology Symposium, Lausanne, Switzerland

2017 Gulf Educational Tour: Emirates, Qatar and Bahrain

2017 Vienna, 2017 St Gallen Early Breast Cancer Conference

2017 ESMO 2017 Meeting, Madrid, Spain

2017 SMEO Scientific Congress, Queretaro , Mexico

2017 ESMO Immuno-Oncology meeting, Geneve, Switzerland

2018 ESMO Immuno-Oncology meeting, Geneve, Switzerland

2019 ESMO Immuno-Oncology meeting, Geneve, Switzerland

2019 American Association for Cancer Research

2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2019 American Society of Clinical Oncology

2020 American Society of Clinical Oncology

2021 American Society of Clinical Oncology

2018 Korean Society of Medical Oncology

2019 Korean Society of Medical Oncology

2020 Korean Society of Medical Oncology

2021 Korean Society of Medical Oncology

2018 Japanese Society of Medical Oncology

2019 Japanese Society of Medical Oncology

2020 Japanese Society of Medical Oncology

2021 Japanese Society of Medical Oncology

2018 San Antonio Breast Cancer Symposium

2019 San Antonio Breast Cancer Symposium

2020 San Antonio Breast Cancer Symposium, USA

2021 San Antonio Breast Cancer Symposium, USA

2019 ESMO Targeted Anticancer Therapies Virtual Congress, Paris

2020 ESMO Targeted Anticancer Therapies Virtual Congress, Paris

2021 ESMO Targeted Anticancer Therapies Virtual Congress, Paris

2021 Plenary lecture at Korean Society of Medical Oncology, Seoul

- 2021 Plenary Lecture on Metastatic Breast Cancer, EOS Annual Conference 2021, Dubai, Emirates
- 2021 Plenary Lecture on Immunotherapy beyond triple negative breast cancer, San Antonio Breast cancer Symposium
- 2022 Honorary Chair, ESMO Breast Cancer, Berlin May 2022
- 2022 ASCO 2022, Educational Session Metastatic Breast Cancer
- 2022 ESMO 2022, Paris, Educational Session Metastatic Breast Cancer
- 2022 San Antonio Breast Cancer Symposium, Educational Session on HER2 low metastatic breast cancer
- 2023 Scientific Chair, San Gallen Early Breast Cancer Symposium, March 2023, Vienna, Austria

## **BIOGRAPHICAL SKETCH**

Giuseppe Curigliano, MD, PhD, is Chair of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, where besides his clinical work. He is a clinician and researcher specializing in breast cancer. He is professor of Medical Oncology at University of Milano. Dr. Curigliano earned his MD at the Università Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection. He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 3 years in the phase I unit, contributing to successful development of several targeted agents and cytotoxics. Since 2001 he is assistant professor of Clinical Pharmacology at University of Milan. In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is co-chair of Division of Clinical Oncology

coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). His clinical experience is based on a daily clinical management of patients with solid tumors, within a comprehensive cancer center accepting every year at least 85.000 first diagnosis patients. He practice in the in patient, out patient and day hospital setting. He served for 3 years on emergency an palliative care section of the Division. He is an active member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is founding member of/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He serves on the Clinical Research Committee of the AIOM. He serves as faculty member in the European School of Oncology (ESO). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG). He is ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference 2009, 2011 and 2013 as scientific secretary. Since October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference 2013.

Dr. Curigliano's research experiences include principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He has been also involved as principal investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting). Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development in breast cancer at European Institute of Oncology. Dr. Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer (more than 500 peer reviewed article, most of them as first and last author) and several book chapters. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Institute, the European Journal of Cancer and many other "breast oriented journals". He is member of the editorial board of Annals of Oncology, Journal of Clinical Oncology. He is associate editor of European Journal of Cancer and Co Editor in Chief of Cancer Treatment Reviews and The Breast. Prof Curigliano serves on the Executive Committee of EUSOMA

(European Society of Breast Cancer Specialists) and was elected as member of the ESMO Nominating Committee in 2017. In 2018 he covered the role of Chair of the Scientific Council for the Lega Italiana Lotta ai Tumori, for which now serves in the Executive Committee. Since January 2019 he is the Chair of the ESMO Guidelines Committee. In 2019 he was nominated by the Italian Ministry of Health as one of the 30 members of the National Health Advisory Council.

Milan, 28.12.2022

Dr. Giuseppe Curigliano has conducted clinical trials according to ICH / GCP. Last training on June 20<sup>th</sup> 2017

Authorizing the processing of personal data as defined by D. Decree Law 196/2003.



**INFORMAZIONI PERSONALI**

Nome **GRAZIA ARPINO**  
Indirizzo  
Telefono  
Fax  
E-mail  
Codice fiscale

Nazionalità

Data di nascita 18/5/73

Sesso

**ESPERIENZA LAVORATIVA**

1994 Partecipazione al Progetto Erasmus in qualità di studente interno, Dipartimento di Oncologia, Università Cattolica di Louvain, Bruxelles

1997-1998 Tirocinio in medicina d'urgenza presso l'Unità di Pronto Soccorso, Ospedale Cardarelli di Napoli

1997-2001 Specializzazione in Oncologia Medica, Università di Napoli Federico II

2001-2005 Postdoctoral fellow, Breast Center, Baylor College of Medicine, Houston, Texas

2006 Faculty Instructor, Breast Center, Baylor College of Medicine, Houston, Texas

2006-2008 Specializzazione in Ematologia ed Oncologia, Baylor College of Medicine, Houston, Texas

2008-2009 Specializzazione in Medicina Interna, Methodist Hospital, Houston Texas

2009-attuale Ricercatore Medico, Dipartimento Assistenziale di Oncologia ed Endocrinologia Clinica, Azienda Ospedaliera Universitaria, University Hospital of Naples Federico II, Via S. Pansini 5, 80131, Napoli, Italy

**ISTRUZIONE E FORMAZIONE**

1990 Maturità scientifica, 60/60, Liceo Scientifico "Mercalli", Napoli

1997 Laurea in Medicina e Chirurgia, 110/110 e Lode, Università degli Studi di Napoli, Federico II

1998 Abilitazione all'esercizio professionale della Medicina e Chirurgia. Esame di Stato per l'abilitazione a tale Ordine conseguito con votazione 90/90

2001 Specializzazione in Oncologia, 70/70, Università degli Studi di Napoli, Federico II

2002-2006 Dottorato di Ricerca in Oncologia ed Endocrinologia Molecolare, Università degli Studi di Napoli, Federico II e Baylor College of Medicine, Breast Center, Houston, Texas

2003 Esame di lingua inglese: Test of English as a Foreign Language (TOEFL) conseguito con votazione 250

2005-2006 Abilitazione alla professione medica negli Stati Uniti con conseguimento degli esami richiesti a tale fine: United States Medical Licensing Examination, UMSLE, Step 1, Step 2, Step 3 e Clinical skill

CAPACITÀ E COMPETENZE  
PERSONALI

Madrelingua(e) **italiano**

Altra(e) lingua(e) **Inglese**

Autovalutazione

Livello europeo (\*)

**Inglese**

**Francese**

**Tedesco**

<b>Comprensione</b>				<b>Parlato</b>				<b>Scritto</b>	
Ascolto		Lettura		Interazione orale		Produzione orale			
B2	Utente autonomo	C1	Utente avanzato	B2	Utente autonomo	B1	Utente autonomo	B1	Utente autonomo
B1	Utente autonomo	B2	Utente autonomo	B1	Utente autonomo	B1	Utente autonomo	A1	Utente base
A1	Utente base	A1	Utente base	A1	Utente base	A1	Utente base	A1	Utente base

***CURRICULUM  
VITAE***

***Prof.ssa VALENTINA GUARNERI***

Dipartimento di Scienze Chirurgiche,  
Oncologiche e Gastroenterologiche (DiSCOG) –  
Università degli Studi di Padova  
Istituto Oncologico Veneto IRCCS



## INFORMAZIONI PERSONALI

*Nome* **VALENTINA GUARNERI**  
*Indirizzo di lavoro* Università di Padova  
Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche  
Istituto Oncologico Veneto IRCCS, Oncologia Medica 2  
Via Gattamelata 64, 35100 Padova

### **ESPERIENZA LAVORATIVA/ POSIZIONE ACCADEMICA**

**Dal 01/10/2021: Direttore UOC Oncologia 2, Istituto Oncologico Veneto IRCCS**

**Dal 18/01/2021: Professore Ordinario Oncologia Medica, Università di Padova, Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Integrazione assistenziale come Dirigente Medico di II Livello presso Oncologia Medica 2 Istituto Oncologico Veneto, IRCCS**

**Dal 15/04/2021: Direttore della Scuola di Specializzazione in Oncologia Medica, Università di Padova**

**Dall'aa 2021-2022: Direttore del Master intra ateneo "La sperimentazione clinica in oncologia: aspetti clinici, gestionali ed operativi"**

**Dal 19/11/2020: Coordinatore del Gruppo Oncologico Multidisciplinare Mammella del Dipartimento Oncologico Funzionale Interaziendale di Padova**

**Dal 01/10/2021 al 30/10/2023 : Coordinatore Dipartimento Oncologico Interaziendale di Padova**

**Dal 1/10/2014 al 17/01/2021: Professore Associato Oncologia Medica, Università di Padova, Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Integrazione assistenziale come Dirigente Medico di II Livello presso Oncologia Medica 2 Istituto Oncologico Veneto, IRCCS**

**Dal 01/12/2018 al 30/09/2021: Responsabile Unità Semplice a Valenza Dipartimentale "Sperimentazioni cliniche di Rete", Istituto Oncologico Veneto IRCCS, Padova**

**Dal Giugno 2017 al 15/04/2021: Vice-Direttore della Scuola di Specializzazione in Oncologia Medica, Università di Padova**

**01/04/2013-30/11/2018: Responsabile Struttura Semplice Ricerca Traslazionale e Terapie Innovative,**

Oncologia Medica 2, Istituto Oncologico Veneto IRCCS

**01/04/2013-30/09/2014: Ricercatore Universitario Confermato Oncologia Medica**, Università di Padova, Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Integrazione assistenziale come Dirigente Medico di II livello, presso Oncologia Medica 2 Istituto Oncologico Veneto, IRCCS

**1/11/2005-04/2013 Ricercatore Universitario Oncologia Medica (Confermato dal 2008)**, Università di Modena e Reggio Emilia, Integrazione assistenziale come Dirigente Medico di II livello, SC Oncologia, Dipartimento Integrato di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena

**05/2011 – 31/03/2013: Coordinatore** del Percorso UNITARIO di Trattamento (PUNTO) Senologico (**Breast Unit**), Azienda Ospedaliero-Universitaria Policlinico di Modena

**9-12/2009 Visiting Professor**, University of Texas MD Anderson Cancer Center, Dept of Breast Medical Oncology, Holcombe Boulevard, Houston, Tx

**11/2005-31/03/2013: Professore Aggregato**, Università di Modena e Reggio Emilia

**11/2003- 11/2005: Professore a Contratto**, Università di Modena e Reggio Emilia

**01/01/2004-31/01/2005 e 01/08/2005-31/10/2005:** Incarico libero-professionale per Attività assistenziale, SC Oncologia, Dipartimento Integrato di Oncologia ed Ematologia, Azienda Ospedaliera Policlinico di Modena

**01/2005- 07/2005: Observer, University of Texas** MD Anderson Cancer Center, Dept of Breast Medical Oncology, Holcombe Boulevard, Houston, Tx

**01/11/2003-30/04/2004: Contratto di Collaborazione Coordinata e Continuativa**, SC Oncologia, Dipartimento Integrato di Oncologia ed Ematologia, Università di Modena e Reggio Emilia

**I sessione 2000: Abilitazione alla professione di Medico Chirurgo**, iscrizione all'Ordine dei Medici di Livorno

## FORMAZIONE

Nel 2013 ha conseguito l'**Abilitazione a Professore di I fascia** raggruppamento concorsuale 06D3, SSD MED06 (*validità 29/01/2015-29/01/2024*)

2013-2014: corso di formazione "Programme for Oncology Leaders in Europe" presso la Scuola di Direzione Aziendale Università Bocconi, Milano

Nel 2012 ha conseguito l'**Abilitazione a Professore di II fascia** raggruppamento concorsuale 06D3, SSD MED06

2006-2007 **Corso di perfezionamento** in Statistica Applicata ai Quesiti Clinici, Università di Modena e Reggio Emilia

2004-2006: Corso di **Dottorato di Ricerca** in Oncologia Sperimentale e Clinica, Università di Modena e Reggio Emilia ( titolo conseguito nel Febbraio 2007)

1999-2003: **Specializzazione in Oncologia** (110/110 e Lode), Università degli Studi di Pisa

1993-1999: **Corso di Laurea in Medicina e Chirurgia**. Università degli Studi di Pisa Titolo conseguito in data 28/09/99, con la votazione di 110/110 e lode

1993: **Diploma di Maturità Classica**, Liceo-Ginnasio GB Niccolini-FD Guerrazzi, Livorno, votazione 60/60

## **Attività didattica**

Dal 2005 a tutt'oggi la Prof. Guarneri svolge l'attività didattica istituzionale prevista dal ruolo universitario. Di seguito sono sintetizzate le principali attività svolte presso i due atenei presso i quali ha prestato servizio:

### Università di Padova

Dal 2013 in qualità di professore aggregato, e dal 2014 in qualità di Professore Associato, svolge regolare attività didattica comprensiva di lezioni frontali, esercitazioni, tutoraggio, partecipazione a commissioni di esame e di diploma di Laurea presso l'Università di Padova nei cdi di Medicina e Chirurgia, Tecniche di Laboratorio Biomedico, Assistenza Sanitaria, Scienze Statistiche. Docente nel Master intra-ateneo "La sperimentazione clinica in oncologia: aspetti clinici, gestionali ed operativi", e in diverse Scuole di Specializzazione e nel corso di Dottorato di ricerca in Oncologia Clinica e Sperimentale e Immunologia.

Segretario della Scuola di Specializzazione in Oncologia Medica dal 2013 al 2017, ne è vice-direttore dal 2017 e Direttore dal 2021. Relatore e correlatore di numerose tesi di Laurea e di Specializzazione. Dal 2014 al 2015 ha fatto parte della Commissione didattica del Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche.

Nell'ambito del programma di indagine Didattica di Ateneo, La prof Guarneri ha sempre ricevuto ottimi giudizi da parte degli studenti (con punteggi anche di 9/10 e 10/10 nei corsi a titolarità esclusiva).

### Università di Modena e Reggio Emilia

Dal 2005 al 2013, in qualità di Professore Aggregato, ha svolto regolare attività didattica presso la Facoltà di Medicina e in alcune Scuole di Specializzazione presso l'Università di Modena e Reggio Emilia. Ha svolto regolare attività di docenza frontale, attività di tutoraggio e partecipazione a commissioni di esami, di diploma di laurea e di specializzazione. Ha fatto parte di numerose commissioni di valutazione per il conferimento e rinnovo degli Assegni di Ricerca presso l'Università di Modena e Reggio Emilia, ed è stata membro del Comitato Ordinatore della Scuola di Specializzazione in Oncologia dell'Università di Modena e Reggio Emilia.

L'attività didattica presso l'Università di Padova (dall'AA 2013-2014), e presso l'Università di Modena e Reggio Emilia (AA2003-2004/2012-2013) è descritta in dettaglio nella Sezione A.

## **Attività di ricerca e Produzione scientifica**

Dal 2001, la Prof.ssa Guarneri è coinvolta in protocolli di ricerca clinica e traslazionale con particolare riferimento alle neoplasie della mammella, allo scopo di valutare nuovi approcci terapeutici nell'ottica di una strategia di personalizzazione del trattamento.

Successivamente, alla luce della progressiva trasversalità degli approcci di terapie a bersaglio molecolare su diversi tipi tumorali, ha ampliato il suo campo di ricerca alla patologia polmonare e ovarica, mantenendo l'interesse su ricerca traslazionale e personalizzazione delle terapie.

Più recentemente, visto le nuove opportunità legate alla creazione della Rete Oncologica Veneta, l'area di ricerca si è ampliato a comprendere studi per generare evidenza dai dati di real world, monitoraggio delle performance dei gruppi di patologia e aderenza ai PDTA, studi di Budget impact, sempre con particolare riferimento alle neoplasie mammarie, polmonari e ginecologiche.

Autore o coautore di 261 pubblicazioni originali in riviste internazionali peer-reviewed. **Impact Factor totale 3049; Impact Factor come primo o ultimo autore 2394**, esclusa la corrispondenza (JCR-ISI WEB 2022). **Al Maggio 2024, L'H index secondo Scopus è 50, le citazioni totali 10220.** E' inoltre autore o coautore di diversi capitoli di libro.

Solide collaborazioni sono state istituite con le seguenti istituzioni sia sul territorio nazionale che a

livello internazionale (molte delle quali ancora in essere): MD Anderson Cancer Center, Insitute Goustave Roussy, IOSI Bellinzona, German Breast Group, Università di Modena e Reggio Emilia, Istituto Nazionale Tumori Milano, Istituto Europeo di Oncologia, Istituto Tumori di Genova, IRCCS Santa Maria Nuova Reggio Emilia, Università di Ferrara, Istituto Tumori Pascale-Napoli, Università di Verona, Policlinico Gemelli, Università del Piemonte Orientale, Hospital Clinic de Barcelona, Institut Régional du Cancer de Montpellier.

Brevetti: HER2Dx, patent pending

### **Attività Assistenziale**

Dal 1/10/2021 la Prof Guarneri ha assunto la Direzione della Struttura Complessa di Oncologia 2 dell'Istituto Oncologico Veneto, e il ruolo di Coordinatore del Dipartimento Oncologico Interaziendale di Padova.

Dal 01/04/2013 al 30/09/2021 la Prof.ssa Guarneri svolge ha svolto attività assistenziale come Dirigente Medico di ruolo a tempo pieno presso l'Oncologia Medica 2 dell'Istituto Oncologico Veneto IRCCS. L'attività assistenziale si svolge nell'ambito dell'attività ambulatoriale e di day hospital e della struttura di degenza omogenea, con particolare riferimento alla patologia mammaria, ginecologica e polmonare. L'attività clinica si focalizza sul processo diagnostico e terapeutico delle suddette neoplasie, e sulla cura delle complicanze delle neoplasie e degli effetti collaterali legati ai protocolli di chemioterapia, immunoterapia, farmaci a bersaglio molecolare e radioterapia, inclusa la gestione delle citopenie, sepsi, shock anafilattici, mucositi e emergenze oncologiche in genere.

Ha capacità pratiche relative a manovre invasive quali biopsia osteomidollare e paracentesi.

Ha contribuito come estensore alla realizzazione del PDTA delle neoplasie mammarie della Rete Oncologica Veneta (2016), e dal 2019 è coordinatore del gruppo di lavoro dell'aggiornamento. E' inoltre coordinatore del PDTA dei tumori eredo-familiari e del PDTA sulla preservazione della fertilità nei pazienti oncologici sempre nell'ambito della Rete Oncologica Veneta. Dal 2020 Responsabile del Gruppo Oncologico Multidisciplinare Tumori Mammari del Dipartimento Funzionale Interaziendale di Padova che include l'Istituto Oncologico Veneto, l'Azienda Ospedaliero-Universitaria di Padova e l'Azienda Territoriale Euganea della Provincia di Padova.

Dal 1/11/2005 al 31/03/2013 ha svolto regolare attività assistenziale come Dirigente Medico presso l'UO di Oncologia Medica, DAI di Oncologia ed Ematologia, Azienda Ospedaliera Policlinico di Modena. La Dr.ssa Guarneri ha svolto attività di consulenza oncologica al Policlinico di Modena e presso l'Ospedale Civile S. Agostino Estense. Dal Maggio 2011 la dr.ssa Guarneri ha ricevuto la nomina di Coordinatore del Percorso UNitario di Trattamento (PUNTO) Senologico (prot n. 11377 del 06/05/2011). Tale incarico è stato svolto fino al 31/03/2013.

Durante lo svolgimento della Specializzazione presso l'Università di Pisa, oltre alle attività assistenziali previste dal percorso formativo formale, si è occupata in prima persona delle procedure di trapianto di cellule staminali autologhe e allogeniche, ivi compreso scongelamento e reinfusione, protocolli di profilassi e gestione degli effetti collaterali.

### **Commissioni e comitati**

- Dal 2023 membro del Comitato Tecnico Scientifico di Europadonna
- Membro del Comitato Scientifico di ESMO Breast 2022
- Membro del Comitato Scientifico di ESMO ASIA 2021 e 2022
- Membro del Comitato Scientifico di ESMO 2021 ed ESMO 2023
- Dal 2020 fa parte del gruppo di lavoro dell'Osservatorio per il monitoraggio e la valutazione delle Reti oncologiche

- Membro del Comitato Scientifico di ESMO Breast 2020
- Dal 2019 è membro del comitato scientifico del consorzio internazionale TRIO (Translational Research In Oncology)
- Dal 2019 è Membro del Molecular Tumor Board della Regione Veneto
- Abstract reviewer del San Antonio Breast Cancer Symposium 2020,2022,2023
- Dal 2017 membro del Global Steering Committee dello studio adiuvante MonarchE
- Dal 2013 è membro del Comitato Scientifico dell'Advanced International Breast Cancer Course, co-presidente dal 2019
- Dal 2015 è membro della giunta del Collegio degli Oncologi Medici Universitari (COMU)
- Dal 2014 è membro del comitato scientifico del Breast and Gynecological International Cancer Conference
- Dal 2014 è membro del comitato scientifico Incontri Oncologici del Triveneto
- Dal 2015 è membro della Commissione Ricerca e Sviluppo del Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova
- Dal 2014 al 2015: membro della Commissione Didattica del DISCOG
- Dal 2016 membro del Comitato scientifico e dal 2018 socio fondatore dell'associazione Women for Oncology Italy
- Dal 2016 membro del Comitato scientifico e dal 2017 socio fondatore associazione PERIPLLO
- 2015-2018: Membro del Comitato Tecnico Sanitario del Ministero della Salute, Commissione Ricerca
- ESMO Breast 2019 : Membro della Faculty (Invited Speaker)
- San Antonio Breast Cancer Symposium 2019: Abstract reviewer e membro della Faculty (invited speaker)
- Congresso nazionale AIOM membro del comitato scientifico (2018, 2015, 2018), referee per il carcinoma mammario (2012, 2017, 2018)
- ESMO OncologyPRO Working Group: mandato 2015-2019, rinnovato 2020-2021
- ESMO Fellowship Committee: mandato 2020-2021
- ESMO Fellowship & Award Committee: mandato 2015-2019
- ESMO Young Oncologists Committee: mandato 2009-2012, rinnovato 2012-2014
- ESMO E-learning and CME Working Group: mandato 2012-2014
- dal 2010 al 2016: membro del Comitato Scientifico dell' International Congress on Anticancer Treatment

### **Premi e Riconoscimenti**

- 2001: premio conferito dall'Ordine dei Medici di Livorno per la migliore tesi di laurea
- 2004: Research Grant della fondazione Komen Italy- Università Cattolica del Sacro Cuore di Roma per progetto di ricerca da svolgere presso MD Anderson Cancer Center, Houston, Texas
- 2004: premio di ricerca della Lega Italiana per la Lotta contro i Tumori
- 2005: premio giovane ricercatore "Associazione Malati Oncologici"
- 2006 e 2007: premio giovane ricercatore associazione "Cestodiliegge"
- 2009: Travel Grant dalla "Fondazione Komen" (MD Anderson Cancer Center, Houston, Texas)
- 2010: Unimore Monica Boscolo Research Grant"
- 2013: premio Giovani Ricercatori della Fondazione Guido Berlucci
- 2013: Lettura Marco Venturini dell'Associazione Italiana di Oncologia Medica

**Affiliazioni a Società scientifiche:** Associazione Italiana di Oncologia Medica (AIOM); European Society Medical Oncology (ESMO) ; American Society Clinical Oncology (ASCO); EBMT (European Bone Marrow Transplantation)

**Editorial Reviewer Board:** Annals of Oncology, Clinical Cancer Research, The Oncologist, Breast Cancer Research, British Journal of Cancer, Clinical Breast Cancer, Annals of Surgical Oncology, American Journal of Clinical Oncology, Cancer Letters, Expert Opinion on Drug Safety, Expert Review of Anticancer Therapy, Expert opinion on Pharmacotherapy, Cancer Chemotherapy and Pharmacology, International Journal of Biomedical Science, Chemotherapy, Oncology, Journal of Oncology, Lancet Oncology

### **Terza Missione**

Con l'associazione Women For Oncology, di cui la Prof Guarneri è socio fondatore, ha avviato attività che mirano al coinvolgimento dei media, dei rappresentanti delle Istituzioni e dei pazienti su tematiche riguardanti l'impatto della patologia neoplastica e delle cure sulla famiglia e sulla persona, oltre che sulla garanzia dell'accesso alle cure. In particolare con l'associazione sono già stati realizzati due eventi presso Palazzo Montecitorio (2018 e 2019), che hanno visto un confronto tra operatori sanitari e Istituzioni, accogliendo le testimonianze dei pazienti e delle associazioni di volontariato.

Nell'ambito delle attività svolte a sostegno delle associazioni di volontariato, la Prof Guarneri ha contribuito alla realizzazione di video divulgativi per l'associazione Europadonna e per l'associazione Freeda nell'ambito della giornata mondiale del tumore ovarico. La prof Guarneri ha inoltre parte attiva nelle attività della LILT di Padova.

### **Comunicazioni orali e relazioni su invito a congressi nazionali e internazionali, organizzazione di attività educazionali**

La Prof.ssa Guarneri ha tenuto più di 400 letture su invito a convegni nazionali, e più di 120 a congressi internazionali. Come membro del comitato scientifico degli "Incontri Oncologici del Triveneto" ha contribuito all'organizzazione di diverse attività educazionali e corsi ECM. Membro del comitato scientifico dell'Advanced International Breast Cancer Course, contribuisce alla realizzazione di un convegno annuale che riunisce i più eminenti esperti di neoplasie della mammella.

Padova, 6 Giugno 2024



## Curriculum Vitae Europass

### Informazioni personali

Nome(i) / Cognome(i) **Riccardo Masetti**

Indirizzo(i) Roma Italia

Telefono(i) Cellulare:

Fax

E-mail

Cittadinanza

Codice Fiscale

Data di nascita 29/09/1954

Sesso

### Settore professionale

Medicina e Chirurgia

### Esperienza professionale

Date

Lavoro o posizione ricoperti **Professore Straordinario di Chirurgia Generale** presso l'Istituto di Semeiotica Chirurgica dell'Università Cattolica del Sacro Cuore

**Direttore del Centro Interdipartimentale di Senologia** del Policlinico Universitario "Agostino Gemelli" di Roma

**Responsabile di Struttura Complessa (Unità Operativa di Chirurgia Senologica)** presso il Policlinico Universitario "Agostino Gemelli" di Roma

Svolge il proprio servizio **a tempo pieno** dal 1982

Principali attività e responsabilità **Docente nel Corso di Laurea in Medicina e Chirurgia** dell'Università Cattolica dall'A.A. 2001-12,

**Docente nelle Scuole di Specializzazione** dell'Università Cattolica per i seguenti corsi:

**Fisiopatologia Generale** presso la Scuola di Specializzazione in Chirurgia Toracica, dall'A.A. 1999-2000 ad oggi

**Chirurgia d'Urgenza e Pronto Soccorso** presso la Scuola di Specializzazione in Medicina dello Sport, dall'A.A. 2000-01 ad oggi.

**Senologia** presso la Scuola di Specializzazione in Chirurgia Generale, dall'A.A. 2005-06 ad oggi.

Nome e indirizzo del datore di lavoro

Tipo di attività o settore

### Istruzione e formazione

Date

Titolo della qualifica rilasciata

**Laurea in Medicina e Chirurgia** con il massimo dei voti e la lode il 3 Novembre 1980 presso l'Università Cattolica del Sacro Cuore di Roma.

**Diploma di Specializzazione in Chirurgia Generale** presso l'Università degli Studi di Ancona con il massimo dei voti nel Luglio 1985.

**Diploma di Specializzazione in Medicina dello Sport** presso l'Università degli Studi di Roma "La Sapienza", con il massimo dei voti e la lode nell'Ottobre 1990.

Principali tematiche/competenze professionali acquisite

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione

Livello nella classificazione nazionale o internazionale

### Capacità e competenze personali

**Ha svolto, come primo operatore, oltre 5000 interventi di chirurgia oncologica** maggiore, con particolare riguardo alla chirurgia dei tumori della mammella.

In particolare, in questo settore ha contribuito con un team internazionale alla messa a punto di nuove tecniche di chirurgia conservativa, denominate tecniche di chirurgia oncoplastica, che associano gli accorgimenti propri della chirurgia oncologica con quelli propri della chirurgia estetica al fine di consentire un miglior controllo locale della malattia ed un più valido risultato cosmetico.

**E' Autore di 215 pubblicazioni scientifiche in extenso**, con un **Impact Factor complessivo pari a 81.462**, prevalentemente su temi di Chirurgia Generale ed Oncologica, di Chirurgia dei Tumori del Seno e di applicazioni della ricerca biologica in chirurgia oncologica.

Ha **svolto numerosi periodi di ricerca clinica e perfezionamento** in centri di eccellenza degli Stati Uniti, tra i quali:

- il Dipartimento di Chirurgia della **University of California San Francisco** (Aprile 1985),
- il **Memorial Sloan Kettering Cancer Center di New York** (Ottobre 1989),
- il **Van Nuys Breast Center di Los Angeles** (Novembre 1990, Febbraio 1991 e Aprile 1992)

E' stato **assegnatario di finanziamenti individuali pluriennali** per la ricerca, da parte di prestigiose Istituzioni Italiane ed estere per un totale complessivo di oltre 2 milioni di Euro.

E' **Membro dell'Editorial Board** della rivista scientifica internazionale "The Breast Journal" e Reviewer per le riviste internazionali "Annals of Surgery" e "European Journal of Cancer"

Nel Febbraio 2000 **ha fondato la Komen Italia onlus**, una associazione non a finalità di lucro, attiva nella lotta ai tumori del seno in Italia, della quale è attualmente Presidente.

Tale Associazione è il primo affiliato internazionale della prestigiosa Susan G. Komen Breast Cancer Foundation di Dallas (Texas), e ad oggi con le sue attività ha contribuito alla creazione del Centro Interdipartimentale di Senologia del Policlinico A. Gemelli ed alla istituzione, dal 2000 ad oggi di oltre 100 premi di studio per giovani ricercatori in Italia.

Dal 2006 è **Coordinatore Scientifico** di un progetto della organizzazione umanitaria internazionale *HopeXchange* per la realizzazione di un nuovo Centro Medico di Formazione Permanente nella città di Kumasi in Ghana.

Tale progetto è svolto in collaborazione con la Yale University di New Haven, il Fred Hutchinson Cancer Center di Seattle, e la University of Innsbruck ed è stato scelto dal Santo Padre Giovanni Paolo II come uno dei 100 progetti per l'Anno del Giubileo 2000.

Madrelingua(e)

**Italiano**



Altra(e) lingua(e)  
Autovalutazione  
Livello europeo (\*)

**Inglese**

**Lingua**  
**Lingua**

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
	C2		C2		C2		C2		C2

Autocertificazione dei dati dichiarati e l'autorizzazione del trattamento dati:

•Avvalendomi delle disposizioni di cui all'articolo 46 del DPR n° 445 del 28/12/2000, consapevole delle pene stabilite per le false attestazioni e mendaci dichiarazioni previste dal codice penale e dalle Leggi speciali in materia, dichiaro che le informazioni contenute nel presente Curriculum Vitae corrispondono a verità

•Autorizzo il trattamento dei miei dati personali presenti nel cv ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e del GDPR (Regolamento UE 2016/679).

Roma, 30 Novembre 2020

(\*) [Qua comune euro riferimento per le lingue](#)

**Allegati** | Enumerare gli allegati al CV. (facoltativo, v. istruzioni)

**Firma** | Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali". (facoltativo, v. istruzioni)



## Curriculum Vitae Europass

### Informazioni personali

Cognome(i) / Nome(i) **Muto Paolo**

Telefono(i)

E-mail

Codice Fiscale

Data di nascita

Luogo di Nascita

### Esperienza professionale

Date	01/04/2020 ad oggi
Lavoro o posizione ricoperti	Direttore del Dipartimento CORP-S dei Servizi diagnostico-clinici di supporto ai percorsi oncologici
Principali attività e responsabilità	Direzione e gestione del dipartimento
Nome e indirizzo del datore di lavoro	Istituto Nazionale dei Tumori IRCCS Fondazione G. Pascale di Napoli Via M. Semmola 100, 80131 Napoli (Italia)
Date	01/10/2010 → ad oggi
Lavoro o posizione ricoperti	Direttore dell' U.O.C. di Radioterapia Oncologica
Principali attività e responsabilità	Direzione e gestione del reparto
Nome e indirizzo del datore di lavoro	Istituto Nazionale dei Tumori IRCCS Fondazione G. Pascale di Napoli Via M. Semmola 100, 80131 Napoli (Italia)
Tipo di attività o settore	U.O.C di Radioterapia Oncologica
Date	01/07/2004- 30/09/2010
Lavoro o posizione ricoperti	Direttore dell'U.O.C di Radioterapia Oncologica del P.O "Cardinale Ascalesi"-Asl NA1 con contratto quinquennale e riconfermata nel Giugno 2009
Principali attività e responsabilità	Direzione e gestione del reparto
Nome e indirizzo del datore di lavoro	P.O "Cardinale Ascalesi" Asl NA1 Via Egiziaca a Forcella 31, 80139, Napoli (Italia)
Tipo di attività o settore	U.O.C. di Radioterapia Oncologica
Date	2009

Lavoro o posizione ricoperti	Consulente per la fondazione muto-onlus per implementazione ed attivazione del primo sistema per Tomoterapia in Italia Meridionale
Principali attività e responsabilità	Direttore comitato scientifico
Nome e indirizzo del datore di lavoro	Fondazione muto-onlus Via Taverna Rossa 167/171, Casavatore (NA) (Italia)
Tipo di attività o settore	Fondazione onlus
Date	1999 - 2004
Lavoro o posizione ricoperti	Attività libero-professionale
Principali attività e responsabilità	Direzione e gestione del reparto di radioterapia presso la Casa di cura "Villa del Sole"
Nome e indirizzo del datore di lavoro	Radioterapia Villa del Sole Via Manzoni 15, 80123 Napoli (Italia)
Tipo di attività o settore	Radioterapia oncologica
Date	1999 - 2004
Lavoro o posizione ricoperti	Attività libero-professionale
Principali attività e responsabilità	Direzione e gestione del reparto di radioterapia presso la "Clinica Mediterranea"
Nome e indirizzo del datore di lavoro	Studio di Radiologia Prof. V. Muto Via Orazio 2, 80122 Napoli (Italia)
Tipo di attività o settore	Radioterapia oncologica
<b>Istruzione e formazione</b>	
Date	05/07/2019
Titolo della qualifica rilasciata	Abilitazione alla carica manageriale di Direttore Generale di Aziende ed Enti del Servizio Sanitario della Regione Campania
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Formez PA
Date	08/05/2019
Titolo della qualifica rilasciata	Abilitazione alla carica manageriale di Direttore Sanitario e Direttore di Unità Organizzativa Complessa di Aziende ed Enti del Servizio Sanitario Regionale
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Formez PA
Date	1989
Titolo della qualifica rilasciata	Specialista in Oncologia Medica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Il Facoltà di Medicina e Chirurgia di Napoli Napoli (Italia)
Date	1985
Titolo della qualifica rilasciata	Specialista in Radiologia (Diagnostica, Medicina Nucleare e Radioterapia)
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Cagliari
Date	30/10/1981
Titolo della qualifica rilasciata	Laurea in Medicina e Chirurgia con 110 e lode/110
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Napoli Federico II Napoli (Italia)

## Capacità e competenze personali

Madrelingua(e) **Italiano**

Altra(e) lingua(e)

Autovalutazione (\*) [Quadro comune europeo di riferimento per le lingue](#)

Livello europeo (\*)

**Inglese**

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
B2	Utente autonomo	B2	Utente autonomo	B2	Utente autonomo	B2	Utente autonomo	B2	Utente autonomo

Capacità e competenze sociali

Ottime capacità di team working, acquisite negli anni con collaborazioni presso istituzioni italiane ed estere quali Istituto Alberti di Brescia l'Istituto Europeo di Oncologia a Milano, il Gustave Roussy in Francia , Gruppo IMO in Spagna e delle Università del Maryland (Baltimora), Detroit, S. Luis e Vancouver .

Buone capacità di negoziazione e comunicazione nell'ambito della propria Unità Operativa e nell'ambito dell'azienda dove presta servizio ottimizzando così la qualità del reparto.

Capacità e competenze organizzative

Presidente Associazione Italiana di Radioterapia Oncologica 2008-2009

Direttore di struttura complessa di Radioterapia

Presidente ed Organizzatore XX Congresso Nazionale AIRO 2010

2010 Presidente XX Congresso AIRO Napoli 13-16 novembre 2010

Coordinatore corso itinerante linee guida AIRO carcinoma mammella (Genova,Perugia,Bologna,Napoli)

2011-2020 Organizza in qualità di Responsabile Scientifico i "Giovedì in Radioterapia" presso la U.O.C. di Radioterapia dell'I.R.C.C.S. Fondazione G. Pascale eventi formativi E.C.M. sulla Radioterapia Oncologica

2007-2013 Responsabile Scientifico del- Progetto "CECAP – Centro Campano Protonterapia" – Codice CUP: H41D11000030007 Finanziamento MIUR – Ministero dell'Istruzione, dell'Università e della Ricerca. Il progetto è stato chiuso con visita Ministeriale il 30/11/2015 con una rendicontazione di spesa del 98%.

2013 Membro del Gruppo Multidisciplinare Neuroendocrini dell'Istituto Nazionale Tumori Fondazione G. Pascale

29-10-2014 Responsabile per l'Istituto Nazionale Tumori I.R.C.C.S. Fondazione G. Pascale del progetto PON03PE\_00128 relativo al progetto esecutivo avente codice identificativo PON03PE\_00128\_1 e dal titolo: eHealthNet – ecosistema software per la sanità elettronica (progetto di ricerca), eHealthLearn (progetto di formazione).

21-22/03/2014 Organizza il I Convegno AIRO Campania. La Radioterapia in Campania: dalla pratica clinica all'innovazione tecnologica . Hotel Royal Napoli

10-11/04/2015 Organizza Il Convegno AIRO Campania " La Radioterapia Campana Incontra L'oncologia Medica E La Chirurgia Oncologica" . Hotel Royal Napoli

22-23/07/2015 Organizza l'evento Conclusivo Progetto "CECAP - CENTRO CAMPANO PROTONI" INT Fondazione G. Pascale \*

Si autorizza al trattamento dei dati personali ai sensi del GDPR e del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" ai fini di attività di Ricerca e Selezione del Personale e contatti lavorativi

Napoli, 13.09.2024

Dott. Paolo Muto

## Prof. Giuseppe Perrone

### Responsabile

Personale Anatomia Patologica

### BIOGRAFIA

Giuseppe PERRONE

DATA DI NASCITA: 27/11/1975

LUOGO DI NASCITA: BARI

CITTADINANZA:

STATO CIVILE:

DOMICILIO:



Contatti

### CURRICULUM

#### CURRICULUM ACCADEMICO

dal 2020 Professore Ordinario, Anatomia Patologica, UCMB

dal 2017 Responsabile Unità di Ricerca Anatomia Patologica, UCMB

2015-2020 Professore Associato, Anatomia Patologica, UCMB

2014-2019 Ricercatore TI confermato, Anatomia Patologica, UCMB

2011-2014 Ricercatore TI non confermato, Anatomia Patologica, UCMB

2010-2011 Ricercatore TD, Anatomia Patologica, UCMB

2009-2010 Ricercatore, Dipartimento di Patologia, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts (USA)

2006-2009 Dottorato di Ricerca in Epatologie Sperimentale e Clinica, Università degli Studi di Roma "La Sapienza"

2001-2006 Diploma di Specializzazione in Anatomia Patologica, UCMB

1995-2001 Diploma di Laurea in Medicina e Chirurgia, UCMB

#### CURRICULUM ASSISTENZIALE

Dal 2020 Responsabile UOS Diagnostica Molecolare Predittiva, Anatomia Patologica, Policlínico Universitario Campus Bio Medico.

2006-2020 Medico responsabile di funzioni di natura professionale - Anatomia Patologica

### PUBBLICAZIONI

1) Guerini-Rocco E, Botti G, Foschini MP, Marchiò C, Mastropasqua MG, Perrone G, Roz E, Santinelli A, Sassi I, Galimberti V, Gianni L, Viale G. Tumori 2021;3008916211062642

DOI: 10.1177/03008916211062642

2) Tavaglione F, De Vincentis A, Bruni V, Gallo IF, Carotti S, Tuolinardi D, Spagnolo G, Ciociola E, Mancina RM, Jamalehmadi O, D'Alessio R, Bottazzi B, Manfredi S, Picardi A, Perrone G, Pozzilli P, Caricato M, Vespasiani-Gentilucci U, Romeo S. Liver Int. 2022 Feb;42(2):374-383.

DOI: 10.1111/liv.15127

3) Pisapia P, Pope F, Baggi A, Barberis M, Galvano A, Cristina V, Mastrelli F, Novillo S, Pagni F, Passini S, Perrone G, Righi D, Russo A, Troncane G, Malapelie U. Crit Rev Oncol Hematol. 2022;169:103825.

DOI: 10.1016/j.critrevonc.2021.103825

4) Carotti S, Lettieri-Barbato D, Piemonte F, Ruggiero S, Rosine M, Zalfa F, Zingarollo M, Aroiprete F, Valentini F, Francesconi M, D'Amico J, De Vincentis A, Balocchi A, Perrone G, Antonelli-Incalzi R, Morini S, Picardi A, Aquilano K, Vespasiani-Gentilucci U. Cell Death Dis. 2021 Nov 18;12(12):1092.

DOI: 10.1038/s41419-021-04382-4

5) Longo UG, Mazzola A, Carotti S, Francesconi M, Capapano S, Magni F, Perrone G, Morini S, De Salvatore S, Denaro V. BMC Musculoskelet Disord. 2021 Oct 20;22(1):891.

DOI: 10.1186/s12891-021-04779-5

6) Corbelli B, Girolami I, Ecoher A, Costarelli L, Taccogna S, Scielpi R, Benevolo M, Lucante T, Luigi Alo P, Stella F, Gamma Pignataro M, Fadda G, Perrone G, D'Amati G, Martini M. Histopathology 2022;80(2):397-406.

DOI: 10.1111/his.14562. DOI: 10.1111/his.14562

7) Schottini F, Chic N, Braad-Mariastany F, Paró L, Pasqual T, Comto B, Martínez-Sáez D, Adamo B, Vidal M, Barnadas E, Fernández-Martínez A, González-Farre B, Sanfeliu E, Casajús JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fosani R, Villegras P, Gavilá J, Barrios CH, Lluh A, Martín M, Loco M, De Placido S, Prat A. (2021) NPJ Breast Cancer 4:7(1):1. DOI: 10.1038/s41523-020-00208-2.

8) Lastraioli E, Fraser SP, Mine Guzel R, Iorio J, Bencini L, Scarpi E, Messerini L, Villanacci V, Cerino G, Ghezzi N, Perrone G, Djingoz MBA, Arcangeli A. (2021) Cancers (Basel) 30(13):3832. DOI: 10.3390/cancers13153832

9) Carotti S, Zingarollo M, Francesconi M, D'Andrea L, Lettase MU, Colyn L, Fernandez-Barrera MG, Fiammra RS, Falchi M, Righi D, Pedini G, Pantano F, Bagni C, Perrone G, Rana RA, Avila MA, Morini S, Zalfa F. (2021). Oncogene 40(23):4033-4049. DOI: 10.1038/s41388-021-01824-3.

10) Orsaria P, Grasso A, Ippolito E, Pantano F, Samimama M, Altomare C, Cagli B, Costa F, Perrone G, Soponaru G, Caggiati L, Vainio G, Buonomo OC, Altomare V. (2021). Anticancer Res 41(5):2697-2709. DOI: 10.21873/anticancerres.15051.



# DOTT. AMBROGGI MASSIMO

---

Data di nascita: 22/08/1977

Luogo di nascita: PIACENZA (PC)

16/01/2004 - Albo Provinciale dei Medici Chirurghi di PIACENZA (Ordine della Provincia di PIACENZA) n. 0000002159	iscrizioni
20/10/2003 - MEDICINA E CHIRURGIA (PARMA)	lauree
2003 / 2 - Medicina e Chirurgia (PARMA)	abilitazioni
06/11/2008 - ONCOLOGIA (PARMA) - Specializzazione	specializzazioni

Data aggiornamento: 19/12/2024

L'elenco dei medici e degli odontoiatri riportati in questo servizio è stato realizzato sui dati comunicati dagli Ordini Provinciali. È opportuno ricordare che ai sensi dell'art. 1 del DPR n. 221 del 5 aprile 1950 la competenza alla tenuta degli Albi dei Medici Chirurghi e degli Odontoiatri spetta ai singoli Ordini Provinciali. Si fa presente altresì che la data di iscrizione all'Ordine Provinciale è riferita alla situazione attuale e non alla data di la iscrizione.

## INFORMAZIONI PERSONALI

## Francesca Corti

 Via GB Pergolesi 33, 20900, Monza, MB, Italia



Sesso | [Data di nascita](#) | [Nazionalità](#) Italiana

ESPERIENZA  
PROFESSIONALE

Gennaio 2023- in corso

**Oncologo Medico presso Fondazione IRCCS San Gerardo dei Tintori**

Oncologia Medica  
Fondazione IRCCS San Gerardo dei Tintori  
Via G.B. Pergolesi 33, 20900 Monza (MB), Italia

Dicembre 2021- Novembre 2022

**Oncologo Medico presso Fondazione IRCCS Istituto Nazionale dei Tumori di Milano**

Oncologia Medica  
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano  
Via G. Venezian 1, 20133, Milano, Italia

## ISTRUZIONE E FORMAZIONE

11 Novembre 2021

**Specializzazione in Oncologia Medica  
con votazione 70 / 70 e Lode**

Università degli Studi di Milano

24 Luglio 2015

**Laurea Magistrale in Medicina e Chirurgia Con votazione 110/110 e Lode e  
Menzione ad Honorem**

Università Vita-Salute San Raffaele di Milano

## COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

Inglese

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	C1	C1	C1	C1	C1

2008: CAE – Certificate in Advanced English

## ULTERIORI INFORMAZIONI

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Monza, 26/4/2024  
Dott.ssa Francesca Corti





## **Curriculum Vitae Europass**

### **Informazioni personali**

Nome(i) / Cognome(i)

**Alessandro Marco Minisini**

Indirizzo(i)

Telefono(i)

Fax

Cellulare:

E-mail

Cittadinanza

Italiana

Data di nascita

Sesso

Maschile

**Occupazione  
desiderata/Settore  
professionale**

**Dirigente Medico, I livello, Dipartimento di Oncologia,  
Azienda Sanitaria Universitaria del Friuli Centrale, Udine**

## Esperienza professionale

- Agosto 1995: studente interno presso il Laboratorio Nazionale del Consorzio Interuniversitario per le Biotecnologie, Area Science Park, Trieste.
- Dicembre 1996: studente interno presso la divisione di Oncologia Sperimentale II del Centro di Riferimento Oncologico di Aviano (PN).
- Settembre 1997- Dicembre 1998: studente interno presso il Laboratorio Co.Ri.Bi, Cattedra di Patologia Generale, Università degli Studi di Udine.
- Agosto 2000- Ottobre 2000: medico volontario presso l'Istituto di Gastroenterologia e Endoscopia Digestiva del Centro di Riferimento Oncologico di Aviano (PN).
- Novembre 2002 – Settembre 2003: research fellow presso EORTC- Investigational Drug Branch Breast Cancer (IDBBC) e Unità di Chemioterapia, Istituto "J. Bordet", Bruxelles, Belgio.
- 19-25 giugno 2004: partecipazione al 6° Workshop "Methods in Clinical Cancer Research" organizzato da Federation of European Cancer Societies, American Association for Cancer Research, American Society of Clinical Oncology, Flims, Svizzera.
- Novembre 2000 - Novembre 2004: medico specializzando presso la Clinica di Oncologia Medica del Policlinico Universitario di Udine, nell'ambito della Scuola di Specializzazione in Oncologia dell'Università degli Studi di Udine.
- Dal gennaio 2005 al dicembre 2007: iscritto al Dottorato di Ricerca in "Scienze e Tecnologie Cliniche" dell'Università degli Studi di Udine.
- Dall'aprile 2005 (a tempo indeterminato dal luglio 2006): dirigente medico presso Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria S.M. della Misericordia di Udine.
- Settembre-Ottobre 2011: Observership presso Breast Cancer Medicine al Memorial Sloan-Kettering Cancer Center di New York

## Istruzione e formazione

- Luglio 2000: laurea in medicina e chirurgia, Facoltà di Medicina e Chirurgia, Università degli Studi di Udine
- Novembre 2004: diploma di specializzazione in Oncologia, Facoltà di Medicina e Chirurgia, Università degli Studi di Udine
- Giugno 2008: dottorato di ricerca in "Scienze e Tecnologie Cliniche" presso l'Università degli Studi di Udine

**Capacità e competenze personali**

Sperimentatore principale e co-investigatore di diverse sperimentazioni cliniche in GCP  
Autore di diverse pubblicazioni in ambito scientifico medico  
Relatore a diversi convegni e corsi di formazione  
Coordinatore del gruppo multidisciplinare "patologie neoplastiche e della cute" dell'Azienda Sanitaria Universitaria del Friuli Centrale  
Coordinatore Gruppo di Patologia Oncologia "neoplasie mammarie" e "melanoma e neoplasie cutanee" Dipartimento di Oncologia ASUFC  
Estensore Linee Guida AIOM "melanoma"  
Docente con incarico di insegnamento presso Scuola di Specializzazione in Oncologia dell'Università di Udine

Madrelingua(e)

**Italiano**

Altra(e) lingua(e)

**Inglese (1), francese (2)**

Autovalutazione

Livello europeo (\*)

**Lingua****Lingua**

		<b>Comprensione</b>		<b>Parlato</b>		<b>Scritto</b>	
		Ascolto	Lettura	Interazione orale	Produzione orale		
1	Buono		Buono		Buono		Buono
2	Buono		Buono		Buono		Discreto

[Autorizzo il trattamento dei dati personali in conformità al d.lgs. 196/2003 e del Regolamento UE 679/2016](#)

[Ai sensi del D.P.R. 445/2000, si dichiara che le informazioni contenute nel presente curriculum corrispondono al vero](#)

**Firma**

13.3.24

## CURRICULUM VITAE



### INFORMAZIONI PERSONALI

Nome Maria Morritti  
Indirizzo  
Telefono  
Fax  
E-mail  
  
Nazionalità italiana  
Data di nascita

### ESPERIENZA LAVORATIVA

- 1987-1990 Ha frequentato come allieva interna l'Istituto di Anatomia e Istologia Patologica dell'Ospedale Sant'Orsola-Malpighi di Bologna negli anni accademici 1987/88, 1988/89, 1989/90.
- 1991-1992
- Ha prestato servizio presso la Casa di Cura "Clinica Leonardo De Luca" in Castenuovo della Daunia (FG) dal 21/05/91 al 15/02/92 .
  - Ha prestato servizio presso la Casa di Cura Villa Maria di Bologna per il periodo intercorrente dal maggio al dicembre 1992 .
  - Ha frequentato come Medico frequentatore la Divisione di Oncologia dell'Ospedale Sant' Orsola Malpighi di Bologna dal gennaio al marzo 1991 e dall'aprile al dicembre 1992.
- 1992-1994
- Ha frequentato come Medico frequentatore volontario la divisione di Oncologia dell'Ospedale "Casa Sollievo della Sofferenza di San Giovanni Rotondo dal mese di dicembre 1992 al maggio 1994.
  - Ha svolto attività di Medico addetto al Servizio di Guardia Medica presso l'Azienda U.S.L. FG/1 e FG/3 dal 1/12/ 1993 al 31/08/1996.
  - Dal 01/01/1993 ha svolto attività di volontariato presso l'associazione di volontariato "U.C.D."(Unità di Cure Domiciliari) della Divisione di Oncologia dell'Ospedale Casa Sollievo della Sofferenza (FG).
  - Le sono state assegnate **n° 4 borse** di studio per Medico ricercatore borsista presso la Divisione di Oncologia dell'Ospedale Casa Sollievo della Sofferenza di San Giovanni Rotondo (FG) (n° 3 borse di studio per lo studio AR/PK1 Letrozole e n° 1 borsa di studio per lo studio di geni oncosoppressori)

DAL 1998 ad oggi	-Dal 31/7/1998 al 31/1/1999 e dal 15/3/1999 a tutt'oggi <b>Dirigente medico</b> a tempo indeterminato presso la Divisione di Oncologia dell'Ospedale Casa Sollievo della Sofferenza di San Giovanni Rotondo (FG).
2012	Dal 1 gennaio 2012 Dirigente medico U.O.C. Oncologia con incarico Professionale di rilievo di "patologia neoplastica mammaria e dolore oncologico" in Casa Sollievo della Sofferenza Partecipa agli incontri multidisciplinari settimanali per la programmazione terapeutica delle pazienti con carcinoma mammario ("Breast Unit "-Casa Sollievo della Sofferenza)
2018	Dal 2018 oncologo medico del gruppo di patologia interdisciplinare della mammella dell'area della Capitanata
2019	Dal 2019 membro del COrO (Centro di Orientamento Oncologico) C.S.S Responsabile clinico <i>WORKING GROUP BREAST CANCER ACC</i> -C.S.S Membro del COSD (Comitato "Ospedale senza Dolore") di C.S.S
2021	Da luglio 2021 Dirigente medico nell' U.O.C. di Oncologia di Casa sollievo della Sofferenza con incarico di alta Professionalità per la patologia neoplastica mammaria
2023	Da maggio 2023 Dirigente medico U.O.C. di Oncologia di Casa Sollievo della Sofferenza con incarico di Responsabile di Struttura Semplice per la patologia neoplastica mammaria e terapia dolore neoplastico

## ISTRUZIONE E FORMAZIONE

25/10/1990	<ul style="list-style-type: none"> <li>• Ha conseguito la laurea in <b>MEDICINA E CHIRURGIA</b> presso l'Università degli Studi di Bologna in data 25/10/1990 con voti 110/110 e lode.</li> </ul>
3/12/1994	<ul style="list-style-type: none"> <li>• Ha conseguito la Specializzazione in Oncologia presso l'Università degli studi di Modena in data 3/12/1994 con voti 50/50.</li> </ul>
Gennaio 1991	<ul style="list-style-type: none"> <li>• E' iscritta all'Albo Professionale dei Medici Chirurghi della provincia di Foggia dal gennaio 1991.</li> </ul>
16/01/1996	<ul style="list-style-type: none"> <li>• Ha conseguito l'Attestato ad esercitare l'attività di medico di medicina generale in data 16/01/1996 presso l'Ordine dei Medici della Provincia di Foggia.</li> </ul>

2007

- Ha conseguito l'attestato di perfezionamento in "Bioetica e Pastorale sanitaria" rilasciato dall'UNIVERSITA' Cattolica del Sacro Cuore nell'anno accademico 2007-2008.

2010

- Ha conseguito in data 13 novembre 2010 il diploma di "Master Universitario di secondo livello in Bioetica e Medicina centrata sul paziente" rilasciato dall'UNIVERSITA' Cattolica del Sacro Cuore per gli anni accademici 2008-2009 e 2009-2010.

## CAPACITÀ E COMPETENZE PERSONALI

PRIMA LINGUA

ITALIANO

ALTRE LINGUE
• Capacità di lettura
• Capacità di scrittura
• Capacità di espressione orale

INGLESE

scolastica

scolastica

scolastica

ALTRE CAPACITÀ E COMPETENZE

E' membro dell'AMCI (associazione medici cattolici) e vicepresidente della sezione di San Giovanni Rotondo

-E' membro dell'AIOM (Associazione Italiana Oncologia Medica)

-E' membro GOIM (Gruppo oncologico Italia Meridionale)

-E' membro OSNA User Society

-E' membro ESMO (European Society for medical Oncology)

ATTIVITA' SCIENTIFICA

I suoi principali settori di interesse sono :

1) il trattamento del carcinoma della mammella,

2) la raccolta e gestione dei dati di studi clinici relativi al carcinoma della mammella o al dolore oncologico;

3) la partecipazione agli incontri multidisciplinari settimanali per la programmazione terapeutica ed la gestione dei trattamenti medici ed il follow-up delle pazienti affette da carcinoma della mammella nell'ambito della Divisione di Oncologia e della Breast Unit di Casa Sollievo della Sofferenza,

4) la terapia di supporto e le cure palliative del malato neoplastico con particolare interesse al dolore da cancro e la bioetica

Ha partecipato a N 160 congressi e/o corsi di interesse oncologico in qualità di uditrice

Ha partecipato in qualità di relatrice a N 156 corsi, congressi di aggiornamento o board meeting relativi all'area di interesse oncologico (in particolare il carcinoma della mammella ).

#### **PUBBLICAZIONI**

- E' autrice di 26 abstract presentati a Congressi
- E' autrice di 55 pubblicazioni in monografie o riviste
- E' autrice di alcuni argomenti relativi alla terapia di supporto presenti sul sito web:[www.oasiinforma.com](http://www.oasiinforma.com)

#### ALTRE INFORMAZIONI

Buona conoscenza degli strumenti informatici

La Sottoscritto Dr.ssa Maria Morritti consapevole che le dichiarazioni false comportano l'applicazione delle sanzioni penali previste dall'art. 76 del D.P.R. 445/2000, dichiara che le informazioni riportate nel presente curriculum vitae corrispondono a verità.

I dati personali contenuti nel presente documento saranno trattati ai sensi del Regolamento UE 2016/679 (GDPR) e si autorizza l'Ente/Società al trattamento dei dati personali qui riportati ai fini esclusivi legati alle collaborazioni professionali.

San Giovanni Rotondo lì 1 giugno 2023

In fede

## Dr.ssa Valentina Rossi

Medico Chirurgo, specialista in Oncologia Medica

### PROFILO

#### Titoli conseguiti

- Specializzazione con Lode in Oncologia Medica conseguita presso l'Università degli Studi di Roma "La Sapienza" (Ottobre 2009);
- Assegnista di Ricerca clinica in campo oncologico presso l'Istituto per la Ricerca e la Cura del Cancro (IRCC), Candiolo, Torino dal 11/2009 a 12/2011.
- Attività clinica routinaria in qualità di medico oncologo presso il Day Hospital e il reparto di Onco-ematologia del IRCC di Candiolo dal 11/2009 al 12/2011.
- Attività di Medico Oncologo dal 01/2012 al 10/2012 presso il Day-Hospital-Ambulatorio di Oncologia medica-reparto di medicina interna-onco-ematologia dell'Azienda ospedaliera di Cremona (Cr).
- Attività di Medico Oncologo e di Ricercatore Clinico presso l'unità Investigative Clinical Oncology (INCO) della Direzione Scientifica dell'IRCC di Candiolo (TO);
- Attività di Docenza nell'ambito di corsi di formazione sulla patologia oncologica della ghiandola mammaria.

#### Curriculum e attività

- Laurea con Lode in Medicina e Chirurgia presso l'Università degli Studi La Sapienza di Roma.
- Dirigente Medico con contratto a tempo determinato presso l'IRCC di Candiolo, To (dal 11/2009 al 12/2011).
- Dirigente Medico con contratto a tempo determinato presso l'Unità di Oncologia Medica dell'Azienda ospedaliera di Cremona (CR);
- Dirigente Medico con contratto a tempo determinato presso l'Unità INCO della Direzione scientifica dell'IRCC di Candiolo (TO);
- Dirigente Medico in qualità di specialista in Oncologia Medica presso l'Oncologia della Mammella dell'Ospedale SanCamillo-Forlanini di Roma.

#### Patologie trattate

- Tumore del seno

#### Metodologie diagnostiche e terapeutiche

- Programma di Prevenzione Oncologica e di Screening per neoplasie della mammella, colon-retto, prostata, polmone; Consulenza genetica per patologie oncologiche eredo-familiari; Consulenza Oncologica per pazienti già in trattamento con agenti terapeutici oncologici (secondo parere); Consulenza Oncologica per pazienti affetti da neoplasia della mammella, dell'ovaio, dell'utero, della prostata, del rene, dei tessuti molli, del polmone, delle ossa, del colon e del retto con la finalità di suggerire la presenza sul territorio nazionale di trial clinici sperimentali che offrano l'opportunità di usufruire di nuovi farmaci; Consulenza per pazienti affetti da neoplasie a primitività ignota con la possibilità di eseguire presso il laboratorio di genetica molecolare dell'IRCC di Candiolo nuovi test al fine di identificare il tumore primitivo; Consulenza per la valutazione di indicazione a manovre di radiologia interventistica per pazienti affetti da metastasi ossee; Consulenza per la diagnosi e cura dell'osteoporosi secondaria al trattamento ormonale nelle donne sottoposte ad intervento chirurgico per pregresso tumore mammario; Visite di Follow Up, valutazione dei fattori di rischio relativi alle abitudini alimentari e allo stile di vita predisponenti alla patologia oncologica della ghiandola mammaria e indicazione delle opportune strategie per la riduzione del rischio; valutazione dei fattori di rischio genetici; identificazione delle pazienti eleggibili al test genetico e indicazione delle opportune strategie di riduzione del rischio; impostazione del programma diagnostico-terapeutico in presenza di riscontro clinico o radiologico di nodulo della ghiandola mammaria; controllo oncologico di follow-up in pazienti con pregressa storia di neoplasia della mammella; supporto clinico per la gestione degli effetti collaterali relativi ai principali trattamenti oncologici (ormonoterapia, chemioterapia, terapia biologica, immunoterapia).

#### Laurea e abilitazione

**Laurea:** 25/03/2005 - Università degli Studi di Roma "La Sapienza"

**Abilitazione:** seconda sessione 2005 - Università degli Studi di Roma "La Sapienza"  
- Iscritto all'Ordine dei Medici Chirurghi e Odontoiatri (FNOMCeO) della Provincia di Frosinone

- Posizione numero: 3443

- Verifica FNOMCeO

#### Dichiarazione di conformità alle linee guida dell'Ordine

Il sottoscritto Dr.ssa Valentina Rossi dichiara sotto la propria responsabilità che il messaggio informativo contenuto nel presente sito è diramato nel rispetto delle linee guida approvate dalla FNOMCeO inerenti l'applicazione degli artt. 55, 56 e 57 del Nuovo Codice di Deontologia Medica.